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Abstract 
 Parkinson’s disease (PD) is a common neurodegenerative disorder that is characterised by 
akinesia, muscular rigidity, and postural instability, due primarily to the loss of 
dopaminergic neurons in the substantia nigra and depletion of upstream dopamine in the 
striatum. Current dopaminergic treatments reduce motor symptoms, but have diminishing 
benefits as the disease progresses. Treatment with the neuroactive steroid natural 
progesterone (PROG) improves outcomes in many experimental models of brain injury 
due to its pleiotropic mechanisms of neuroprotection, many of which may also benefit 
PD. This thesis investigated the influence of PROG on motor impairments in the 
unilateral intrastriatal 6-hydroxydopamine (6-OHDA) lesion model of PD in rats. We 
established a PD-like impairment with a d-amphetamine induced rotation test at day 7 
after large lesions and then administered PROG (4 mg/kg or 8 mg/kg) once daily for 7 
days starting at day 8. Both PROG doses markedly improved the primary outcome 
measure, forelimb akinesia on the adjusting steps test, with improvement sustained for six 
weeks after treatment had stopped. In a second study the beneficial influence of PROG (8 
mg/kg) on akinesia was replicated for rats with large lesions and was extended to rats 
with small lesions so that the latter rats were now similar to sham operated controls. We 
also found that PROG modestly improved postural instability of the ipsilateral forelimb 
on the postural instability test, and sensorimotor integration on the whisker test, but did 
not improve skilled reaching accuracy on a single-pellet reaching task, forelimb use 
asymmetry on the cylinder test, sensory neglect on the corridor test, or rotation bias after 
apomorphine. Furthermore, PROG did not change striatal tyrosine hydroxylase density 
when assessed in rats with large lesions. This study has provided the most thorough 
examination to date regarding PROG’s influence on motor skills in an animal model of 
PD. Furthermore, this study has produced novel evidence of the beneficial effects of 
PROG treatment on forelimb akinesia. These initial promising findings suggest that 
PROG is an effective therapy for akinesia and thus provides an impetus to further 
investigate PROG’s efficacy for the treatment of PD. 
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Chapter 1   
Introduction 
This introductory chapter provides a brief orientation of the thesis. The “General 
Introduction” outlines each of the introductory chapters (chapters 3-5). The “Aims of the 
Current Study” and the experimental chapters (Chapters 5-7) are then introduced. The last 
section of this chapter, “Outline of the Thesis”, details the structure and direction of the 
thesis.  
1.1.  General Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and affects 
around 1% of the population over the age of 55 (Lees et al., 2009). The disorder is 
characterised by slowness in the initiation of movement, muscular rigidity, postural 
instability, and tremor at rest; however, these motor impairments are often accompanied by 
non-motor symptoms such as cognitive impairment, sleep disturbance, and olfactory deficits 
(Chaudhuri et al., 2006; Dauer and Przedborski, 2003; Jankovic, 2008). The primary 
neuropathological hallmark of PD is the loss of dopaminergic neurons in the substantia nigra 
pars compacta (SNpc), in association with the presence of intracytoplasmic inclusions called 
Lewy bodies which leads to substantial depletion of dopamine (DA) upstream in the striatum 
(Blesa et al., 2012; Shulman et al., 2011). Although the loss of DA leads to the major clinical 
symptoms of PD, the disorder is complex and has a widespread pathology (Dawson and 
Dawson, 2003). Other potentially important mechanisms in the pathophysiology of PD 
include inflammation, oxidative stress, mitochondria dysfunction, decreased levels of 
neurotrophins, and prion like cell-to-cell transfer of aggregated α-synuclein (Dunning et al., 
2013; Levy et al., 2009; Macphee and Stewart, 2012; Nagatsu and Sawada, 2005).  
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Despite nearly 200 hundred years of research since James Parkinson first described 
PD in his classic 1817 monograph “An Essay on the Shaking Palsy” (Parkinson, 2002) the 
cause of and especially the cure for PD are still unknown (Dauer and Przedborski, 2003; 
Valadas et al., 2014). However, current drug treatments such as L-3,4-
dihydroxyphenylalanine (L-DOPA) that replace DA effectively reduce motor symptoms, but, 
with chronic use the benefits wear off and severe side effects such as dyskinesia (abnormal 
involuntary movements) occur in the majority of patients, especially as the condition worsens 
(Ahlskog and Muenter, 2001; Valadas et al., 2014). Additionally, there are no treatments that 
slow, halt, or reverse the degenerative process. Thus, there is clearly a need to explore new 
treatment options. 
 A novel possible treatment is natural progesterone (PROG), a hormone that is now 
clearly recognised as a neurosteroid, synthesized locally in the brain by neurons and glia 
(Guennoun et al., 2014). There is a substantial literature that shows that PROG treatment is 
beneficial in experimental models of traumatic brain injury (TBI), stroke, and several other 
models of brain injury and disease (see Deutsch et al., 2013 for a review). Interestingly, 
PROG’s neuroprotective properties are pleiotropic and include decreasing inflammation, 
neuronal apoptosis, and oxidative stress, increasing neurotrophic support, and improving 
mitochondria function (Deutsch et al., 2013; Wei and Xiao, 2013). Many of PROG’s pro-
recovery effects are also plausible mechanisms of neuroprotection in PD. For example, 
inflammation is now considered an important mediator regarding DA degeneration in PD 
(Barcia, 2013). In the PD brain, activation of microglia produces pro-inflammatory cytokines 
such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 (Dzamko et al., 2014; 
Nagatsuand Sawada, 2005). It is relevant, then, that PROG is effective at reducing the 
expression of activated microglia and pro-inflammatory cytokines following experimental 
brain injury (Stein, 2008, 2012). PROG’s ability to inhibit inflammation is promising as 
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current evidence suggests that other anti-inflammatory treatments may improve outcomes in 
PD (see Barcia, 2013 for a review). Despite numerous reports regarding PROG’s beneficial 
influence in various experimental models of brain injury and disease, surprisingly few studies 
have examined PROG’s influence in the context of an experimental model of PD. None of 
these PD studies have thoroughly examined the beneficial influence of PROG on motor skill 
functions or directly compared PROG treatment in models of the early and late stages of 
degeneration in PD. 
Animal models of PD are useful to examine the beneficial influence of novel 
treatments. These models can be classified into those using environmental or synthetic 
neurotoxins, and those using in vivo expression of PD-related genetic mutations (Blesa et al., 
2012; Duty and Jenner, 2011). The most commonly used model, and the one used in this 
thesis, are unilateral nigrostriatal dopamine lesions produced by intracerebral infusions of the 
neurotoxin 6-hydroxydopamine (6-OHDA, Blandini et al., 2008; Kirik et al., 1998). While far 
from perfect, the 6-OHDA model reproduces many of the key pathological features of PD, 
including progressive nigrostriatal degeneration, inflammation, mitochondrial dysfunction, 
and oxidative stress (Duty and Jenner, 2011). Additionally, the 6-OHDA model produces 
clinically relevant motor deficits such as akinesia, postural instability, impaired skilled 
reaching, and impaired sensory function (Dowd et al., 2005a; Meredith and Kang et al., 2006; 
Metz et al., 2003; Woodlee et al., 2008). The beneficial influence of novel treatments such as 
PROG can be assessed against these pathological and functional consequences of 6-OHDA 
lesions.  
1.2.  Aims of the Current Study 
This brief introduction, expanded in subsequent chapters, shows that PD is a complex 
disorder with a number of mechanisms that contribute to the degenerative process. Current 
treatments for PD provide initial symptomatic relief but eventually become ineffective in 
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most patients. Thus, there is an unmet need for additional treatment options. PROG is a 
neuroprotective agent that has improved morphological and functional outcomes in many 
experimental models of brain injury and disease. Despite these promising reports, PROG has 
received little attention in the context of PD. PROG may be beneficial in a model of PD due 
to its pleiotropic mechanisms such as reducing inflammation and increasing trophic support.  
 The main aim of the current study was to examine the beneficial influence of PROG 
treatment following unilateral 6-OHDA lesions that model PD degeneration and motor 
impairments. The unilateral 6-OHDA lesion model is useful for examining the beneficial 
influence of novel treatments such as PROG as it reproduces many of the pathological and 
functional changes observed in human PD. This study investigated whether 7 days of PROG 
treatment started at day 8 after 6-OHDA lesion surgery would improve motor impairments in 
both the short and long-term after lesion surgery. Furthermore, one experiment investigated 
whether PROG treatment could improve striatal tyrosine hydroxylase fibre deafferentation. In 
addition, the current study examined the beneficial influence of PROG following 6-OHDA 
lesions that model the early and late stages of PD degeneration. These aims were examined 
across three experiments. 
 The first experiment was a pilot study that established the time-course for motor 
impairments following unilateral 6-OHDA infusions to the dorsal striatum that produce large 
lesions. Establishing the time-course for impairments in our laboratory was a new task, and 
was essential to identifying an ideal treatment time-point for subsequent studies using PROG. 
Prior to surgery, rats were tested for forelimb akinesia on the adjusting steps test and skilled 
forepaw use on the sunflower seed handling test then given 6-OHDA lesions or sham 
surgery. At day 7 after surgery the dopamine depleting lesions were verified with a rotation 
after d-amphetamine test. To assess striatal supersensitivity contralateral rotation after 
apomorphine was tested at days 24 and 61. Forelimb akinesia and skilled forepaw use were 
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examined at three repeated intervals between post-surgery days 15 and 58, as the emergence 
and progression of motor impairments following intrastriatal 6-OHDA lesions can be time-
sensitive (Kirik et al., 1998). Rats were perfused at day 65 after surgery and tyrosine 
hydroxylase immunohistochemistry of the striatum was performed in a random sample of 
rats.  
 The second experiment examined the beneficial influence of two doses of PROG after 
large unilateral 6-OHDA striatal lesions. Rats were trained and tested pre-operatively on a 
single-pellet skilled reaching test and the adjusting steps test for forelimb akinesia then given 
6-OHDA lesions or sham surgery. Rats with sufficient lesions according to the d-
amphetamine rotation test at day 7 were assigned to PROG treatment groups. Rats with 
lesions were administered either 8 mg/kg PROG, 4 mg/kg PROG, or sesame oil vehicle once 
daily for 7 days starting at day 8 after surgery. Importantly, the dose was tapered by 
sequential halving on the sixth and seventh days of treatment. Sham surgery rats received 
sesame oil vehicle alone. Forelimb akinesia was investigated at four occasions between days 
17 and 53 and skilled reaching was tested on days 24-26 and 49-51 post-surgery. 
Contralateral rotation after apomorphine was tested at days 29 and 62. Rats were perfused at 
day 64 and striatal tyrosine hydroxylase fibre density was examined. An additional group of 
lesion-only control rats were perfused at day 8 to serve as a reference for striatal tyrosine 
hydroxylase deafferentation at the time when PROG treatment was started.  
 The third experiment investigated the beneficial influence of a single dose of PROG 
after small and large unilateral 6-OHDA striatal lesions. This experiment included a larger 
battery of tests to assess the extent of PROG’s beneficial influence on motor impairments. 
Rats were tested pre-operatively on the adjusting steps test for akinesia, postural instability 
test, cylinder test for forelimb use asymmetry, whisker evoked forelimb placing test for 
sensorimotor integration, and the corridor test for sensory neglect then given small or large 6-
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OHDA lesions or sham surgery. Rotation after d-amphetamine was tested at day 7 to confirm 
the lesions then PROG treatment was administered for 7 days starting at day 8 after surgery. 
Rats with small and large lesions and sham rats received 8 mg/kg PROG or sesame oil 
vehicle once daily with tapered withdrawal as previous. The above motor skills were tested at 
repeated intervals between days 17 and 62 and contralateral rotation after apomorphine was 
assessed at day 66 post-surgery. Rats were sacrificed at day 68 and the brains stored for 
histology at a later date due to time constraints.  
1.3.  Outline of the Thesis 
The following chapter details the characteristics of PD and briefly describes its symptoms, 
pathogenesis, and current and emerging treatment approaches. Chapter three reviews the 
literature regarding PROG and neuroprotection with a focus on TBI and ischemia. Towards 
the end of this chapter PD models that have examined the beneficial influence of PROG 
treatment are also described. Chapter four briefly describes animal models of PD with a focus 
on the 6-OHDA model used in this thesis. The following three chapters (Chapters 5-7) report 
the findings of the three experiments conducted in this thesis. Chapter 8 provides a general 
discussion regarding the implications of the findings in relation to the literature reviewed in 
Chapters 2-4. The limitations of the current thesis and suggestions for future research are also 
discussed towards the end of Chapter 8.  
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Chapter 2   
Overview of Parkinson’s disease 
2.1.  Objectives 
This chapter provides an overview of Parkinson’s disease. The clinical characteristics of 
Parkinson’s disease are described before the pathological factors that contribute to the disease 
are discussed. The final section examines current and emerging treatments for Parkinson’s 
disease then discusses the need for new treatment options.  
2.2.  Characteristics of Parkinson’s disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterised by 
a large number of motor and non-motor features. The majority of PD cases are sporadic 
(90%) with an unknown cause while the remaining fraction is familial where a number of 
causative gene mutations have been identified (Valadas et al., 2014). PD is more common in 
males than females which suggests an influence of sex hormones on the development of the 
disease (Smith and Dahodwala, 2014). PD affects an estimated 6 million patient’s worldwide 
(Dorsey et al., 2007) and as life expectancy increases the incidence of PD will rise as 
advancing age is the greatest risk factor (Collier et al., 2011). Current treatments provide 
effective relief of motor symptoms, but as the disease progresses these treatments become 
ineffective (Valadas et al., 2014). With an ageing population the need for improved therapies 
is becoming increasingly important.  
2.2.1.  Risk factors and evolution 
Despite substantial research the causes of PD is still largely unknown. Epidemiology studies 
have identified advancing age as the primary risk factor for PD with a prevalence of about 
1% at age 65 rising to nearly 5% at age 85 (Collier et al., 2011; de Lau and Breteler; 2006; 
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Van Den Eeden et al., 2003). There is a greater risk for first degree relatives of PD patients, 
especially for siblings than for parents or children (Sundquist et al., 2006). Environmental 
studies have also associated pesticide exposure and repeated traumatic loss of consciousness 
as risk factors for PD (Dick et al., 2007). Interestingly, there is some evidence that smoking 
and caffeine use are associated with decreased risk (Qi and Li, 2014; Ritz et al., 2007). Since 
inflammation contributes to the pathogenesis of PD researchers have examined the 
relationship between non-steroidal anti-inflammatory drugs and the risk of developing the 
disease. Some studies have reported a decreased risk, especially for ibuprofen use (Gao et al., 
2011; Wahner et al., 2007), while others have found no relationship (Driver et al., 2011). 
These findings have been valuable for identifying at risk groups, but they do not explain the 
evolution of PD once the disease process has initiated.  
To explain the evolution of PD Braak and colleagues proposed a now widely accepted 
staging system according to the regional distribution of Lewy bodies and Lewy neurites 
(Braak et al., 2003, 2006).  Lewy bodies and Lewy neurites are composed of aggregates of α-
synuclein and are considered a pathological hallmark of PD (Braak et al., 2003). Braak et al. 
(2003) examined the regional distribution of Lewy pathology in the brains of people with 
clinically diagnosed PD and those with incidental Lewy pathology without clinical features. 
They found there was an association between the presence and distribution of Lewy 
pathology and the symptoms of PD. With these findings they were able to categorise PD into 
six stages. In Braak stages 1 and 2, Lewy pathology is restricted to the medulla 
oblongata/potine tegmentum and the anterior olfactory structures. During these early stages 
patients are pre-symptomatic with respect to motor impairments. As the disease progresses to 
Braak stages 3 and 4 the substantia nigra (SN) and other areas of the basal mid- and forebrain 
become involved. During these stages the motor symptoms manifest. Finally, in Braak stages 
5 and 6 the pathology presents in the neocortex which may in turn explain some of the 
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cognitive symptoms associated with PD (Braak et al., 2003, 2006). The Braak staging system 
assumes that Lewy pathology begins in the gastrointestinal system then progresses in a 
predictable and characteristic sequence where it advances through the vagal nerve to the 
brainstem then subsequently ascends to the SN, and eventually spreads to the neocortex 
(Brundin et al., 2008). This characteristic spread of Lewy pathology allows for accurate 
prediction of disease advancement.  
Although the Braak staging system is widely accepted not everyone agrees that it is a 
useful marker for disease progression. One challenge to the Braak system is that it lacks 
predictive validity. This challenge stems from observations of subjects with widespread Lewy 
pathology (Braak stages 5-6) whom showed no neurological impairment (Parkkinen et al., 
2005, 2008). Others argue there is no relationship between Lewy pathology and disease 
duration and/or clinical severity which questions if the Braak system actually represents the 
temporal evolution of PD (Burke et al., 2008; Jellinger et al., 2008). Another challenge comes 
from reports where Lewy pathology has been reported throughout the brain but with 
preservation of the medullary nuclei which according to the Braak system should be the first 
affected areas (Jellinger, 2003). 
Similarly, according to the Braak system the severity of the Lewy pathology in the 
affected areas should increase as the disease progresses. It would therefore be expected that 
areas affected earlier in the disease would have higher α-synuclein loads compared to areas 
affected later in the disease. However, one study found that in about 65% of subjects the α-
synuclein loads in the SN and locus coeruleus were about equal to the loads observed in the 
dorsal motor nucleus of the vagus nerve (DMV), the point of departure for Lewy pathology in 
the brain (Attems and Jellinger, 2008). Furthermore, another study reported cases that had 
substantial Lewy pathology in the SN without any pathology observed in the DMV 
(Kalaitzakis et al., 2008).  
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 The Braak system assumes that Lewy pathology first appears in the peripheral 
nervous system such as enteric neurons in the gut then advances in a caudal-rostro direction 
to the DMV prior to progressing to the midbrain regions. Beach et al. (2010) have questioned 
this “gut to brain” spread of Lew pathology. Beach et al. propose that the pathology spreads 
from “brain to gut” according to their findings of decreasing density and frequency of 
phosphorylated  α-synuclein in a rostro-caudal direction of the gastrointestinal tract. In 
comparison, a recent finding provided the first direct evidence of “gut to brain” spread of α-
synuclein via the vagal nerve to the DMV in a rat model (Holmqvist et al., 2014). Taken 
together these findings suggest that Lewy pathology could spread in both an anterograde and 
retrograde direction although a bi-directional spread of pathology is not assumed in the Braak 
system.   
 Despite the challenges and criticisms of the Braak staging model the system seems to 
be valid in most cases.  Kalaitzakis et al. (2008) reported that the spread of Lewy pathology 
was consistent with Braak staging in 53% of cases whereas others have reported a much 
higher compatibility of about 82% (Attems and Jellinger, 2008; Jellinger, 2003; Parkkinen et 
al., 2008). Therefore, the Braak staging system remains a useful system for staging the 
evolution of PD in the majority of cases.  
2.2.2.  Motor Symptoms 
The cardinal motor features of PD are summarised in Table 2.1. These symptoms include 
tremor at rest, bradykinesia, rigidity, postural instability, and gait abnormalities (Jankovic et 
al., 2008; Smith et al., 2012). The presence of these characteristic motor features is used to 
make a clinically probable diagnosis of PD (Jankovic, 2008).  
Tremor at rest is the most common and easily recognised symptom that usually 
manifests in the early stages of PD although it is not the most diagnostic feature of the 
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disease (Fahn, 2003). Tremors typically occur asymmetrically in the hands at a frequency of 
4-6Hz but can also involve the legs, lips, chin, and jaw (Jankovic, 2008). Tremors usually 
decrease with action although they can increase when walking. Tremor at rest occurs in most 
patients although approximately 11% never develop the symptom in the course of the disease 
(Jankovic, 2008). 
Bradykinesia usually manifests in the early stages of PD and is considered the most 
diagnostic feature of the disorder (Jankovic, 2008). Bradykinesia is defined as the slowness 
of movement and is often used synonymously with akinesia and hypokinesia. Akinesia is the 
paucity of spontaneous movement such as arm swing during walking. Hypokinesia are 
movements that are both slower and smaller than normal such as micrographia (Berardelli et 
al., 2001). These three symptoms occur in PD although not all patients will present with each 
(Berardelli et al., 2001). Another cardinal feature that manifests early in the disease is 
rigidity. Rigidity refers to the increased resistance to passive movement that is usually 
accompanied by the “cogwheel” phenomenon (Jankovic, 2008). Patients may complain of 
muscle stiffness although this is not a major source of disability (Smith et al., 2012).   
 Postural instability is common in the late stages of PD and usually manifests after the 
onset of other motor symptoms (Jankovic, 2008). Postural instability has clinical importance 
as it contributes to the danger of frequent falls in PD (Jessop et al., 2006). The final cardinal 
feature of PD is gait impairments. A common gait impairment is “freezing”, a debilitating 
symptom that also contributes to the danger of falls (Giladi et al., 2001). Freezing episodes 
present as a sudden and transient inability to move where the patients feet appear “glued to 
the floor”. Freezing episodes are most common in relation to starting to walk, when turning, 
when walking in a narrow passage, and when approaching a destination (Jankovic, 2008).  
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As stated at the start of this section, the cardinal motor features of PD are used to 
make a clinically probable diagnosis of PD. However, individual patients show considerable 
variation in the presentation of these motor manifestations and accompanying symptoms 
(Kang et al., 2005). The accompanying non-motor symptoms of PD are often under reported 
and underappreciated in clinical practice (Bonnet et al., 2012). These non-motor 
complications are briefly described in the following section.   
Table 2-1 
Cardinal Motor Features of Parkinson’s disease. 
Early features Late Features 
Bradykinesia/akinesia 
 Slowness of movement, fatiguing 
with decreased amplitude of 
movement, arrests in ongoing 
movement 
 Decreased spontaneous movements 
such as eye blinking, swallowing, and 
arm swing 
 
Postural change 
 Flexed posture 
 Postural instability – retropulsion, 
propulsion, falls (en bloc) 
Tremor 
 Rhythmic sinusoidal movement of a 
body part due to regular contractions 
of reciprocally innervated muscles 
(either synchronous or alternating) 
 Occurs at rest 
Gait disorder 
 Shuffling, lack of arm swing 
 Festination: going from walking to 
running 
 Freezing: Feet ‘sticking to the floor 
like glue’, occurs with turning, gait 
initiation, enclosures like doorways 
Muscle rigidity 
 Increase in resistance to passive 
movement 
 ‘Cogwheel’ 
 Patients may complain of stiffness but 
not a major source of disability 
 
(Table adapted from Smith et al., 2012). 
 
2.2.3.  Non-motor Symptoms 
The symptoms described in the previous section represent the cardinal motor features 
of PD. However, non-motor symptoms are also a common feature of PD (Table 2.2). Non-
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motor features include cognitive impairment, neuropsychiatric symptoms, sleep dysfunction, 
autonomic symptoms, and sensory deficits (Chaudhuri et al., 2006). Non-motor symptoms 
occur throughout the course of the disease and in some instances precede the motor 
symptoms (Bonnet et al., 2012; Slow et al., 2014; Wu et al., 2011).  
Neuropsychiatric symptoms of PD include depression, anxiety, and apathy 
(Chaudhuri and Schapira, 2009). Depression affects up to 27.6% of patients and can occur at 
any stage of the disease (Ravina et al., 2007). Reports show that depression is a major 
contributor to reduced quality of life (Rahman et al., 2008; Visser et al., 2008). Anxiety 
usually exists alongside depression and can affect up to 50% of patients during the course of 
the disease (Bonnet et al., 2012; Chaudhuri and Schapira, 2009). Apathy is another common 
behavioural change in PD that affects 32% of patients (Starkstein et al., 2009). Mild cognitive 
impairment and frank dementia are prevalent non-motor features of PD. Mild cognitive 
impairment in domains such as executive function, psychomotor speed, visuospatial abilities, 
language, and memory have been reported in 18-55% of patients without dementia (Goldman 
et al., 2011). Frank dementia is common during the latter stages of PD and is the most 
debilitating aspect of the disorder with 83% of patients experiencing dementia after 20 years 
disease duration (Hely et al., 2008).  
 In addition to cognitive and neuropsychiatric symptoms patients often experience 
sleep, autonomic, and sensory dysfunction. Sleep dysfunction is present in up to 90% of PD 
patients and includes insomnia, hypersomnia, nightmares, sleep fragmentation, nocturnal 
movements, and rapid eye movement (REM) sleep behaviour disorder (Chaudhuri et al., 
2010; Stacy, 2002). REM sleep behaviour disorder consists of excessive motor activity 
during dreaming in association with loss of skeletal muscle atonia during REM sleep which 
enables patients to physically enact their dreams (Chaudhuri et al., 2006). During these 
episodes patients can injure themselves and their bed partners. REM sleep behaviour disorder 
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occurs in up to 60% of patients and can precede the motor stage of PD by several years 
(Chaudhuri et al., 2006; Claassen et al., 2010; Olson et al., 2000; Slow et al., 2014).  
Autonomic symptoms in PD include constipation, bladder and sexual dysfunction, and 
increased sweating (Chaudhuri et al., 2006). Constipation is one of the most common non-
motor symptoms in PD (Abbott et al., 2001). Constipation can precede the motor stage and is 
associated with a 4.5 fold increase in risk of developing PD (Abbott et al., 2001).  Sensory 
symptoms such as olfaction dysfunction, pain, and paresthesia are frequent in PD (Jankovic, 
2008). Hyposmia, a disorder of odour detection and discrimination could be an early sign of 
PD as one study found it was associated with a 10% increase risk of developing the disease 2 
years later (Ponsen et al., 2004).  
 The symptoms described in this section show that non-motor complications often 
accompany the cardinal motor features of PD. Some of the non-motor symptoms such as 
hyposmia and REM sleep behaviour disorder can precede the motor stages of the disease and 
may be the earliest signs of PD.   
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Table 2-2 
Non-motor Features of Parkinson’s disease. 
Neuropsychiatric 
 Psychosis (hallucinations, delusions, 
illusions) 
 Depression 
 Apathy 
 Anxiety 
 Anhedonia 
 Attention deficit 
 Impulsive and compulsive behaviours 
 Panic attacks 
 Cognitive impairments* 
 Dementia 
Autonomic symptoms 
 Orthostatic hypotension (related falls) 
 Gastrointestinal dysfunctions 
(constipation, fecal incontinence)
*
 
 Bladder disturbances (urgency, 
frequency) 
 Nausea 
 Vomiting 
 Drooling 
 Increased sweating 
 Sexual dysfunctions (hypersexuality, 
erectile dysfunction)  
 Dysphagia/choking 
Sleep disorders 
 Rapid eye movement (REM) sleep 
behaviour disorder (loss of atonia)
*
 
 Vivid dreaming 
 Restless legs syndrome 
 Excessive daytime somnolence 
 Insomnia 
Sensory deficits 
 Amosmia (olfactory deficits)* 
 Ageusia (taste deficits)* 
 Pain 
 Paresthesia 
 
Other symptoms 
 Fatigue 
 Diplopia 
 Blurred vision 
 Seborrhoea 
 Weight loss 
 Weight gain (possibly drug induced) 
*
Nonmotor symptoms that often precede PD motor impairments (table adapted from 
Chaudhuri et al., 2006; Smith et al., 2012).   
 
2.3.  Pathological Factors in Parkinson’s disease 
PD is characterised by the depletion of striatal DA due to the degeneration of dopaminergic 
neurons in the SNpc (Dauer and Przedborski, 2003). This section starts with a description 
regarding the role of DA depletion and basal ganglia dysfunction as these are considered key 
to the motor impairments in PD. The factors that contribute to the death of SNpc neurons is 
not fully understood although inflammation, prion-like propagation of α-synuclein, oxidative 
stress, mitochondrial dysfunction, reduced neurotrophic factors, and vascular degeneration 
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are possible candidates that contribute to the pathogenesis of PD. These mechanisms are 
briefly described and are summarised in Figure 2.1.  
 
Figure 2.1. Flow chart summarising the factors that contribute to the pathogenesis of 
Parkinson’s disease.  
 
2.3.1.  Basal ganglia and dopamine theory  
There is little doubt that loss of dopaminergic neurons in the SNpc significantly contributes to 
the cardinal motor features of PD (Fahn and Sulzer, 2004). Degeneration of dopaminergic 
neurons in the SNpc leads to depletion of striatal (caudate nucleus and putamen) DA and 
subsequent dysfunction of the basal ganglia (Smith et al., 2012). Due to the remarkable 
compensatory capacity of the dopaminergic system motor symptoms do not manifest until 
striatal DA is depleted to ~80% and ~60% SNpc dopaminergic neurons have been lost (Dauer 
and Przedborski, 2003). Abnormalities of basal ganglia function due to dopamine depletion 
are thought primarily responsible for PD motor impairments (Galvan and Wichmann, 2008). 
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Therefore, a brief description of the basal ganglia is necessary to understand the motor 
dysfunctions that develop in PD.  
The basal ganglia are a group of interconnected structures that comprise the striatum, 
the globus pallidus (both the internal, GPi; and external segments, GPe), the subthalamic 
nucleus, and the pars reticulata (SNr) and pars compacta of the substantia nigra (Galvan and 
Wichmann, 2008). The basal ganglia are components of re-entrant cortico-subcortical circuits 
of which the motor circuit is the most researched due to its importance for movement 
disorders such as PD (see Figure 2.2; DeLong and Wichmann, 2007). In the classic motor 
circuit cortical information flows through the basal ganglia via two major striatal projection 
systems known as the “direct” and “indirect” pathways (Smith and Wichmann, 2014). In the 
normal state, activation of the direct pathway inhibits the GPi/SNr which in turn has an 
excitatory effect on thalamocortical interactions. Indirect pathway activation has an 
excitatory effect on the GPi/SNr thereby producing an inhibitory effect on thalamocortical 
interactions. Dopamine’s net action is to reduce GPi/SNr activity, thereby facilitating activity 
of thalamocortical interactions leading to greater activation of the cerebral cortex which 
facilitates movement (Galvan and Wichmann, 2008). In the PD state, depletion of striatal DA 
causes insufficient activation of the direct pathway and insufficient inhibition of the indirect 
pathway. This imbalance leads to over-activity of the GPi/SNr with an overall inhibitory 
effect on thalamocortical interactions. This leads to under-activation of the cerebral cortex 
and subsequently clinical hypokinesia (Braak and Del Tredici, 2008). 
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Figure 2.2. A schematic representation of the basal ganglia motor circuits in normal and 
parkinsonian states. The direct pathway, represented by the red lines, indicates inhibitory 
projections. The indirect pathway, represented by the blue lines, indicates excitatory 
projections. The changes in the thickness of the arrows in the parkinsonian state indicate the 
increase (larger arrow) or decrease (thinner arrow) in activity of specific connections. 
Denervation of the dopaminergic projection from the SNc to the putamen in the parkinsonian 
state is represented by the dashed lines. CM, centromedian nucleus; CMA, cingulate motor 
area; GPe, globuspallidus, external segment; GPi, globuspallidus, internal segment; M1, 
primary motor cortex; PMC, pre-motor cortex; PPN, pedunculopontine nucleus; SMA, 
supplementary motor area; SNc, substantia nigra pars compacta; SNr, substantia nigra pars 
reticulata; STN, subthalamic nucleus; VA/VL, ventral anterior/ventral lateral nucleus (figure 
and description adapted from Galvan and Wichmann, 2008; Smith et al., 2012). 
 
While SNpc neurons are preferentially lost in PD their degeneration are by no means 
exclusive. Although nigrostriatal DA degeneration and subsequent basal ganglia dysfunction 
significantly contributes to motor and perhaps some other impairments, numerous non-motor 
symptoms associated with PD cannot be explained by DA deficiency alone (Ahlskog, 2007; 
Bonnet et al., 2012; Shulman et al., 2011). Furthermore, the pathological changes in PD are 
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not limited to DA depletion. Therefore, it is important to examine the pathogenesis of PD 
beyond DA deficiency alone.  
2.3.2.  Inflammation 
Neuroinflammation is an important contributor to the pathogenesis of PD. Interest in 
neuroinflammation resulted from a post-mortem analysis of the SN of PD patients which 
revealed the presence of activated microglia, a sign of inflammation (McGeer et al., 1988). 
More recently, increased levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 
have been observed in the brain, cerebrospinal fluid, and peripheral blood mononuclear cells 
of PD patients (see Dzamko et al., 2014 for a review). This shows that inflammation is 
clearly associated with the pathogenesis of PD. 
Microglia play an integral role in the coordination of inflammation in PD. In the brain 
microglia typically exist in a resting state where they perform surveillance of the surrounding 
brain environment but become activated in response to cues such as brain injury or 
immunological stimuli (Block et al., 2007). Once activated, microglia can serve beneficial 
functions to neuronal survival through the release of anti-inflammatory and neurotrophic 
factors, and the removal of damaged neurons and foreign substances (Garden and Moller, 
2006). However, microglia can become over activated which produces a self-sustaining cycle 
of inflammation that drives progressive neurodegeneration (Qian et al., 2010). In PD, 
microglia activate in response to the molecules released by damaged and dying dopaminergic 
neurons. Activated microglia increase the expression of pro-inflammatory cytokines such as 
TNF-α and IL-1β and increase the production of harmful reactive oxygen (ROS) and nitrogen 
species (Dias et al., 2013). The release of large levels of proinflammatory cytokines and ROS 
is toxic to the neighbouring neurons, resulting in a self-sustaining cycle of neurodegeneration 
and inflammation (Barcia, 2013). Thus therapies that reduce neuroinflammation may be 
beneficial in the treatment of PD.  
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2.3.3.  Alpha-synuclein and the prion hypothesis  
A pathological hallmark of PD is α-synuclein pathology in the form of Lewy bodies and 
Lewy neurites (Braak et al., 2003). α-synuclein is a neuronal protein but its abnormal 
aggregation contributes to the pathogensis of PD (Stefanis, 2012). Braak et al. (2004) 
described the regional distribution of α-synuclein and proposed that this distribution 
correlated with the disease stage. However, Braak et al. was unsure what mechanism was 
responsible for the spread of α-synuclein.  
A new and exciting hypothesis is that α-synuclein is a prion-like protein and that PD 
is a prion-like disease (Olanow and Brundin, 2013). Prions are proteins that acquire 
alternative conformations that become self-propagating (Prusiner, 2014). Prions cause 
neurodegenerative disease by misfolding into a β-sheet rich conformation that polymerizes to 
form toxic oligomers and amyloid plaques (Olanow and Brundin, 2013). Like prions, α-
synuclein can also adopt a β-sheet rich conformation (Prusiner, 2012). The misfolded protein 
acts as a template to promote conformational change in other proteins and once established 
the process becomes self-propagating causing a chain-reaction that leads to 
neurodegeneration (Olanow and Brundin, 2013; Prusiner, 2012). 
The suggestion that PD might be a prion disorder stemmed from the observation of 
Lewy body pathology in the fetal mesencephalic tissue grafted into the putamen of PD 
patients. After a PD patient died 18 months after fetal mesencephalic tissue transplantation, 
initial histology revealed good graft survival that was well integrated to the host striatum 
without discernible Lewy bodies (Kordower et al., 1995). However, two independent studies 
reported that the actual grafted neurons of other patients who died 11-16 years after 
transplantation had α-synuclein positive Lewy bodies that were identical to the Lewy body 
pathology in PD (Kordower et al., 2008; Li et al., 2008). These patients had Lewy bodies in 
2-8% of the grafted neurons which is comparable to the levels detected in non-grafted PD 
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patients. Furthermore, these grafts showed signs of dysfunction as there was less staining for 
tyrosine hydroxylase and the DA transporter. These findings were supported in a subsequent 
report of a patient who received grafts at 12 and 16 years before death (Li et al., 2010). In this 
study, they found that 2% of the 12-year old and 5% of the 16-year old grafted dopamine 
neurons contained Lewy bodies positive for α-synuclein. This suggests that Lewy bodies 
develop gradually in grafted neurons (Li et al., 2010). Since the grafts in these studies were 
derived from multiple genetically unrelated donors it is likely that the Lewy pathology in the 
transplants resulted from host-to-graft propagation (Olanow and Brundin, 2013). This host-
to-graft propagation suggests that α-synuclein is  prion-like and PD is a prion-like disorder.   
In support of the prion hypothesis laboratory studies have shown in vitro and in 
animal models that α-synuclein is transferred from neurons to neurons (Desplats et al., 2009; 
Hansen et al., 2011; Lee et al., 2010; Luk et al., 2009). These studies show that α-synuclein is 
taken up by neurons and promotes misfolding in the host α-synuclein which leads to 
dopaminergic neurodegeneration (for reviews see Dunning et al., 2013; Geroge et al., 2013; 
Olanow and Brundin, 2013; Sato et al., 2014; Visanji et al., 2013). If PD can be confirmed as 
a prion like disorder it will revolutionise our understanding of the disease and will provide 
new targets for neuroprotective treatments.  
2.3.4.  Mitochondrial dysfunction, oxidative stress, and cell death 
Mitochondrial dysfunction and oxidative stress are implicated in the pathogenesis of PD. 
Mitochondrial dysfunction was first implicated in PD after several drug users accidentally 
injected themselves with the heroine analogue 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). Within days they developed parkinsonism and post-mortem analysis confirmed 
significant dopaminergic neuron loss in the SNpc (Langston et al., 1983). MPTP crosses the 
blood-brain barrier (BBB), and then is metabolized to 1-methyl-4-phenylpyridinuim (MPP+). 
MPP+ is taken up by the DA transporter into dopaminergic neurons where it inhibits complex 
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I of the mitochondrial transport chain which leads to cell death (Hauser and Hastings, 2013). 
Similarly, decreases in mitochondrial complex I activity in the SNpc of patients with sporadic 
PD has been reported (Schapira et al., 1990; Hattori et al., 1991). Inhibition of complex I 
activity generates excessive levels of ROS which leads to oxidative stress and subsequently 
cell death (Subramaniam and Chesselet, 2013).  
 In addition to deficient complex I activity, inflammation and decreased levels of 
antioxidants also contributes to oxidative stress in PD.  As discussed above, 
neuroinflammation contributes to oxidative stress as microglia when activated are a major 
source of ROS. The production of ROS by microglia damages neurons which in turn activate 
additional microglia thus creating a self-sustaining inflammatory-oxidative environment 
(Taylor et al., 2013). Decreased levels of the antioxidant glutathione in the SN of PD brains 
have been reported (Pearce et al., 1997; Perry et al., 1982; Sian et al., 1994; Sofic et al., 1992; 
Riederer et al., 1989). Glutathione is a molecule that is transported to the mitochondria where 
it functions as a major antioxidant (Hauser and Hastings, 2013). Depletion of glutathione in 
the SN results in selective decrease of mitochondrial I complex activity and thus contributes 
to oxidative stress (Dias et al., 2013). Taken together these findings suggests that deficient 
mitochondrial function, neuroinflammation, and decreased levels of the antioxidant 
glutathione all contribute to oxidative stress and subsequent cell death in PD.  
The mechanisms underlying cell death in PD are thought to involve a combination of 
cell-autonomous (mechanisms that take place inside the dying neuron) and non-cell-
autonomous mechanisms (mechanisms that originate from outside of the neuron; Hirsch et 
al., 2012). Hirsch et al. (2012) propose that cell-autonomous mechanisms include the build-
up of damaged mitochondria and non-cell-autonomous mechanisms involve prion like 
misfolded proteins and inflammation. These mechanisms combine to initiate cell death and 
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propagate the neurodegenerative process. For a neuroprotective treatment to be effective it 
would need to address the multifactorial cascade that leads to cell death.  
2.3.5.  Neurotrophic factors 
Alterations in the expression of neurotrophic factors (NFTs) have been implicated in the 
pathogenesis of PD. NTFs are proteins that support the survival and function of neurons 
(Ramaswamy et al., 2009). NTFs can enhance mitochondrial function by acting as anti-
excitotoxins and anti-oxidants (Kordower and Bjorklund, 2013).  
Brain-derived neurotrophic factor (BDNF) is a NFT that is required for the normal 
development of dopaminergic neurons and is expressed in the nigrostriatal system of adult 
brains (Peterson and Nutt, 2008). In post-mortem samples, BDNF expression was 
significantly reduced in the caudate, putamen, and SN of patients with PD (Mogi et al., 
1999). In a similar study, BDNF mRNA expression was reduced by 70% in the SN (Howells 
et al., 2000). The reduced expression of BDNF was likely due in part to the loss of 
dopaminergic neurons that contain BDNF. However, the surviving DA neurons in patients 
expressed 20% less BDNF compared to neurons of controls (Howell et al., 2000).  
 Altered BDNF expression in the serum of PD patients has also been reported. In one 
study serum BDNF was decreased in patients that had moderately severe motor impairments 
compared to healthy controls (Scalzo et al., 2010). However, among patient’s higher levels of 
serum BDNF was associated with longer disease duration and severity of motor impairments 
(Scalzo et al., 2010). In contrast others found that serum BDNF levels were actually 
increased in patients with severe motor impairments (Ventriglia et al., 2013). Taken together 
these findings suggest that serum BDNF levels are reduced during the early stages of the 
disease but increase with advancing disease duration and symptom severity. The increase of 
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serum BDNF levels with disease progression suggests a compensatory role of BDNF during 
the latter stages of PD.  
 Other NTFs of interest to PD are glial cell line-derived neurotrophic factor (GDNF) 
and neurturin which are both essential for dopaminergic neuron survival (Peterson and Nutt, 
2008). Neither GDNF nor neurturin are reduced in PD brains but both have improved 
outcomes in both in vitro and animal models of PD. Similarly, BDNF administration has 
improved outcomes in animal and in vitro models of PD (see Peterson and Nutt, 2008; 
Kordower and Bjorklund, 2013 for reviews). These suggest that therapies which improve 
NTF expression may be beneficial for the treatment of PD.  
2.3.6.  Vascular degeneration  
Vascular degeneration also contributes to the pathology of PD. Guan et al. (2012) examined 
cerebrovascular markers in post-mortem PD brains and found compromised BBB, due to 
endothelial cell ‘clusters’, as well as capillaries that had a larger diameter, shorter length, and 
less branching in the SN, middle frontal cortex, and brain stem nuclei compared to age-
matched controls. Loss of the integrity of the BBB and poorer micro-vasculature reduces 
oxygen supply and expose the brain to harmful agents such as pro-inflammatory cytokines, 
which are known to be elevated in the periphery of patients with PD (Dzamko et al., 2014; 
Guan et al., 2012). Thus treatments that improve the integrity of the BBB, counter 
inflammation and reduce exposure to free radicals would be expected to improve outcomes in 
PD.  
2.3.7.  Current and emerging therapies  
Current pharmacological therapies for PD primarily focus on treatments that restore DA 
depletion. DA is synthesised in the brain in two stages from the essential amino acid tyrosine. 
First, tyrosine is converted to L-3,4-dihydroxyphenylalanine (L-DOPA) by the rate-limiting 
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enzyme tyrosine hydroxylase. In the second stage L-DOPA is converted to DA by the 
enzyme aromatic L-amino acid decarboxylase (DOPA decarboxylase; Elsworth and Roth, 
1997). DA is metabolised to its inactive metabolites by the enzymes monoamine oxidase 
(MAO), aldehyde dehydrogenase, and catechol- O-methyl transferase (COMT; Elsworth and 
Roth, 1997). 
 Since DA does not cross the BBB its precursor L-DOPA has remained the gold-
standard therapy for the motor symptoms of PD for over fifty years (Smith et al., 2012). L-
DOPA readily crosses the BBB where it is converted to DA and subsequently improves 
motor symptoms for several hours before another dose is required (Hornykiewicz, 2002). L-
DOPA is usually co-administered with a DOPA decarboxylase inhibitor (carbidopa) to 
decrease peripheral conversion to DA and thereby reduce side effects such as nausea and 
vomiting (Schapira et al., 2008). L-DOPA/carbidopa formulations can also be administered 
with a COMT inhibitor to extend the beneficial duration of each dose (Smith et al., 2012). 
Despite its beneficial influence on motor symptoms chronic L-DOPA treatment is associated 
with significant complications such as aggravation of hallucinations, motor fluctuations, 
abnormal involuntary movements (dyskinesia), and the “wearing-off” effect where, over 
time, the beneficial duration of each dose progressively shortens (Schapira et al., 2008; Tarazi 
et al., 2014). The development of these complications advances over time so that about 90% 
of patients with PD will experience these debilitating side-effects after 10 years of L-DOPA 
treatment (Ahlskog and Muenter, 2001). There are also several DA agonists available for the 
treatment of PD that effectively reduce motor symptoms both alone and in combination with 
L-DOPA. DA agonists can delay the time until L-DOPA is needed and enable a lower dose 
of L-DOPA to be used thereby reducing L-DOPA related motor complications (Schapira et 
al., 2008). However, DA agonists can induce dyskinesia in some cases and produce troubling 
non-motor symptoms to a greater extent than L-DOPA treatment (Smith et al., 2012). 
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Another current dopaminergic treatment is MAO-B inhibitors (e.g. selegiline and 
rasagiline) which increase synaptic DA by blocking its metabolism (Schapira, 2011). MAO-B 
inhibitors provide milder symptomatic relief compared to L-DOPA and DA agonists but can 
extend the beneficial influence of each L-DOPA dose during the more advanced stages of PD 
(Schapira, 2011). 
 An effective non-pharmacotherapy is deep brain stimulation (DBS). DBS is used as 
an adjunctive therapy for reducing the motor symptoms of advanced, L-DOPA -responsive 
PD that is not adequately controlled by medication (Okun, 2012). The procedure involves 
electrode implantation to the subthalamic nucleus or the internal segment of the globus 
pallidus (Bronstein et al., 2011). The electrode is connected to an impulse generator which 
delivers electrical stimulation to the target area affecting the firing rate and patterns of 
neurons (Okun, 2012; Tarazi et al., 2014). The DBS procedure improves motor symptoms, 
reduces dyskinesia and can allow for reductions in medication (Bronstein et al., 2011). 
However, DBS is only available to a small number of carefully selected patients who are 
judged as good candidates for the procedure (Bronstein et al., 2011). The procedure can have 
adverse side effects such as intracranial haemorrhage, infection, post-operative seizures, and 
sometimes cognitive impairment (Tarazi et al., 2014). Despite the improvement of motor 
symptoms after DBS there is little evidence that the procedure prevents the progression of 
PD. Eventually many patients who have had DBS develop L-DOPA resistant symptoms such 
as freezing of gait, postural instability, and cognitive decline (Bronstein et al., 2011).   
 The treatments currently available to patients can significantly reduce motor 
symptoms and thus improve quality of life. However, the beneficial influence of these 
treatments is limited and are associated with side effects that contribute to reduce quality of 
life. Furthermore, none of the available treatments prevent the progression of the disease. 
Therefore, there is an urgent need for novel therapies.  
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 There are several emerging therapies for PD that have shown promise in recent years. 
One approach is cell replacement therapy where dopaminergic neurons derived from the 
human embryonic brain are grafted into the striatum of patients with PD. The assumption of 
cell replacement therapy is that DA neurons grafted into the striatum can restore 
dopaminergic neurotransmission and thereby improve motor symptoms (Grealish et al., 
2014). The early clinical trials of cell replacement therapy provided proof of principle that 
transplantation of fetal dopaminergic neurons into the striatum could reduce rigidity and 
bradykinesia, improve the beneficial duration of L-DOPA doses (reduced “off” period), and 
restore DA synthesis in the grafted area (Lindvall et al., 1988, 1990). Furthermore, one study 
showed that grafts provided very long-term reduction in motor impairments for two patients 
when examined at 15 and 18 years after transplantation (Kefalopoulou et al., 2014). Despite 
these very promising results many transplant recipients have not shown improvement and in 
some cases have developed graft-induced dyskinesia (see Barker et al., 2013 for a review). 
More recently, Grealish and colleagues showed that transplanted DA neurons derived from 
human embryonic stem cells provided widespread restoration of DA neurotransmission in a 
rat model of PD thus highlighting their potential use in patients with PD (Grealish et al., 
2014). Although fetal and human embryonic stem cell replacement therapies are promising 
their efficacy will only ever be as good as the best dopaminergic drugs such as L-DOPA, but 
if used early they could significantly reduce the amount of medication required thereby 
adding years of quality life for patients (Barker et al., 2013).  
 An emerging neurorestorative therapy is the use of GDNF as discussed in the 
previous section. The efficacy of GDNF has been examined in several small clinical trials. 
Nutt et al. (2003) administered recombinant GDNF protein into the lateral ventricle for 8 
months using mechanical pumps but found it did not improve motor symptoms and was 
associated with nausea and vomiting. A subsequent post-mortem analysis of one patient 
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revealed that the GDNF did not diffuse out of the ventricles. Therefore, it was unlikely the 
GDNF reached its target tissues, the SN and striatum. In another trial Gill et al. (2003) 
delivered GDNF into the putamen of five patients for one year. This method of delivery 
produced progressive and sustained improvement in motor symptoms, increased flurodopa 
uptake, and did not produce side effects. Similarly, Slevin et al. (2005) found that unilateral 
infusions of GDNF to the putamen for six months in 10 patients produced bilateral 
improvement of motor symptoms with little side effects. These findings are promising 
although they need to be tested in larger studies. In addition, the use of GDNF is limited as it 
does not cross the BBB thus requiring constant intracerebral delivery. A possible solution 
would be to transplant cells that are genetically coded to release GDNF though the use of a 
viral vector. This method of ex vivo gene therapy has produced good results in pre-clinical 
models and was proved to be safe in an initial Phase I clinical trial, however, a Phase II trial 
did not report any beneficial influence on its primary outcome measure after bilateral  
putamen injections (see Kordower and Bjorklund, 2013 for a comprehensive review). Despite 
the negative clinical findings GDNF may prove to be an effective therapy for PD once 
improved routes of delivery have been identified.   
2.3.8.  Need for New Treatments 
The pharmacotherapies currently available for PD provide alleviation of motor symptoms but 
with chronic use significant adverse effects such as dyskinesia and motor fluctuations occur. 
The current surgical treatments available also provide significant improvement of motor 
symptoms but are only available to a small number of ideal patients who over time develop 
medication resistant symptoms despite the surgical intervention. Neither of these treatments 
halts nor reverses the progression of the disease or the eventual worsening of symptoms. 
Several promising treatment approaches have emerged although further research and 
development of these therapies is needed before they can be safely used in patients with PD. 
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Therefore, there is an urgent need to identify novel therapies that will have a beneficial 
influence for patients with PD.   
2.4.  Summary 
PD is a neurodegenerative disorder that is characterised by both motor and non-motor 
symptoms. Current treatments, while initially efficacious for motor symptoms, eventually 
lose their beneficial influence resulting in significant side effects. Therefore, there is a need 
for additional treatment options. One such treatment could be natural progesterone, a 
neurosteroid that has improved outcomes in over 170 preclinical studies of brain injury and 
disease. The following chapter examines the evidence regarding the beneficial influence of 
exogenous progesterone’s treatment after brain injury and disease. The evidence presented in 
this chapter will provide a compelling case for the use of progesterone in an animal model of 
PD.  
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Chapter 3   
Progesterone and Neuroprotection 
3.1.  Objectives 
This chapter provides an overview of the considerable literature over the last 25 years 
regarding the beneficial influence of natural progesterone (PROG) treatment after brain 
injury and disease. This first section overviews the evidence of PROG’s beneficial influence 
in animal models of brain injury. This section briefly summarises literature reviews, key 
findings, and recent studies in this field with a focus on TBI and ischemia as PROG has 
received the most attention in these injury models. The recent Phase II and III clinical trials 
that have used PROG to treat TBI will also be summarised. A key section reviews the modest 
literature regarding the influence of PROG treatment in animal models of PD. Lastly, the 
neuroprotective mechanisms of PROG will be briefly described with an emphasis on those 
mechanisms that are most relevant for the treatment of PD. The evidence presented in this 
chapter will provide a compelling case for the use of PROG treatment in an animal model of 
PD. 
3.2.  Progesterone – Animal Models 
Interest in PROG began in the late 1980s when Stein’s group followed up evidence that 
female rats had less impairment than male rats after acute brain injury. They examined 
pseudopregnant rats (a condition in which PROG levels are high compared to estrogen) and 
found that high levels of PROG was associated with  improved functional outcomes on a 
delayed-spatial alternation task and reduced cerebral edema after experimental TBI compared 
to normal cycling female rats (Attella et al., 1987).  
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To examine more formally this hormonal basis of improved recovery after TBI the 
Stein group measured cerebral edema 24 hours after medial frontal cortex contusions in both 
male and female rats (Roof et al., 1993a). Again, cycling females in proestrus (when levels of 
estrogen are high but PROG is at its lowest level), were compared with  pseudopregnant 
females. They found that female rats in proestrus had less edema than male rats. However, 
the pseudopregnant females, the group with highest levels of PROG, developed almost no 
post-injury edema. Subsequently they administered PROG or estrogen to female 
ovariectomized rats prior to injury and confirmed that PROG was the critical factor 
responsible for reduced edema. This finding showed that PROG had a protective effect 
following TBI. However, for PROG to be considered a realistic treatment for TBI it needed 
to be administered after injury.  
In a series of studies the Stein group showed that exogenous PROG treatment, started 
1 hour after cortical contusion injury, significantly reduced edema levels even in male rats, to 
equivalent levels to female rats treated with PROG (Roof et al., 1992). In addition PROG 
improved spatial navigation in the Morris water maze and reduced secondary neuronal loss in 
the mediodorsal thalamic nucleus (Roof et al., 1994), was able to reduced edema within 6 
hours after injury (Roof et al., 1996), and substantially reduced lipid peroxidation suggesting 
an antioxidant effect of PROG (Roof et al., 1997). Furthermore, they then showed that PROG 
could reduce edema even when the treatment was delayed up to 24 hours after injury 
although the sooner PROG was given, the better the outcome (Roof et al., 1994). These 
studies by the Stein group showed that post-injury administration of PROG improved 
outcomes in rats following TBI. Their research set the stage for future investigations 
regarding PROG’s beneficial influence following brain injury.  
Many publications have now demonstrated the beneficial influence of PROG in the 
treatment of TBI (Cutler et al., 2007; Geddes et al., 2014; Pettus et al., 2005), ischemic stroke 
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(Gibson and Murphy, 2004; Wali et al., 2014; Yousuf et al., 2014) and other injury models 
such as experimental brain resection (Xu et al., 2014), motor neuron disease (Deniselle et al., 
2012), and Alzheimer’s pathology (Carroll et al., 2010). Recent literature reviews have 
identified more than 170 papers using 22 different injury models from 25 independent 
laboratories that report beneficial effects of PROG in experimental models of brain injury and 
disease (Stein and Cekic, 2011; Stein, 2013). The volume of positive findings suggests that 
PROG may be a useful therapeutic and neuroprotective agent for improving outcomes after 
brain injury in general and thus possibly neurodegenerative diseases such as PD.  
It is important to note that all studies considered in this thesis administered the natural 
form of PROG. PROG, a natural progestogen, should not be confused with progestins which 
are synthetic and often proprietary hormones such as medroxyprogesterone acetate (MPA; 
Provera) which is widely used as an oral contraceptive (‘the pill”) and in hormone therapy 
(Stein, 2008). Progestins such as MPA do not mimic all of the beneficial effects of PROG 
and in some cases can exacerbate glutamate excitotoxicity (Stein, 2013). Furthermore, current 
thinking is that the neuroprotective properties of PROG are due in part to its metabolism to 
allopregnanolone (ALLO). Most progestins including MPA do not metabolise to ALLO and 
therefore have a limited range of actions compared to PROG (Schumacher et al., 2014). 
Therefore, PROG can be expected to produce more benefits than progestins due to its far 
wider range of actions.   
The beneficial influence of PROG after brain injury and disease has been extensively 
reviewed in recent publications (e.g. Deutsch et al., 2013; Guennoun et al., 2014; 
Schumacher et al., 2014; Sayeed and Stein, 2009). The general consensus among the reviews 
is that PROG treatment, when given soon after the injury, improves functional and 
pathological outcomes. The reviews give particular attention to experimental models of TBI 
and ischemic stroke as these injuries have received the most attention in the literature. 
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However, extensive research has also found that PROG treatment can prevent seizures in 
animal models (Deutsch et al., 2013). PROG is also beneficial in models of spinal cord 
injury, peripheral nerve injury, motor neuron disease, demyelinating disease, Alzheimer’s 
pathology, intracerebral hemmorage, and meningeal edema (Deutsch et al., 2013). According 
to the Deutsch et al. (2013) review, there is now sufficient preclinical evidence to advance 
PROG to human clinical trials for TBI and stroke. Since their review two Phase III clinical 
trials for TBI have been completed (discussed below) although stroke trials have not yet 
started.  
According to the reviews PROG can improve motor, cognitive, sensory, and affective 
behaviours after injury. For example, PROG improved rotarod performance, spontaneous 
locomotor activity, learning and memory in the Morris water maze and radial arm maze, 
neurological function, grip strength, depression and anxiety-like behaviours, and sensory 
deficits after brain injury (Deutsch et al., 2013; Sayeed and Stein, 2009). This suggests that 
PROG can improve a comprehensive range of functional outcomes. There are a wide range of 
neuroprotective effects that underlie PROG’s ability to improve functional outcomes. These 
include reduced edema, inflammation, apoptosis, and oxidant activity, enhanced myelination, 
and increased brain derived neurotrophic factor (BDNF) to name a few (Deutsch et al., 2013; 
Guennoun et al., 2014; Schumacher et al., 2014; Sayeed and Stein, 2009). The 
neuroprotective mechanisms of PROG are discussed in more detail below. 
 In addition to these literature reviews, there has been a systematic review and a meta-
analysis regarding PROG treatment in experimental models. A systematic review by Gibson 
et al. (2008) found that PROG was effective at reducing lesion volume after ischemia and 
TBI as long as the treatment was initiated soon after injury. However, the authors note that 
PROG was only effective for TBI when the studies had the highest quality score whereas 
PROG was effective following ischemia regardless of the quality score. A recent meta-
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analysis by Wong et al. (2013) assessed lesion volume and mortality after ischemia using 
individual animal data provided by authors of both published and un-published papers. They 
found that PROG significantly reduced lesion volume but was associated with an increase in 
mortality, especially for young female ovariectomized rats. In addition, Wong et al. reported 
a publication bias on lesion volume (i.e. studies that did not find reduced lesion volume were 
less likely to be published). In light of these findings the authors recommended that future 
experiments and meta-analyses report mortality in addition to lesion volume as death rates 
are particularly relevant to future clinical trials. A limitation of the systematic review and 
meta-analysis is that neither study assessed functional outcomes. Future reviews and meta-
analyses should include functional outcomes as current recommendations from the Stroke 
Therapy Academic Industry Roundtable (STAIR) for stroke studies require functional 
assessments before proceeding to clinical trials (Fisher et al., 2009). 
 The reviews and meta-analysis summarised here show that PROG effectively 
improves functional and pathological outcomes after brain injury. In addition to these 
reviews, this chapter provides an overview of the key and recent studies in this field. Key 
examples were selected from the key literature reviews. Recent studies published after the 
literature reviews were also considered.  Table 3.1 provides a summary of key and recent 
studies that have examined the beneficial influence of PROG in animal models of brain injury 
or disease. A brief summary regarding the key features of this table are discussed after its 
presentation. 
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Table 3-1. 
Summary of Progesterone Treatment Studies in Experimental Models of Brain Injury and Disease. 
Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
2010 Carroll et al. Mice, ovx and 
sham female 
transgenic 
AD 2.8mg or 
25mg 
pellet 
Subcutaneous 
implant for 
3x10 (cyclic) 
or 90 
(continuous) 
days 
1. Memory 2.  β-amyloid 
accumulation  
Cyclic but not 
continuous 
treatment 
improved 1, 2
#
 
2008 Frye and 
Walf 
Mice, ovx 
female 
transgenic 
AD 25mg 
pellet 
Subcutaneous 
implant for 6 
months 
1. Memory 
tasks 
Nil Improved 
hippocampus-
cortex mediate 
memory tasks.
#
 
2014 Xu et al.
+
 Rats, adult 
male 
Brain resection 
(surgical brain 
injury) 
10, 20 -12h, +1h, 
+24h, +48h, 
+72h. 
Nil 1. Edema 
2. BBB 
permeability  
3. Inflammation 
4. MMP-9 
Improved all 
outcomes.
#
 
2014 Wali et al.
+
 Rats, 12 
months old 
males. 
FCI(P)  8-32 +1h, +6h, 
+24h then 
every 24h till 
7 days post 
injury
*
 
1. Motor 
2. Sensory 
3. Memory 
4. Infract size Improved all 
outcomes with 
8 and 16 mg/kg 
doses.
#
 
2014 Perez-
Alvarez et al.
 
+
 
Rats, adult 
male 
FCI(P) 4 
combined 
with 0.04 
+6h, +24h, 
+48h 
1.Neurological 
 
2. Reactive 
gliosis 
3. Neuronal 
PROG 
estradiol 
combination 
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
estradiol damage improved 1, 2
.#
 
2012 Ishrat et al. Rats, adult 
males 
FCI(P) 8 +1h, +6h, 
+24h, +48h 
Nil 1. Infract size 
2. Edema 
3. BDNF 
4. Apoptosis 
5. VEGF 
Improved all 
outcomes.
#
 
2010 Ishrat et al. Rats, adult 
males 
FCI(P) 8  +1h, +6h, 
+24h, +48h 
Nil 1. Infract size 
2. BBB 
permeability 
3. Inflammation 
 
Improved all 
outcomes.
#
 
2009 Ishrat et al. Rats, adult 
males 
FCI(P) 8 +1h, +6h, 
+24h, +48h 
1. Motor 
2. Grip 
strength 
3. Infract volume Improved all 
outcomes.
#
 
2007 Sayeed et al. Rats, 90 day 
old males 
FCI(P) 8 +1h, +6h, 
+24h, +48h 
1. Motor 2. Infract volume Improved 1 
and 2.
#
 
1990 Betz and 
Coester 
Rats, adult 
males 
FCI(P) 2 -1h Nil 1. Edema 
2. BBB 
permeability  
Improved 1.
#
 
2005 Gibson et al. Mice, adult 
male 
FCI(T and P) 8 +1h, +6h, 
+24h 
Nil 1. Edema 
2. Infract volume 
3. Inflammation 
Improved all 
outcomes.
#
 
2014 Yousuf et al.
 +
 Rats, 13 
month old 
males 
FCI(T) 8-32 +1h, +6, then 
every 24h till 
7 days post-
1. Motor 
2. Sensory 
3. Memory 
4. Infract size Improved all 
outcomes with 
8 mg/kg
#
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
injury
*
 
2014 Spratt et al.
 +
 Rats, adult 
male 
spontaneously 
hypertensive 
FCI(T) 8 +105mins, 
+6h 
1. Motor 
2. Sensory 
3. Infract volume No 
improvement 
on any 
outcome 
2006 Sayeed et al. Rats, 60 day 
old males 
FCI(T) 8  +2h, +6h Nil 1.Infract volume Improved 1.
#
 
2004 Gibson and 
Murphy 
Mice, adult 
male  
FCI(T) 8 +1h, +6h, 
+24h 
1. Motor 
2. Memory 
3. Infract volume 
4. Body weight 
5. Survival 
Improved 1 
and 3-5.
#
 
2004 Toung et al. Rats, 
reproductively 
senescent 
adult females 
FCI(T) 5 -30min, +2h, 
+6h 
Nil 1. Infract volume No 
improvement  
2002 Murphy et al. Rats, adult 
ovx females 
FCI(T) 5-20 -30min OR -
30, +2h, +6 
Nil 1. Infract volume Repeated 
treatment at 5 
mg/kg 
improved 1.
#
 
2000 Murphy et al. Rats, adult 
ovx females 
FCI(T) 30 or 60 -30mins or 
daily for 7-10 
days prior to 
injury 
Nil 1. Infract volume Exacerbated 
striatal infract 
1999 Chen et al. Rats, adult 
male 
FCI(T) 4-32 +2h 1. Motor 
2. Sensory 
3.Neurological 
4. Infract volume 8 mg/kg 
improved all 
outcomes
.#
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
1996 Jiang et al.  Rats, adult 
males 
FCI(T) 4 -30min, +6h, 
+24h OR 
+2h, 
+6h+24h 
1.Neurological  2. Body weight 
3. Infract volume 
Pre and 
delayed 
treatment 
improved all 
outcomes.
#
 
2014 Li et al.
 +
 Rats, 7 days 
old 
HIE 8 -30mins Nil 1. Neuronal 
structure 
2. Inflammation 
Improved 1 
and 2.
#
 
2012 Deniselle et 
al. 
Wobbler 
mice, male 
and female 
Motor neuron 
disease 
20mg 
pellet 
Subcutaneous 
implant for 
18 days 
Nil 1. Mitochondrial 
function 
2. Amyloid 
precursor protein 
(indicates axon 
degeneration) 
Improved both 
outcomes.
#
 
2002 Gonzalez 
Deniselle et 
al. 
Wobbler 
mice, male 
and female 
Motor neuron 
disease 
20mg 
pellet 
Subcutaneous 
implant for 
15 days 
Nil 1. α3 subunit of 
Na,K-ATPase 
2. Motor neuron 
pathology 
Improved both 
outcomes
.#
 
2014 Liu et al.
 +
 Rats, adult 
male 
Neuropathic 
pain 
5-20 +1min then 
once daily for 
5 or 10 days 
OR +21 days 
then once 
daily for 5 or 
10 days 
1. Allodynia 2. Translocater 
protein 
10 day 
treatment 
started 
immediately 
improve both 
outcomes.
#
 
2011 Coronel et al. Rats, adult SCI 16 Once daily 1. Allodynia 2. Spinal Improved both 
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
males after injury 
for duration 
of study 
(28d) 
noiceptive 
signalling 
outcomes.
#
 
2007 Fee et al. Rats, adult 
male and 
female 
SCI 4-16 +30mins, 
+6h, then 
once daily for 
6 or 14 days 
1. Locomotion 2. Spinal cord 
morphology 
No 
improvement 
although some 
possible grey-
matter sparing 
2014 Si et al.
 +
 Rats, adult 
male 
TBI 16 +1h, +6h, 
+12h 
1.Neurological 2. Inflammation 
3. Edema 
4. BBB 
permeability  
Improved all 
outcomes.
#
 
2014 Robertson 
and 
Saraswati
+
 
Rats, 
immature 
males and 
females 
TBI 10 +1h, + 6h Nil 1. Mitochodrial 
respiratory 
control ratio  
2. glutathione 
(oxidative stress 
marker) 
Males: 1. 
Preseved, 2. 
Prevented loss 
 
Females: 1. 
Not improved 
2. Loss not 
prevented but 
tissue loss 
reduced
#
 
2014 Geddes et al.
+ 
 Rats, males 
28 days old at 
injury 
TBI 4-16 +1h, +3h, 
+24, then 
every 24h till 
7d post-
1. Motor 
2. Memory 
3. Locomotion 
4. Anxiety 
5. Lesion size Improvement 
on all 
outcomes with 
8-16 mg/kg.
#
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
injury
*
 
2013 Tang et al.
 +
 Rats, middle 
aged vitamin 
D deficient 
males. 
TBI 16 and 
VDH 
(5µg/kg) 
PROG +1h, 
+6, then 
every 24h till 
7 days post-
injury
*
 
 
VDH +1h 
1. Memory 
2. Sensory 
3. Grip 
strength 
4. Locomotor 
5. Necrotic cavity 
6. Neuronal loss 
7. GFAP  
Improved 1. 
Combination 
with VDH also 
improved 6 and 
7.
#
 
2012 Cekic et al.
 
 Rats, young 
adult males 
TBI 16 +1h, +6h, 
+24h, then 
every 24h till 
up to 7d post-
injury
*
 
1. Locomotion 2. Pro-apoptotic 
precursors  
3. NGF 
4. BDNF 
Improved 1-3. 
Decreased 
injury 
associated 
increase of 4.
#
 
2012 Peterson et al. Rats, adult 
male 
TBI 10-20 +4h, then 
every 12h for 
72h. 
1. Memory 1. Cortical and 
hippocampal 
tissue loss 
10 mg/kg 
improved both 
outcomes.
#
 
2012 Hua et al. Rats, adult 
male 
TBI 16 and 
 
VDH (1, 
2.5 or 
5µg/kg) 
PROG +1h, 
+6, then 
every 24h till 
7 days post-
injury
*
 
 
VDH +1h 
1. Memory 
2. Sensory 
3. Locomotor  
4. Necrotic cavity 
5. Neuronal death 
6. GFAP 
PROG 
improved 1, 6. 
PROG + VDH 
more 
effective.
#
 
2011 Barha et al. Rats, adult 
male 
TBI 16 +1h, +6, then 
every 24h till 
7 days post-
Nil 1. Cell 
proliferation and 
cell death in the 
Normalized 1.
#
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
injury
*
 
 
dentate gyrus 
2011 Cekic et al. Rats, aged 
males vitamin 
D normal and 
deficient   
TBI 16 +1h, +6, then 
every 24h till 
up to 72h 
post-injury 
1. Locomotion 2. Inflammation Improvement 
on both 
outcomes for 
vitamin D 
normal rats 
only.
#
 
2011 Hua et al. Mice, adult 
male 
TBI 16 +1h, +6h Nil 1. Inflammation 
2. Toll-like 
receptors 
Improved 1. 
Did not change 
2.
#
 
2005 Pettus et al. Rats, adult 
male 
TBI 16 +1h, +6h, 
+24h 
Nil 1. Inflammation Improved 1.
#
 
2005 Djebaili et al. Rats, adult 
male 
TBI 16 +1h, +6h, 
then every 
24h till 5 
days post-
injury 
1. Memory 2. Anti-apoptotic 
proteins 
3. Apoptotic 
DNA 
fragmentation 
4. GFAP 
5. Lesion size 
Improved 1-4.
#
 
2005 Cutler et al. Rats, adult 
male 
TBI 16 +1h, +6h, 
+24h, then 
daily till 7 
days post-
injury (with 
and without
*
) 
1. Anxiety 2. Inflammation 
3. Apoptosis 
Improved all 
outcomes 
although 
sudden 
withdrawal of 
PROG 
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
increased 1 and 
some 
expressions of 
2 and 3.
#
 
2004 Djebaili et al. Rats, adult 
male 
TBI 16 +1h, +6h, 
then every 
24h till 5 
days post-
injury 
1. Memory 2. Apoptosis 
3. Lesion size 
Improved 1 
and 2.
#
 
2003 Goss et al. Rats, adult 
male 
TBI 8-32 +1h, +6h, 
+24h, then 
every 24h ti 5 
days post 
injury 
1. Memory 
2. Anxiety 
3. Sensory 
4. Lesion size Improve 1 but 
not 4. Did not 
change or 
exacerbate 2 
and 3.
#
 
1996 Roof et al. Rats, adult 
males and 
females 
TBI 4 +1h, +6h, 
+24h, then 
every 24h till 
up to 7d post-
injury 
 1. Edema Improved 1 
within 6h. 
Treatment 
delayed for 24h 
still effective.
#
 
1994 Roof et al. Rats, adult 
males 
TBI 4 +1h, +6h, 
+24h, then 
every 24h till 
five days 
post-injury  
1. Memory 2. Neuronal loss 
in mediodorsal 
thalamus 
Improved both 
outcomes.
#
 
2008 Gilmer et al. Rats, young 
adult males 
TBI(moderate) 8-16 +15mins, 
+6h, then 
Nil 1. Edema 
2. Cortical tissue 
No 
improvement 
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Year Authors Species Model of injury 
or disease 
Dose 
range 
(mg/kg) 
Timing of 
dose 
Behavioural 
task type 
Histology Outcomes 
 
every 24h till 
4 days post-
injury (with 
and without
*
) 
sparing on either 
outcome 
Abbreviations:AD=Alzehimer's disease; BBB=blood-brain barrier; BDNF=brain-derived neurotrophic factor; FCI(P)=permanent focal cerebral 
ischemia; FCI(T)=transient focal cerebral ischemia; GFAP=glial fibrillary acidic protein; HIE-hypoxic‑ischemic encephalopathy; MMP-
9=matrix metalloproteinase 9; NGF=nerve growth factor; ovx=ovariectomized; SCI=spinal cord injury; TBI=traumatic brain injury; 
VDH=vitamin D hormone; VEGF=vascular endothelial growth factor; 
*
=studies that used tapered withdrawal of progesterone treatment; 
#
=studies that found progesterone treatment was beneficial.
 +
=recent publications not in reviews; other examples were selected from key reviews.   
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The summary presented in Table 3.1 reports 44 studies across 9 different 
experimental models of key and recent literature regarding PROG’s influence after 
experimental brain injury or disease. Male animals were exclusively used in 39 of the studies 
while females were used in only10 studies of which three studies used ovariectomized 
females (see Table 3.1). The higher proportion of studies that used either male or 
ovariectomized females is not surprising as normal cycling females can complicate findings 
in PROG treatment studies due to hormonal fluctuations during the estrus cycle. 
 Nine of the studies used tapered withdrawal of PROG treatment (Barha et al., 2012; 
Cekic et al., 2012; Cutler et al., 2005; Geddes et al., 2014; Gilmer et al., 2008; Hua et al., 
2012;  Tang et al., 2013; Wali et al., 2014; Yousuf et al., 2014). Each of these studies gave 
repeated doses of PROG for up to 7 days post-injury. Tapered withdrawal of PROG 
following repeated dosing is important as abruptly ceasing treatment can exacerbate the 
injury, produce an inflammatory rebound effect, and increase anxiety like behaviours (Cutler 
et al., 2005; Cutler et al., 2006).  Tapered withdrawal of PROG overcomes this withdrawal 
syndrome (Cutler et al., 2005). 
Thirty-nine of the 44 studies found that PROG treatment was beneficial. PROG 
improved functional and/or neuropathological outcomes following TBI in 17 studies (Barha 
et al., 2012; Cekic et al., 2011; Cekic et al., 2012; Cutler et al., 2005; Djebaili et al., 2004; 
Djebaili et al., 2005; Geddes et al., 2014; Goss et al., 2003; Hua et al., 2011; Hua et al., 2012; 
Peterson et al., 2012; Pettus et al., 2005; Robertson and Saraswati, 2014;  Roof et al., 1994; 
Roof et al., 1996; Si et al., 2014; Tang et al., 2013), permanent focal cerebral ischemia in six 
studies (Betz and Coester, 1990; Gibson et al., 2005; Ishrat et al., 2012, 2011, 2010; Perez-
Alvarez et al., 2014; Sayeed et al., 2007; Wali et al., 2014), transient focal ischemia in seven 
studies (Chen et al., 1999; Gibson and Murphy, 2004; Gibson et al., 2005; Jiang et al., 1996; 
Murphy et al., 2004; Sayeed et al., 2006; Yousuf et al., 2014), motor neuron disease in two 
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studies (Deniselle et al., 2012; Gonzalez Deniselle et al., 2002), Alzheimer’s pathology in 
two studies (Carroll et al., 2010; Frye and Walf, 2008), spinal cord injury in two studies 
(Coronel et al., 2011; Si et al., 2014), hypoxic‑ischemic encephalopathy in one study (Li et 
al., 2014), surgical brain injury in one study (Xu et al., 2014), and neuropathic pain in one 
study (Liu et al., 2014). Taken together, these studies show that PROG has consistently 
improved outcomes across numerous brain injury and disease models.  
 Table 3.1 also shows that PROG improves functional outcomes after brain injury. For 
example, PROG treatment improves motor skill on the rota-rod, spatial memory and learning 
in the Morris water maze, and neurological severity score after TBI (e.g. Djebaili et al., 2004; 
Geddes et al., 2014; Si et al., 2014;). Likewise, after ischemic injury PROG treatment 
improves each these outcomes in addition to improving grip strength and sensory deficits in a 
sticky adhesive removal task (e.g. Chen et al., 1999;Ishrat et al., 2009; Wali et al., 2014; 
Yousuf et al., 2014). In addition, PROG improves numerous pathological consequences 
following brain injury. For example PROG reduces cerebral edema, inflammation, BBB 
permeability, and apoptosis, and increases trophic factors and neuronal survival following 
TBI (e.g Barha et al., 2011; Cekic et al., 2012; Culter et al., 2005; Hua et al, 2011; Roof et al., 
1996; Si et al., 2014;). PROG treatment also reduces infract volume, inflammation, BBB 
permeability, and apoptosis, and increases trophic factors after ischemic injury (e.g. Ishrat et 
al., 2009, 2010, 2012; Sayeed et al., 2007; Wali et al., 2014). Such findings show that PROG 
is a pleiotropic agent with complex effects that improves functional outcomes via numerous 
pathophysiological and biochemical mechanisms. 
Despite the large number of studies reporting positive outcomes not everyone agrees 
that PROG is beneficial. Five of the 44 studies did not report beneficial outcomes following 
PROG treatment. The study by Fee et al. (2007) found no beneficial influence of PROG in a 
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model of spinal cord injury although there was some possible grey-matter sparing. Another 
study found no benefit of PROG treatment following a moderate unilateral TBI injury, even 
with tapered withdrawal of PROG treatment (Gilmer et al., 2008). The authors suggested that 
that PROG may not be beneficial for all types of brain injuries which is a possibility that 
needs to be investigated further. Three studies found that PROG did not improve outcomes 
following transient focal cerebral ischemia (Murphy et al., 2000; Spratt et al., 2014; Toung et 
al., 2004). Toung et al. (2004) reported that PROG treatment did not reduce infract volume in 
reproductively senescent female rats. In their study, however, they administered PROG prior 
to injury then abruptly stopped treatment six hours after injury. The lack of improvement in 
their study could be explained by the sudden withdrawal of PROG triggering a withdrawal 
syndrome during the post-ischemic reperfusion period. In another study, Murphy et al. (2000) 
found that PROG treatment actually exacerbated striatal stroke injury. In that study PROG 
was administered at very high doses (30 or 60 mg/kg) for up to 10 days prior to injury and 
then abruptly stopped. This finding is readily explained by PROG withdrawal syndrome 
exacerbating the injury as was confirmed by Cutler et al. (2005). Therefore, rather than 
weakening the case for PROG this study highlights the importance of tapered withdrawal, 
especially when large doses are used. More recently, Spratt et al. (2014) did not find any 
beneficial influence of PROG treatment administered at 105mins and again at 6 hours after 
ischemic injury in hypertensive rats. Therefore, it is possible that PROG is not beneficial in 
subjects with comorbidities such as hypertension.  
 In summary, the studies reported in Table 3.1 provide very strong evidence that 
PROG improves outcomes following brain injury or disease. There were a surprisingly small 
proportion of negative reports regarding the influence of PROG following brain injury. The 
findings of some of these negative reports are explained by PROG withdrawal syndrome that 
is triggered by abrupt cessation of treatment thus highlighting the importance of tapered 
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withdrawal following repeated dosing of PROG. Importantly, PROG treatment improved 
numerous functional and neuropathological outcomes in 39 of the 44 studies across 9 
different models of brain injury or disease. As discussed above, PROG has improved 
outcomes in over 170 pre-clinical studies across 22 injury models with few negative reports 
(Stein, 2013). Therefore, it is possible that PROG will be beneficial in an animal model of PD 
also.  
3.3.  Progesterone – Clinical Studies 
Based on the compelling preclinical data presented earlier in this chapter two independent 
Phase II clinical trials using PROG to treat TBI were completed, with encouraging findings. 
Each of these studies were single-centre, randomized, double-blind, placebo-controlled trials 
(Table 3.2).  
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Table 3-2. 
Summary of the Phase II Clinical Trials Used to Examine Progesterone’s Efficacy in TBI 
Patients. 
Characteristics ProTECT II  
(Wright et al., 2007) 
Xiao et al. (2008) 
Country US China 
Glasgow coma scale (GCS) at 
enrolment  
4 to 12 ≤8 
Time after injury <11h <8h 
Deliver method (length) Intravenous (3 days) Intramuscular (5 days) 
Outcome assessment post-
injury 
30 days 3 and 6 months 
Patients 100 159 
Primary endpoint GOS-E; DRS; Mortality  GOS; Mortality and the 
modified FIM 
Abbreviations:GOS=Glasgow Outcome scale; GOS-E=Glasgow Outcome Scale-extended; 
DRS=Disability Rating Scale; FIM=Functional Independence Measure (adapted from Wei et 
al., 2013). 
 
ProTECT II (Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment) 
enrolled 100 patients presenting with moderate to severe brain injury (Wright et al., 2007). 
Patients with severe brain injury who were given 3 days of intravenous PROG had a 50% 
reduction in mortality at day 30 compared to placebo control patients (p<0.06). In 
comparison, patients with moderate brain injury showed significant signs of improvement on 
their disability rating scale outcome at day 30 after injury (p<0.02). These findings suggested 
that PROG was beneficial for both moderate and severe brain injury. These findings were 
supported in a second independent Phase II trial conducted in China that enrolled 159 patients 
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with severe brain injury (Xiao et al., 2008). The Xiao et al. (2008) trial administered PROG 
intramuscularly for five days then tracked patient outcomes at 3 and 6 months after injury. 
PROG treated patients had significantly better survival and functional outcomes at both 3 and 
6 months after injury. Therefore, in both trials PROG improved survival, but more 
importantly it also improved functional outcomes.   
 Building on the compelling preclinical evidence and the encouraging Phase II clinical 
trials two independent large-scale, multi-centre Phase III trials were conducted. As 
previously, these were randomized, double-blind, placebo-controlled trials (Table 3.3).  
Table 3-3. 
Summary of the Phase III Clinical Trials Used to Examine Progesterone’s efficacy in TBI 
Patients. 
Characteristics ProTECT III  
(Wright et al., 2014) 
SyNAPSe 
(Skolnick et al., 2014) 
Country US International  
Glasgow coma scale (GCS) 
at enrolment 
4 to 12 ≤8 
Time after injury <4h <8h 
Deliver method (length) Intravenous (4 days) Intravenous (5 days) 
Primary outcome measures GOS-E GOS 
Secondary outcome measures  Mortality, DRS Mortality, SF-36 
Patients  882 1195 
Abbreviations:GOS=Glasgow Outcome Scale; GOS-E=Glasgow Outcome Scale-extended; 
DRS=Disability Rating Scale; SF-36=Short-Form Health Survey. 
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 ProTECT III enrolled 882 of the planned 1140 patients presenting with moderate-
severe brain injury before the trial was stopped for futility with respect to the primary 
outcome measure (Wright et al., 2014). There was no significant difference between the 
PROG treated and placebo control groups on either the Glasgow Outcome Scale-extended 
primary measure or for the mortality or Disability Rating Scale secondary outcome measures. 
In a similar finding, the SyNAPSe (Study of a Neuroprotective Agent, Progesterone, in 
Severe Traumatic Brain Injury) trial enrolled 1195 patients presenting with severe brain 
injury (Skolnick et al., 2014). In this trial there was no significant difference between the 
PROG treated and placebo control groups on either the Glasgow Outcome Scale primary 
outcome measure or for the mortality or Short-Form Health Survey secondary outcome 
measures. The conclusion of these trials is that PROG showed no clinical benefit over 
placebo for any of the outcome measures. Despite the compelling preclinical data and 
encouraging Phase II clinical findings PROG did not translate to large-scale multi-centre 
clinical trials for human TBI.  
 The disappointing results of these two Phase III trials could be due to several factors 
such as heterogeneity of the injury, insensitive outcome measures, and characteristics of 
individual patients such as pre-existing conditions (Skolnick et al., 2014; Wright et al., 2014). 
In preclinical work using animals each of these factors can be well controlled yet they are 
significant contributors to outcomes in human TBI (Wright et al., 2014). Wright et al. (2014) 
suggests that success at translating from bench to bedside may require new clinical testing 
paradigms such as adaptive trial design and profiling of patients who had a response during 
early phase trials.  
Another approach, recommended by Stein (2014), is instead of enrolling patients with 
many different kinds of brain injury, restrict enrolment to more limited injuries such as 
temporal cortex damage. These trials would better parallel the precise modelling used in high 
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quality laboratory research. Stein argues that performing clinical trials in this manner would 
save time and money as fewer patients across fewer centres would need to be enrolled. The 
data gathered would be more concise, easier to interpret, and thus more likely to reveal 
consistent treatment effects where they exist. Employing this paradigm would mean 
numerous smaller, more affordable, and more focused trials could be run. Conversely, 
Jickling and Sharp (2014) argue that preclinical models should be overhauled to better 
replicate the clinical picture. This would include producing heterogeneous injuries and 
adopting similar outcome measures in the laboratory that are used in clinical trials.  Whether 
future clinical trials for PROG in other injury models should use the current paradigm or an 
alternative approach such as adaptive trial design will no doubt be debated. 
 Despite the negative findings in the Phase III trials for TBI, considerable evidence 
still exists regarding PROG’s beneficial influence in models of TBI and ischemia. The 
convincing preclinical evidence nonetheless lends support to establish PROG’s efficacy in 
other disease models such as PD. 
3.4.  Progesterone in Animal Models of Parkinson’s disease 
To the author’s knowledge, nine studies have examined the beneficial influence of PROG 
treatment in animal models of PD. These studies are summarised in Table 3.4. 
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Table 3-4. 
Summary of Progesterone Treatment Studies in Animal Models of Parkinson’s disease. 
Year Authors Species Model of 
Parkinson’s 
disease 
Dose  Timing of 
dose 
Behavioural 
tasks 
Histology Outcomes 
2015 Yunes et al. Rats, adults male 6-OHDA – 
Striatal one 
site 
 
4 mg/kg Once 
daily for 
three days 
starting 7 
days after 
surgery 
1. Rotation after 
amphetamine 
2. Rotation after 
apomorphine 
3. 3α-
hydroxysteroid 
oxidoreductase  
Improved 1 and 
2. Increased 
ipsilateral 
striatal 
expression of 3. 
2013 Casas et al. Rats, adult male 6-OHDA – 
Striatal one 
site 
 
4 mg/kg  Once 
daily for 
three days 
starting 7 
days after 
surgery 
1. Rotation after 
amphetamine  
2. Open field. 
3. K
+
 evoked, 
[
3
H]-DA, [
3
H]-
Glutamate, and 
[
3
H]-GABA 
release from 
striatal slices 
No behavioural 
change, ↑DA, 
↓glutamate, no 
change in 
GABA. 
#
 
 
2011 Casas et al. Rats, adult male 6-OHDA – 
Striatal one 
4 mg/kg Once 
daily for 
1. Rotation after 
apomorphine  
Syringe 
placement only 
Prevented 
contralateral 
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Year Authors Species Model of 
Parkinson’s 
disease 
Dose  Timing of 
dose 
Behavioural 
tasks 
Histology Outcomes 
site 
 
three days 
starting 7 
days after 
surgery 
2. Open field  
3. Novel object 
recognition  
4. Forced swim 
test 
rotation, 
↑object 
recognition, 
↑forced swim 
test.
#
 
 
2011 Chao et al. Rats, adult male 6-OHDA – 
Striatal four 
sites 
 
4 mg/kg and 8 
mg/kg  
Once 
daily for 
13 days 
starting 
24 hours 
after 
surgery 
1. Spontaneous 
and 
2. apomorphine 
rotation 
3. Grid walking, 
4. Cylinder 
5. Open field 
6. DA,  
7. DOPAC  
8. HVA, 
9. 5-HIAA 
striatal 
concentrations 
↑Spontaneous 
rotation 
asymmetry, 
↑foot slips on 
grid, 
↓Symmetrical 
forelimb use in 
cylinder, 
↑DOPAC/DA 
ratio.
!
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Year Authors Species Model of 
Parkinson’s 
disease 
Dose  Timing of 
dose 
Behavioural 
tasks 
Histology Outcomes 
2002 Yu et al. Gonadectomized 
male and female 
mice at 4 and 6 
weeks of age 
MA (four 
injections, 
10 mg/kg 
s.c. at 2-h 
intervals) 
 
0.47µg/day  Three 
days prior 
to first 
MA 
injection 
Nil 1. DA 
2. DOPAC  
3. 5-HIAA 
Striatal 
concentrations 
No change for 4 
week old mice 
 
↑DA and 
DOPAC for 6 
week old male 
mice only.
#
 
 
2001 Callier et al. Retired breeder 
male mice 
MPTP (four 
injections, 
15 mg/kg 
i.p. at 2-h 
intervals) 
 
2 µg/day  Ten days 
starting 5 
days 
before 
MPTP 
injections. 
Nil 1. DAT-specific 
binding in 
striatum  
2.DAT mRNA 
in SN.  
3. Striatal [
3
H]-
Glutamate, and 
[
3
H]-AMPA 
binding 
↑DAT in 
striatum but not 
SN.
#
 
 
Striatal [
3
H]-
Glutamate, and 
[
3
H]-AMPA 
binding 
unchanged 
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Year Authors Species Model of 
Parkinson’s 
disease 
Dose  Timing of 
dose 
Behavioural 
tasks 
Histology Outcomes 
  
2000 Grandbois et 
al. 
Retired breeder 
male mice 
MPTP (four 
injections, 
15 mg/kg 
i.p. at 2-h 
intervals) 
 
2 µg/day  Ten days 
starting 
five days 
before 
MPTP 
injections. 
Nil 1. DA 
2. DOPCA  
3. HVA 
striatal 
concentrations 
↑DA, DOPAC, 
HVA 
concentrations
#
 
 
2000 Yu and Liao Ovariectomized 
female mice 
MA (four 
injections, 
10 mg/kg 
s.c. at 2-h 
intervals) 
 
0.467 mg/day  Three 
days prior 
to first 
MA 
injection 
Nil 1. DA  
2. DOPAC 
3. HVA 
4. 5-HIAA  
Striatal 
concentrations 
↑DA with 
PROG 
↑DOPAC when 
combined with 
estradiol 
benzoate
#
 
1992 Gomez-
Mancilla and 
Bedard 
Ovariectomized 
female 
cynomolgus 
monkeys 
MPTP 
(0.3mg/kg 
i.v injection)  
0.1 mg/day Once 
daily for 7 
days. 
1. Canadian 
disability scale, 
2. L-DOPA 
induced 
Nil PROG did not 
improve the 
beneficial 
influence of L-
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Year Authors Species Model of 
Parkinson’s 
disease 
Dose  Timing of 
dose 
Behavioural 
tasks 
Histology Outcomes 
dyskinesia DOPA on 1 or 
2. 
Abbreviations: 5-HIAA=5-Hydoxyindoleacetic acid; 6-OHDA=6-hydroxydopamine; AMPA=α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; DA=dopamine; DAT=dopamine transporter; DOPAC=3,4-Dihydroxyphenylacet acid; GABA=gamma-Aminobutyric 
acid; HVA=homovanillic acid; MA=methamphetamine; MPTP=1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; mRNA=messenger ribonucleic 
acid; SN=substantia nigra; 
#
=studies that found progesterone treatment was beneficial; 
!
=studies that found progesterone treatment exacerbated 
motor impairments. 
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Four different models of PD have been used. Four of these studies used unilateral 6-
hydroxydopamine (6-OHDA) lesions of the striatum in adult male rats (Casas et al., 2011, 
2013; Chao et al., 2011; Yunes et al., 2015). Two studies used systemic administration of 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in adult male mice (Callier et al., 2001; 
Grandbois et al., 2000). One study used systemic administration of MPTP in adult female 
monkeys (Gomez-Mancilla & Bedard, 1992). Two studies used the less common model of 
systemic administration of methamphetamine and this was in gonadectomized male and 
female mice (Yu et al., 2002; Yu and Liao, 2000). Each of these models produces a 
parkinsonian syndrome by selectively killing dopaminergic neurons in the SN (see Chapter 4 
for further discussion regarding animal models of PD). Seven of the nine studies found that 
PROG treatment was beneficial (Casas et al. 2013, 2011; Yu et al., 2002; Callier et al., 2001; 
Grandbois et al., 2000; Yu and Liao, 2000) while one study found that PROG was not 
beneficial (Gomez-Mancilla & Bedard, 1992) and one study found that PROG exacerbated 
impairments (Chao et al., 2011). 
Casas et al. (2011) administered 4 mg/kg PROG once daily for three days starting at 
day 7 after unilateral striatal 6-OHDA lesion surgery in male rats. At four weeks after surgery 
PROG prevented depressive like behaviour in a forced swim test, improved memory deficit 
in a novel object recognition test, and prevented contralateral rotation after apomorphine. In a 
subsequent study Casas et al. (2013) examined open field behaviour and rotation after d-
amphetamine at two weeks and K
+
-evoked [
3
H]-DA, [
3
H]-Glutamate, and [
3
H]-gamma-
Aminobutyric acid (GABA) release from striatal slices at eight weeks using the same model 
of PD and PROG treatment. They found that PROG treatment did not influence open field or 
rotation after d-amphetamine behaviour but it increased DA, decreased glutamate, and did not 
influence GABA release in the lesioned striatum. This second study suggested a 
neuroprotective and neuromodulatory effect of PROG after 6-OHDA lesions. In another 
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study using the same lesion and PROG treatment protocols as Casas et al. (2011, 2013) 
Yunes et al. (2015) found that PROG reduced rotation after d-amphetamine at two weeks and 
apomorphine at eight weeks after lesion surgery. PROG also increased ipsilateral striatum 
expression of 3α-hydroxysteroid oxidoreductase, an enzyme that catalyses PROG to its 
neuroactive and neuroprotective metabolite allopregnanolone (Ishrat et al., 2010). This 
finding suggested a sustained neuroprotective effect of PROG that could be modulated 
through increased expression 3α-hydroxysteroid oxidoreductase. The findings by Casas et al. 
(2011, 2013) and Yunes et al. (2015) are encouraging as they show that brief PROG 
treatment initiated seven days after lesion surgery can improve functional and pathological 
outcomes in the long term after lesion surgery. 
 The Grandbois et al. (2000) study found that low dose PROG treatment, initiated prior 
to MPTP, prevented loss of DA and its metabolites 3,4-Dihydroxyphenylacet acid (DOPAC) 
and homovanillic acid (HVA) when measured six days after MPTP administration. In a 
follow-up study the same group investigated the mechanism by which PROG exerted its 
neuroprotective activity using the same PROG and MPTP treatment methods (Callier et al., 
2001). They found that PROG treatment prevented loss of dopamine transporter (DAT) in the 
striatum but not in the SN suggesting PROG provided its neuroprotection by blocking MPTP 
entry to the SN nerve terminals in the striatum which then led to increased DA in the 
extracellular space (Callier et al., 2001).  
 Improved outcomes after PROG treatment have also been observed in 
methamphetamine models of PD. Yu and Liao (2000) found that a low dose PROG 
(0.467mg/day) treatment prior to methamphetamine administration reduced loss of striatal 
DA in female mice ovariectomized at 6 weeks of age. In a similar study Yu et al. (2002) 
administered a very low dose of PROG (0.47µg/day) and methamphetamine as previous but 
to male and female mice gonadectomised at 4 and 6 weeks of age. The only beneficial 
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influence they found was reduced DA and DOPAC loss for 6 week old male mice. Hence 
PROG’s beneficial influence after methamphetamine toxicity may be age and sex dependent. 
The inconsistency in their studies regarding PROG’s beneficial influence in female 
ovariectomized rats is explained by the different PROG doses they used. The beneficial 
influence observed in first study (Yu and Liao, 2000) used a higher dose of PROG than the 
second study (Yu et al. 2002). Therefore, females may require a higher dose of PROG to 
experience benefits in the methamphetamine model (Yu et al., 2002).  
 The study by Gomez-Mancilla and Bedard (1992) used monkeys with L-DOPA 
induced dyskinesia that had been rendered Parkinsonian by MPTP injections. PROG 
treatment was started approximately two-three months after the MPTP injection. PROG was 
administered at 0.1 mg/day for seven days then combined with L-DOPA on day 8. PROG did 
not reduce L-DOPA induced dyskinesia or provide any additional relief of Parkinsonism. The 
lack of benefit of PROG was likely due to the timing of treatment. PROG was administered 
after the MPTP induced neuronal death was complete thus reducing PROGs opportunity for 
neuroprotection. This finding suggests that PROG treatment should be started before the 
lesion is complete to give PROG an opportunity to provide neuroprotection.  In contrast 
to the positive findings one study found that PROG actually exacerbated impairments after 
unilateral 6-OHDA lesions of the striatum which could be explained by the timing of PROG 
treatment after surgery (Chao et al., 2011). These authors administered PROG daily for 13 
days, starting 24 hours after lesion surgery. Compared to vehicle treated rats with lesions, 
PROG increased hindlimb slips on an elevated grid, decreased symmetrical use of the 
forelimbs in a cylinder task, increased spontaneous rotation, increased DA/DOPAC ratio, and 
a produced non-significant trend for reduced striatal DA. However, PROG treatment did not 
influence rotation after apomorphine or ipsilateral forelimb use asymmetry in the cylinder. 
Following 6-OHDA infusions to the striatum the neurotoxin takes approximately 3 days to 
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metabolise and produce SN cell death (Cicchetti et al., 2002; Walsh et al., 2011). 
Administering PROG at 24 hours after surgery would have produced interactions with 6-
OHDA metabolism that could have exacerbated the lesion and subsequent motor 
impairments. Therefore, like Casas et al. (2011, 2013), PROG treatment should be started 
sometime after day 3 post 6-OHDA lesion surgery.   
 The studies reviewed here show that PROG treatment can protect mid brain dopamine 
and improve some functional outcomes in animal models of PD. However, the literature 
regarding PROG’s beneficial influence in animal models of PD is scarce leaving a number of 
critical questions unanswered. First, none of the studies thoroughly examined PROG’s 
influence on motor impairments. The Chao et al. (2011) study is good in that it included 
several motor skill tests, but it only tested rats in the short-term and gave PROG too soon 
after lesion surgery. Casas et al. (2011, 2013) and Yunes et al. (2015) investigated affective 
and cognitive behaviour but only examined motor skills using drug induced rotation and open 
field. The Gomez-Mancilla and Bedard (1992) study assessed relief of Parkinsonian 
symptoms in monkeys but gave PROG too long after MPTP lesions. A broad examination of 
motor skills is required to demonstrate which symptoms might be improved by PROG 
treatment. Second, none of the studies examined functional impairments in both the short and 
long-term after lesion surgery. Testing motor skills in both the short and long-term is 
essential to demonstrate both initial and sustained benefit of PROG treatment. Finally, none 
of the reviewed studies directly compared PROG’s influence following small and large 
dopamine depleting lesions. Investigating PROG’s influence after small and large lesions will 
determine if PROG is beneficial at different stages of striatal-SN degeneration. Each of these 
questions is addressed in the experimental chapters of this thesis (Chapters 5-7). 
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3.5.  Neuroprotective Mechanisms of Progesterone  
This section provides a brief overview regarding the mechanisms that underlie PROG 
neuroprotection (Fig. 3.1). This section places an emphasis on those mechanisms that are 
particularly relevant to the treatment of PD.  
As discussed above there is substantial preclinical evidence that shows PROG is 
beneficial in the treatment of TBI (Culter et al., 2005; Cekic et al., 2012; Geddes et al., 2014), 
ischemia (Ishrat et al., 2012; Wali et al., 2014; Yousuf et al., 2014), and models of 
neurodegenerative disease such as Alzheimer’s pathology (Frye and Walf, 2008) and motor 
neuron disease (Deniselle et al., 2012). It is likely that the observed benefits in these models 
are due to the interacting pleiotropic actions that underlie PROG’s neuroprotection. These 
pleiotropic actions are briefly described below.  
Figure 3.1. Flow chart summarising progesterone’s neuroprotective mechanisms that are 
relevant to the pathology of Parkinson’s disease (figure adapted from Sayeed and Stein, 
2009). 
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Inflammation. Inflammation is a key contributor to secondary loss after brain injury. 
PROG’s actions on the inflammatory pathway contribute to neuroprotection following brain 
injury (Deutsch et al., 2013). Activated microglia are cells that have pro-inflammatory effects 
after injury or disease. PROG is known to reduce microglia activation in models of spinal 
cord injury (Labombarda et al., 2011) and demyelinating disease (Garay et al., 2012). 
Interestingly, in one study PROG actually increased the expression of activated microglia 
after TBI although edema was still reduced (Grossman et al., 2004). The production of pro-
inflammatory cytokines such as TNF-α and IL-1 is another inflammatory response to brain 
injury and disease (Qian and Flood, 2008). PROG reduces the production of pro-
inflammatory cytokines after TBI (Chen et al., 2008; Cutler et al., 2007; Pettus et al., 2005), 
ischemia (Gibson et al., 2005; Ishrat et al., 2010; Jiang et al., 2009), and demyelinating 
disease (Garay et al., 2012). Reduction of inflammation is critical for the treatment of brain 
injury and disease as prolonged inflammation can promote additional injury and 
neurodegeneration (Skaper, 2007). Furthermore, activated microglia and increased expression 
of pro-inflammatory cytokines are implicated in the neurodegenerative process in PD 
(Peterson and Flood, 2012). Therefore, PROG treatment may be beneficial in PD by reducing 
inflammation.  
Lipid peroxidation, mitochondrial function, and oxidative stress. Another 
mechanism underlying PROG’s neuroprotection is the reduction of oxidative stress. After 
TBI PROG reduces lipid peroxidation (Roof et al., 1997), prevents reduction of the 
antioxidant glutathione (Robertsonson and Sarawati, 2014), and normalises mitochondrial 
respiration (Robsertson et al., 2006). Following ischemic injury PROG administration 
attenuated the stroke-induced expression of inducible nitric oxide synthase and the 
production of inducible nitric oxide synthase-derived nitric oxide (Coughlan et al., 2005). In 
addition, PROG attenuated the ischemia-induce reduction of glutathione in one study 
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(Ozacmak and Sayan, 2009). In another study, it decreased lipid peroxidation and increased 
the expression of the antioxidants glutathione, superoxide dismutase, and catalase after 
ischemic injury (Aggarwal et al., 2008). PROG treatment prevented the increase of 
mitochondrial nitric oxide synthase and prevented reduction of mitochondrial respiratory 
complex I in the Wobbler mouse model of amyotrophic lateral sclerosis (Deniselle et al., 
2012). Reducing oxidative stress is relevant to the treatment of PD as reactive oxygen species 
and nitric oxide are generated by activated microglia and deficient mitochondrial complex I 
respiration (including reduced levels of glutathione), which in turn mediate 
neurodegeneration (Dias et al., 2013; Peterson and Flood, 2012; Subrananiam and Chesselet, 
2013).  
Neuronal apoptosis and survival. Another beneficial influence of PROG after brain 
injury is to enhance neuronal survival and decrease apoptosis. After TBI PROG reduced 
neuronal loss in the CA1 and CA3 subfields of the hippocampus (Robertson et al., 2006), 
reduced secondary neuronal loss in the mediodorsal thalamic nucleus (Roof et al., 1994) and 
normalized cell proliferation and cell death in the dentate gyrus (Barha et al., 2011). 
Similarly, PROG improved survival of pyramidal neurons in the CA1 and CA2 sub-regions 
of hippocampus after ischemia (Morali et al., 2005). Related to neuronal survival is the well-
established finding that PROG reduces infract volume after ischemia (e.g. Ishrat et al., 2009, 
2010, 2012; Murphy et al., 2002; Wali et al., 2014; Yousuf et al., 2014). The increased 
survival of neurons may be due in part to PROG’s influence on apoptosis. PROG reduces 
pro-apoptotic factors such as caspase-3, bax, and bad (Cutler et al., 2007; Djebaili et al., 
2005; Yao et al., 2005) and increases the anti-apoptotic factors Bcl-2 and Bcl-XL in the 
injured cortex after TBI (Yao et al., 2005). Likewise, following ischemia PROG reduces 
caspase-3 expression (Ishrat et al., 2012). The mechanisms regarding neuronal cell death in 
PD are not fully understood although it is thought to involve a combination of  Lewy body 
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pathology, mitochondrial dysfunction, oxidative stress, and inflammation (Hirsch et al., 2012; 
Levy et al., 2009). PROG administration can improve several of these triggers which would 
in turn improve neuronal survival in PD.  
Neurotrophic support. Neurotrophic factors promote development, survival, 
restoration, and growth in the central nervous system (Althaus et al., 2008; Smith et al., 
2012). PROG treatment upregulates brain-derived neurotrophic factor (BDNF) following 
TBI, while simultaneously downregulating the expression of the proBDNF and proNGF 
which are pro-apoptotic precursors to BDNF and nerve growth factor (NGF; Cekic et al., 
2012). PROG also upregulates the expression of BDNF after ischemia (Coughlan et al., 
2009), spinal cord injury (De Nicola et al., 2006), and motor neuron disease (Meyer et al., 
2013). PROG’s ability to increase the expression of BDNF is interesting as this neurotrophic 
factor is a target of interest for the treatment of PD (Smith et al., 2012). 
Midbrain dopamine. Loss of nigrostriatal DA is one of the pathological hallmarks of 
PD (Dauer and Przedborski, 2003). PROG can protect midbrain DA in models of PD. For 
example, exogenous PROG administered prior to MPTP or methamphetamine prevented loss 
of striatal DA (Grandbois et al., 2000; Yu et al., 2002; Yu and Liao, 2000). Additionally, 
PROG when administered for three days starting at day 7 after 6-OHDA lesions improved 
K
+
-evoked release of DA from striatal slices. Protection of midbrain DA by PROG would 
improve outcomes in PD.  
Edema and blood-brain barrier. Cerebral edema is a serious side effect of brain 
injury. Edema can produce intracranial swelling, free radicals, and subsequently neuronal 
death. Controlling edema can improve functional outcomes (Roof et al., 1996). PROG when 
administered after injury reduces cerebral edema following TBI (Grossman et al., 2004; Roof 
et al., 1992, 1996), ischemia (Betz and Coester, 1990; Gibson et al., 2005), and experimental 
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surgical brain injury (Xu et al., 2014). PROG reduces cerebral edema through several 
mechanisms. PROG preserves BBB integrity which prevents the indiscriminate flow of 
water, ions, and inflammatory factors across the membrane (Stein et al., 2008). PROG 
reduces expression of aquaporin-4, a molecule that controls water drainage, in the area 
around the lesion and lateral ventricles (Guo et al., 2006). PROG also reduces the second 
phase of edema which involves the accumulation of fluid inside neurons and reactive 
astrocytes (Guo et al., 2006; Stein et al., 2008). Although not usually associated with PD, 
PROG’s ability to control edema contributes to the growing evidence that PROG is a 
pleiotropic agent. Interestingly, there is speculation that altered aquaporins may contribute to 
the pathology of PD (Foglio and Fabrizio, 2010; Fukuda and Badaut, 2012). Aquaporins may 
represent a novel therapeutic target for PD; however, their role in PD pathology is poorly 
understood.   
Breakdown of the BBB contributes to neuronal injury after TBI and ischemia (Ishrat 
et al., 2010). PROG preserves BBB integrity by reducing the expression of matrix 
metalloproteinases (MMPs) after ischemia and experimental surgical brain injury (Ishrat et 
al., 2010; Xu et al., 2014). MMPs are agents that contribute to the breakdown of BBB 
integrity by degrading endothelial tight junction proteins (Ishrat et al., 2010). PROG could 
improve BBB integrity in PD as altered expression of MMPs (Rosenberg, 2009) and damage 
to endothelial cells (Guan et al., 2012) have been implicated in the disease.  
3.6.  Summary 
The evidence presented in this chapter shows that PROG is a pleiotropic agent that produces 
complex effects on multiple systems to produce neuroprotection. PROG has improved 
functional and pathological outcomes in over 170 preclinical studies with few reports of 
negative findings (Stein et al., 2013). The substantial preclinical evidence shows that PROG 
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improves outcomes by attenuating the complex pathology that accompanies brain injury and 
disease. Similarly, PD is a disorder with a complex pathology that includes midbrain DA 
loss, activation of microglia, production of pro-inflammatory cytokines, oxidative stress, and 
mitochondrial dysfunction. PROG as a pleiotropic agent has improved each of these PD 
related pathologies in other models of brain injury and disease. The pleiotropic actions of this 
neurosteroid combined with the compelling preclinical data make PROG an attractive 
candidate for investigation in an animal model of PD.  
To date few studies have examined the beneficial influence of PROG in an animal 
model of PD. None of these studies have thoroughly examined PROG’s influence on motor 
impairments nor have any directly compared PROG treatment following small and large 
dopamine depleting lesions. To addresses these shortcomings a suitable animal model of PD 
is required. The following chapter (Chapter 4) discusses animal models of PD and provides a 
justification for the model used in this thesis.   
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Chapter 4   
Animal Models of Parkinson’s disease 
4.1.  Objectives 
An appropriate animal model of PD is required to examine the beneficial influence of PROG. 
Animal models of PD have traditionally involved the systemic or intracerebral administration 
of neurotoxins or pesticides that reproduce most of the essential features of the disease. 
However, with recognition that about 10% of all PD cases are familial several genetic rodent 
models have also been developed. This chapter describes the most popular neurotoxin and 
pesticide models and briefly describes some of the more common genetic models, 
highlighting the strengths and disadvantages of each. Also described is the newer prion-like 
model. A justification for the model used in this thesis is then provided. Table 4.1 
summarises the key features of each model.  
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Table 4-1. 
Animal Models of Parkinson’s disease.  
 Model Motor 
impairments 
Nigrostriatal 
damage 
Lewy 
pathology 
Other pathology Advantages Disadvantages 
Toxin-based 6-OHDA rats Akinesia, 
rotation, skilled 
forelimb use 
Loss of DA/TH 
and SNpc 
neurons 
No Inflammation, 
Mitochondrial 
dysfunction, 
oxidative stress 
Progressive SN 
degeneration 
after striatal 
injections, 
highly 
reproducible 
Requires 
stereotaxic 
injection, little 
Lewy 
pathology 
 MPTP mice Bradykinesia, 
reduced 
locomotion 
Loss of DA/TH 
and SNpc 
neurons 
No Inflammation, 
Mitochondrial 
dysfunction, 
oxidative stress 
Easy to perform, 
highly 
reproducible, 
bilateral lesion 
Non-
progressive 
model of cell 
death, little 
Lewy 
pathology 
 MPTP primate Bradykinesia, 
akinesia, 
rigidity, 
postural tremor  
Loss of DA/TH 
and SNpc 
neurons 
No Inflammation, 
Mitochondrial 
dysfunction, 
oxidative stress 
Closely 
replicates PD 
motor 
impairments, 
bilateral lesion 
Non-
progressive 
model of cell 
death, no Lewy 
pathology 
Pesticide-based Rotenone  Reduced 
locomotion, 
rigidity 
Loss of DA/TH 
and SNpc 
neurons 
Yes Mitochondrial 
dysfunction, 
oxidative stress, 
inflammation 
Ecological 
validity, Lewy 
pathology, 
bilateral lesion  
Substantial 
morbidity and 
mortality. Low 
reproducibility. 
 Paraquat/maneb Reduced 
locomotion 
Loss of DA/TH 
and SNpc 
No Mitochondrial 
dysfunction, 
Ecological 
validity, 
Inconsistent 
lesions, high 
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 Model Motor 
impairments 
Nigrostriatal 
damage 
Lewy 
pathology 
Other pathology Advantages Disadvantages 
neurons oxidative stress bilateral lesion mortality 
Genetic-based α-synuclein- 
viral-vector 
overexpression   
Akinesia, 
rotation 
Loss of DA/TH 
and SNpc 
neurons 
Yes Inflammation Lewy pathology, 
progressive 
model of cell 
death 
Variable motor 
impairments, 
requires further 
predictive 
value 
validation. 
        
 Mutations - α-
synuclein, 
LRKK2, PINK1, 
PARKIN, DJ-1  
Reduced 
locomotor 
activity 
Little, 
inconsistent 
No Mitochondrial 
dysfunction, 
altered reactive 
oxygen species 
production.  
Studying 
contribution of 
mutations to PD 
pathogenesis  
Little or no 
nigrostriatal 
degeneration. 
Limited motor 
impairments 
        
Prion-like 
model 
α-synuclein- 
inoculation  
Motor 
coordination, 
grip strength 
Loss of DA/TH 
and SNpc 
neurons 
Yes  Prion-like 
propagation of 
Lewy pathology, 
progressive 
model of cell 
death  
Requires 
further 
development, 
prion-
hypothesis not 
confirmed. 
        
Abbreviations: 6-OHDA=6-hydroxydopamine; DA=dopamine; MPTP=the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine; PD=Parkinson's 
disease; SNpc=substantia nigra pars compacta; TH=tyrosine hydroxylase (Table adapted from Blesa and Przedborski, 2012, 2014). 
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4.2.  Neurotoxin Models 
Neurotoxic models are the most common animal models of PD. The most popular 
neurotoxins are the 6-hydroxydopamine (6-OHDA) model in rats and the 1-methyl-4- 
phenyl-1,2,3,6-tetrahydropyridine (MPTP) model in mice.  
6-OHDA 
Ungerstedt (1968) first used the 6-OHDA model almost fifty years ago to lesion the 
dopaminergic nigrostriatal pathway in the rat. The 6-OHDA model remains widely used 
(Duty and Jenner, 2011) and is the model used in this thesis. Dopaminergic lesions produced 
by 6-OHDA are highly reproducible and can be varied to yield different degrees of 
nigrostriatal denervation depending on the dosage and site chosen for infusion (Blandini et 
al., 2008; Kirik et al., 1998). 6-OHDA does not cross the blood-brain barrier (BBB) and so 
requires direct infusion to the brain. The neurotoxin can be injected into the cell bodies in the 
SN or into the medial forebrain bundle (MFB) to produce a ‘complete’ lesion or it can be 
injected to the terminal region of the striatum to produce a ‘partial’ lesion (Blandini et al., 
2008). Unilateral infusions of 6-OHDA are almost always used as bilateral lesions produce 
severe aphagia and adipsia, requiring the rat to be tube feed to keep it alive (Sakai and Gash, 
1994). Furthermore, unilateral lesions allow each rat to serve as its own control as the 
impaired side can be compared to the intact unimpaired side. 
After its injection 6-OHDA is taken up by the DA and to a lesser extent the 
noradrenalin transporters where it selectively destroys catecholaminergic neurons by a 
combined effect of reactive oxygen species (ROS) and quinones (Blesa and Przedborski, 
2012; Duty and Jenner, 2011). The model cannot replicate PD but it does mimic the essential 
features of the disease including progressive striatal deafferentation and nigral cell loss, 
motor impairments, and pathogenesis such as inflammation, mitochondrial dysfunction, and 
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oxidative stress (Baldini et al., 2008; Cicchetti et al., 2002; Jin et al., 2008; Walsh et al., 
2011). The model, however, does not address pathology elsewhere in the brain or induce 
Lewy bodies which is considered a pathological hallmark of PD (Blesa and Przedborski, 
2012, 2014; Braak et al., 2006). The formation of Lewy body pathology is desirable but not 
essential. Also, a small number of PD cases occur without classic Lewy bodies and the 
pathology is not observed in the parkin-related familial form of PD (Dauer and Przedborski, 
2003). The 6-OHDA model shows good predictive validity as all drugs in clinical use 
excluding antimuscarnic drugs have demonstrated efficacy in this model (Duty and Jenner, 
2011). 
Unilaterally injecting 6-OHDA to the MFB or SN produces a ‘complete’ lesion that 
models the late stages of PD degeneration (Duty and Jenner, 2011). Injection of 6-OHDA to 
the MFB or SN causes near total degeneration (>90%) of dopaminergic neurons than begin to 
die within 12 hours of injection in conjunction with near complete striatal DA depletion that 
is established within 2-3 days after surgery (Blandini et al., 2008; Deumens et al., 2002; 
Walsh et al., 2011). This rapid onset of cell death is a disadvantage of this model as 
neurodegeneration is progressive in PD. However, rats with complete lesions display 
profound and stable motor impairments that can be used to test the efficacy of symptomatic 
treatments (Duty and Jenner, 2011). Rats with complete lesions display marked rotation in 
response to peripheral administration of DA agonists and robust impairments on tests of 
forelimb akinesia, skilled reaching, and forelimb use asymmetry (Metz et al., 2001; Olsson et 
al., 1995; Woodlee et al., 2008; see experimental chapters 5-7 for a detailed description of the 
motor skill tests used in this thesis).  
In order to achieve a more progressive and less severe lesion the 6-OHDA neurotoxin 
can be unilaterally injected to the striatum (Kirik et al., 1998). The intrastriatal injection 
causes rapid striatal tyrosine hydroxylase (TH, the rate limiting enzyme in DA synthesis) 
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denervation followed by a progressive cell loss due to retrograde transport of the 6-OHDA 
neurotoxin from the striatum to the SN (Berger et al., 1991). A smaller lesion that models the 
earlier stages of PD degeneration can be produced by two injections whereas a substantial yet 
not complete lesion that models the later stages can be achieved by four injections made 
along rostro-caudal extent of the dorsal striatum (Decressac et al., 2012; Kirik et al., 1998; 
Shin et al., 2014). Previous studies have shown that striatal denervation occurs within 6-24 
hours but reaches its maximum at about 1 week after striatal 6-OHDA lesion surgery 
(Blandini et al., 2007; Grealish et al., 2008; Rosenblad et al., 2000). In comparison, 
dopaminergic cell bodies in the SN slowly degenerate over several weeks after striatal lesions 
(Cicchetti et al., 2002; Walsh et al., 2011). Similar to the MFB model, large lesions also 
produce robust drug induced rotation bias and impairments on tests of forelimb akinesia, 
skilled reaching, and forelimb use asymmetry (Kirik et al., 1998; Plowman et al., 2014; Shin 
et al., 2014) while small lesions produce less substantial deficits (Decressac et al., 2012; Shin 
et al., 2014). Importantly, the development of motor impairments after intrastriatal lesions is 
more gradual than the MFB model (Decressac et al., 2012; Kirik et al., 1998). The slower 
evolving lesion and progressive motor impairments achieved by intrastriatal 6-OHDA 
injections is excellent for testing novel therapies that are designed to interfere with the 
degenerative process (Blandini et al., 2008). 
MPTP 
MPTP is another commonly used neurotoxin to model PD. As discussed in Chapter 2, the 
selective dopaminergic neurotoxicity of MPTP was discovered when a group of drug users 
accidentally injected themselves with MPTP, an analogue by-product of heroin production 
(Langston et al., 1983). MPTP readily crosses the BBB then is converted to its toxic 
metabolite 1-methyl-4-phenylpyridinuim (MPP+) which subsequently kills dopaminergic 
neurons (Hauser and Hastings, 2013). MPTP can be systemically injected to produce bilateral 
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degeneration in monkeys and selected strains of mice although rats are relatively insensitive 
to its toxic effects (Duty and Jenner, 2011; Sonsalla and Heikkila, 1988). MPTP also causes 
oxidative stress, mitochondria dysfunction, and inflammation, key pathogenic factors of PD 
(Jackson-Lewis et al., 2012). However, MPTP administration does not produce Lewy bodies 
(Blesa and Przedborski, 2014). The most common procedures for inducing MPTP 
neurotoxicity in mice involve either a single high dose injection, giving 80-90% striatal DA 
depletion, or one lower dose injection given every 2 h for a total of four doses, leading to 60-
90% DA depletion (Duty and Jenner, 2011; Jackson-Lewis and Przedborski, 2007). Cell 
death is rapid after MPTP, emerging within 12-72 hours and reaching maximum within one 
week post injections (Jackson-Lewis et al., 1995; Jackson-Lewis and Przedborski, 2007; 
Novikova et al., 2006). 
MPTP treated mice show signs of akinesia, catalepsy, and reduced locomotion, 
although these impairments can be transient thereby reducing the usefulness of this model to 
study therapeutic interventions (Duty and Jenner, 2011; Taylor et al., 2010). On the other 
hand the MPTP monkey displays a parkinsonian syndrome consisting of akinesia, 
bradykinesia, rigidity, and postural tremor thus closely replicating the cardinal motor features 
of PD, but like MPTP in the mouse the SN cell death and the onset of symptoms is rapid 
(Blesa and Przedborski, 2012). The MPTP mouse and primate are highly useful models of PD 
although the rapid onset of cell death and motor impairments limits the therapeutic window 
for administration of novel treatments aimed at neuroprotection.  
4.3.  Pesticide Models 
Another approach to modelling PD in animals is with the administration of pesticides. This 
approach has validity as lifetime exposure to pesticides has been associated with an increased 
risk of PD (Dick et al., 2007) although others have argued that the evidence for this link is 
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inconclusive (Berry et al., 2010). Nonetheless, several studies have shown in rodents that 
systemic administration of the herbicide paraquat alone or in combination with the fungicide 
maneb can cause a PD like syndrome. Similarly, systemic or intracerebral administration of 
the herbicide/insecticide rotenone can also model PD. 
Paraquat/maneb 
Paraquat (1,1′-dimethyl-4,4′-bipyridinium) exerts it toxicity through induction of redox 
cycling which in turn generates harmful ROS (Day et al., 1999). Paraquat also induces the 
activation of microglia, a marker of inflammation in PD (Peng et al., 2009). In comparison, 
maneb (manganese ethylene-bis-dithiocarbamate) mediates toxicity by selective inhibition of 
complex III of the mitochondrial respiratory chain (Zhang et al., 2003). Following systemic 
administration of paraquat, mice show reduced ambulatory activity and modest loss of striatal 
TH and SN neurons but no Lewy pathology (Brooks et al., 1999; Mccormack et al., 2002; 
Rappold et al., 2011). In comparison, systemic administration of maneb alone reduced 
locomotor activity in older rats for up to 3 months after the last injection but had little 
influence on striatal TH or the number of SNpc cells (Thiruchelvam et al., 2003). However, 
maneb when co-administered with paraquat produced enhanced toxicity in mice although the 
nigrostriatal degeneration was only modest (Thiruchelvam et al., 2000, 2003). The strength of 
the paraquat/maneb model is its ecological validity with respect to pesticide exposure 
increasing the risk of PD in humans. However, the use of this model is limited due to high 
mortality and  inconsistent findings such as SN cell loss without depletion of striatal DA, a 
hallmark of PD (Duty and Jenner, 2011; Miller, 2007). 
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Rotenone 
Rotenone readily crosses the BBB where it inhibits complex I of the mitochondria electron 
transport chain leading to reduced adenosine triphosphate production and electron leakage 
that can form harmful ROS and subsequently oxidative stress (Johnson and Bobrovskaya, 
2015). The first demonstration of the rotenone model showed that chronic systemic 
administration in rats caused selective nigrostriatal dopaminergic degeneration, Lewy 
pathology, hypokinesia, and rigidity (Betarbet et al., 2000). Systemic administration also 
produced selective activation of microglia in the SN and striatum thus mimicking PD 
inflammation (Sherer et al., 2003). However, systemic administration is also associated with 
marked peripheral organ toxicity which confounds findings and contributes to the high rates 
of morbidity and mortality observed in this model (Ravenstijn et al., 2008).  
 To overcome these limitations some studies have unilaterally injected rotenone into 
the nigrostriatal pathway. Injection to the striatum, MFB or the SN and ventral tegmental area 
caused progressive dopaminergic lesions with no associated peripheral organ toxicity or 
mortality (Mulcahy et al., 2011; Ravenstijn et al., 2008; Xiong et al., 2009). However, the 
intracerebral rotenone model can be difficult to reproduce, and can cause liquefactive 
necrosis and glia scaring at the injection site (Blesa and Przedborski, 2014; Johnson and 
Bobrovskaya, 2015). We have previously trialled the MFB and SN/VTA rotenone models in 
our laboratory but were unable to produce any detectable motor impairments (Ravenstijn et 
al., 2008; Xiong et al., 2009). However, we have not trialled the newer striatal infusion model 
which could be a better alternative to the MFB and SN/VTA models (Mulcahy et al., 2011). 
Thus the variable nature of the rotenone model in the literature and in our laboratory 
prevented it use in the current study.  
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4.4.  Genetic Models 
Monogenetic mutation models of PD have been developed to better simulate the mechanisms 
underlying the rare familial forms of the disease. These models usually employ mice bearing 
mutations of PD associated genes such as the autosomal dominant α-synuclein and LRRK2 
genes or the autosomal recessive genes PINK1/Parkin and DJ-1 (Valadas et al., 2014). Other 
approaches have used viral-vector driven overexpression of α-synuclein to reproduce the 
pathological features of PD.  
Genetic mutation models  
Genetic models reproduce several pathogenic factors of PD including mitochondrial 
dysfunction, altered ROS production, and protein misfolding but often fail to produce 
nigrostriatal degeneration (Blesa and Przedborski, 2014). For example, α-synuclein mutations 
cause a rare form of autosomal dominant PD and was the first gene linked to familial PD 
(Blandini and Armentero, 2012). To date, several α-synuclein transgenic mouse models have 
been developed. In these mice, some motor impairment occurs along with decreased levels of 
striatal TH or DA but with little or no nigrostriatal degeneration (Chesselet, 2008). Similarly, 
mutations of the other main PD associated genes LRRK2, PINK1/Parkin, and DJ-1 produce 
some motor impairment but often fail to produce dopaminergic neuron degeneration (see 
Blesa and Przedborski, 2014 for a reivew). Therefore, genetic models are valuable for 
studying how genetic mutations contribute to the pathogenesis of PD but are less suitable for 
screening therapies aimed at improving motor symptoms related to nigrostriatal dopaminergic 
degeneration.  
Viral-vector α-synuclein overexpression model 
Another approach to modelling PD is via viral-vector driven overexpression of α-synuclein. 
In these models a viral-vector expressing either wild type or mutated human α-synuclein is 
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unilaterally injected in rats to the dopaminergic regions of the SN. In contrast to the 
transgenic α-synuclein models discussed above, viral-vector mediated overexpression of α-
synuclein produces reliable dopaminergic degeneration and α-synuclein pathology 
(Decressac et al., 2011, 2012; Kirik et al., 2002). In this model the degeneration of SN cell 
bodies and denervation of striatal TH is progressive, reaching a maximum of about 50-70% at 
8 weeks after surgery (Decressac et al., 2011, 2012; Kirik et al., 2002; Yamada et al., 2004). 
However, some recovery of SN cell bodies and striatal TH occurs over longer periods of 
about 6 months after surgery (Kirik et al., 2002). This model also produces activated 
microglia and pro-inflammatory cytokines, key features of PD (Chung et al., 2009). Impaired 
motor skills are also observed in the α-synuclein overexpression model but its occurrence can 
be variable (Decressac et al., 2012; Kirik et al., 2002).  
Taken together these studies show that the α-synuclein model closely recapitulates the 
key features of PD i.e. progressive dopaminergic neurodegeneration, α-synuclein pathology, 
inflammation, and motor impairments. However, others argue that the model may require 
further assessment regarding its predicative validity before it can be used to evaluate 
treatments (Lindgren et al., 2012). A recent study found that impaired forelimb use 
asymmetry was reduced by L-DOPA treatment after α-synuclein overexpression (Van der 
Perren et al., 2015). This finding improves the predictive validity of this model encouraging 
further study to examine the influence of novel treatments. 
4.5.  Prion-like α-synuclein Models 
As discussed in Chapter 2, it has been proposed that aggregated α-synuclein is a prion-like 
protein and that PD is a prion-like disease (Olanow and Brundin, 2013). As a result prion-like 
models have been investigated and are the latest approach to model PD.  
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Several studies have shown that α-synuclein can spread via cell to cell transmission 
and produces a PD like impairment in mice models. In one study young asymptomatic α-
synuclein transgenic mice that received injections into the neostriatum of brain homogenates 
of α-synuclein derived from older transgenic mice already expressing α-synuclein pathology 
had accelerated formation of Lewy pathology, earlier onset of motor impairments, and 
reduced TH expression in the SN (Luk et al., 2012b). In a similar study wild type non-
transgenic mice given a single inoculation of synthetic α-synuclein fibrils into the striatum 
showed cell to cell transmission of α-synuclein, PD like Lewy pathology, progressive loss of 
dopaminergic neurons in the SN and DA in the striatum, and reduced rotarod performance 
and motor strength (Luk et al., 2012a). This finding was supported by a recent study that also 
observed prion-like spread of α-synuclein and impaired rotarod performance and motor 
strength after SN or striatal injections (Masuda-Suzukake et al., 2014). Another recent study 
found that injections into the SN or striatum of pathological α-synuclein, purified from post-
mortem PD brains, caused progressive nigrostriatal degeneration and triggered the 
pathological conversion of host α-synuclein in both mice and monkeys (Recasens et al., 
2014). Taken together these findings suggest that exposure to small quantities of pathological 
α-synuclein can cause a prion-like spread of α-synuclein and a PD like syndrome in mice and 
monkeys. The prion model is potentially a close replication of PD although its use for 
examining novel treatments is currently limited as the model requires further development 
and, importantly, the prion hypothesis of PD has not yet been confirmed.  
4.6.  Animal Model Used in this Thesis 
An ideal model of PD should recapitulate the cardinal features of the disease. These features 
should include some of the key aspects of pathogenesis, motor impairments, neurochemistry, 
and pathology to PD (Duty & Jenner, 2011). The model should preferably produce at least 
some progressive impairment, as is the case with PD. In addition, the choice of the model 
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also depends on the aim of the study. The primary aim of the current thesis was to examine 
PROG’s influence on motor impairments in a clinically relevant model of PD. The model 
used in this thesis, therefore, should be suitable for testing novel therapeutics. The four-site 
unilateral intrastriatal 6-OHDA lesion model is widely used and has been found suitable for 
testing novel treatments aimed at symptomatic reduction (Blandini and Armentero, 2012; 
Blesa and Przedborski, 2012, 2014; Dauer and Przedborski, 2003; Kirik et al., 1998). The 
intrastriatal model has some progressive injury characteristics and thus provides a therapeutic 
time-window with which to administer PROG. In addition, the two-site intrastriatal 6-OHDA 
lesion model can be used to produce smaller lesions and consequently less severe motor 
impairments if required (Descressac et al., 2012; Kirik et al., 1998; Shin et al., 2014). Thus, 
the ability of the intrastriatal model to mimic many of the essential features of PD supports its 
use as a clinically relevant model with which to examine PROG’s influence on motor 
impairments.  
4.7.  Summary 
There are numerous animal models of PD available to the researcher, each with strengths and 
disadvantages. A given model should not be used exclusively but rather selected on the basis 
of being relevant for the question being asked. If a substantial and reproducible dopaminergic 
lesion is required for the purpose of testing a novel therapy then a neurotoxin model is 
suitable. Conversely, pesticide models may be better suited to test the influence of 
environmental toxins on the pathogenesis of PD, while genetic models are appropriate for 
investigating the role of specific mutations. The newer viral-vector mediated expression of α-
synuclein and prion-like models replicate most of the key features of PD although both 
models perhaps require further development and validation before they are suitable for testing 
novel therapeutics.  
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Of the models reviewed in this chapter the intrastriatal 6-OHDA model was selected 
as most suitable for examining PROG’s beneficial influence at this point in time. This model 
recapitulates the essential features of PD and has been found suitable for testing novel 
therapies. The following chapter reports the first of three experiments presented in this thesis. 
This experiment established the time-course for motor-impairments in the intrastriatal 6-
OHDA model and in doing so identified a suitable treatment time-point for subsequent 
experiments using PROG.   
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Chapter 5   
Study One: Motor Impairments in the 
Intrastriatal 6-OHDA Model 
5.1.  Objectives 
This chapter reports the first of three experiments (see also: Chapters 6 and 7) and involves a 
pilot investigation to establish the unilateral striatal 6-OHDA lesion model of PD. The main 
objective of this chapter was to determine the time-course for motor impairments in this 
model. The second objective was to identify a suitable treatment time-point for subsequent 
experiments using PROG. Motor function tests of akinesia, skilled forepaw use, and drug 
induced rotation are investigated. Rats were tested pre-surgery on the adjusting steps test for 
akinesia, and the sunflower seed handling test for skilled forepaw use, then given 6-OHDA 
lesions or sham surgery. Ipsilateral rotation after d-amphetamine was used to verify the 
functional effect of the lesion at day 7 after surgery. Post-operative impairments in the 
adjusting steps test were measured on days 15-17, 28-30, and 49-51 and in the sunflower seed 
test on days 20-22, 34-36, 56-58. Contralateral rotation after apomorphine was measured at 
days 24 and 61. Rats were sacrificed at day 65 for tyrosine hydroxylase 
immunohistochemistry of the striatum. This chapter begins with a brief justification of the 6-
OHDA lesion model and the motor skills tests used in this experiment.  
5.2.  Introduction 
As discussed in Chapter 4, an ideal model of PD should recapitulate the key features of the 
disease including similar neurochemistry, pathology, and motor impairments (Duty and 
Jenner, 2011). The model used in this thesis should also be suitable for investigating novel 
treatments as the primary aim of this thesis is to examine PROG’s influence on motor 
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impairments in a clinically relevant model of PD. As stated in Chapter 4, the four-site 
unilateral intrastriatal 6-OHDA partial lesion model is ideal as it mimics many of the 
essential features of PD and has been found suitable for testing novel treatments aimed at 
symptomatic reduction (Blandini and Armentero, 2012; Blesa and Przedborski, 2012; 2014; 
Dauer and Przedborski, 2003; Kirik et al., 1998). Before examining PROG in the context of 
this model the time-course of motor impairments needed to be established in a pilot 
experiment. 
Rats were tested for forelimb akinesia using the adjusting steps test described by 
Olsson et al. (1995). The adjusting steps test is useful because it is one of the few tests able to 
detect motor deficits after moderate dopamine depletion following unilateral 6-OHDA lesions 
(Decressac et al., 2012; Kirik et al., 1998; Krishnamurthi et al., 2009; Torres et al., 2008). 
Additionally, previous studies have shown that forelimb stepping in the adjusting steps test 
decreases as the dopamine content is reduced (Kirik et al., 2001b; Winkler et al., 1996). The 
adjusting steps test was selected as the primary behavioural outcome measure as akinesia is a 
cardinal motor feature of clinical PD (Dauer and Przedborski, 2003; Olsson et al., 1995). 
Furthermore, the presence of symptoms associated with akinesia significantly contributes to 
reduced quality of life in PD patients (Rahman et al., 2008). 
 Loss of manual dexterity of the hands is another debilitating motor impairment 
observed in PD patients (Klein et al., 2012). Rats demonstrate the equivalent of manual 
dexterity when they skilfully handle food items such as pasta and sunflower seeds (Whishaw 
and Coles, 1996). To assess skilled forepaw use rats were assessed using a modified version 
of the pasta handling and sunflower seed handling tests. Intact rats handle lengths of 
uncooked vermicelli by repeatedly adjusting their forepaw hold on the pasta piece whereas 6-
OHDA lesioned rats make fewer adjustments with their impaired paw (Allred et al., 2008). 
Prior to this pilot study we trialled the vermicelli handling test without success as our rats 
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adopted a handling style that did not allow the experimenter to observe forepaw adjustments.  
Instead, we used a modification of the sunflower seed handling test as forepaw adjustments 
could be observed when shelling and eating the seeds (Kane et al., 2011). Rats typically 
consume a sunflower seed by holding the seed at each end, biting the corner, splitting the 
seed longitudinally into two pieces, and then consuming the seed. Rats with 6-OHDA lesion 
take longer to eat the seed, produce more shell pieces, and should make fewer adjustments 
with the impaired forepaw as compared to the vermicelli handling test (Allred et al., 2008; 
Kane et al., 2011).  
 The most common motor behaviour assessment of unilateral 6-OHDA lesions is the 
rotational behaviour induced by systemic administration of the indirect dopamine agonist d-
amphetamine, which induces a circling behaviour towards the lesion side (Torres and 
Dunnett, 2007; Ungerstedt and Arbuthnott, 1970). This ipsilateral to lesion rotation occurs 
because the dopamine release induced by d-amphetamine favours the intact side thus 
producing an imbalance in dopamine transmission and subsequent movement imbalance 
(Duty and Jenner, 2011). Following partial intrastriatal 6-OHDA lesions rotations after d-
amphetamine are consistently observed after about 50% of dopaminergic neurons in the SN 
are lost (Kirik et al., 1998). However, similar rates of rotation are sometimes observed over a 
wide range of SN cell loss following partial lesions (e.g. Fang et al., 2006; Sun et al., 2010) 
but  rats with larger lesions tend to rotate more (Kirik et al., 1998, 2001b). The d-
amphetamine rotation test is therefore useful as an ante-mortem validation of the lesion but 
may not be reliable at detecting functional improvements in partial lesion models (Duty and 
Jenner, 2011).  Hence rats were tested for rotations after d-amphetamine at day 7 after 
surgery to validate the presence of the 6-OHDA striatal lesion. 
 Rats were also tested for rotation after apomorphine at days 24 and 61 after surgery. 
The test is similar to d-amphetamine rotations other than rats will rotate in the contralateral to 
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lesion direction as a result of denervation-induced dopamine receptor supersensitivity in the 
lesioned hemisphere (Ungerstedt, 1971). The dopamine receptor supersensitivity required to 
produced contralateral rotations after apomorphine typically occurs only after there is >90% 
nigral cell loss such as is observed in the MFB complete lesion model. Partial lesion models 
usually produce <90% SN cell loss although contralateral rotations after apomorphine will 
occur if there is localized dopamine loss of >90% in the circumscribed area of the striatal 
lesion (Kirik et al., 1998). Rotation after apomorphine is therefore a useful ante-mortem assay 
for supersensitivity induced by large 6-OHDA striatal lesions and was therefore included. 
The main objective for this pilot experiment was to determine the time-course for 
motor impairments following partial unilateral 6-OHDA lesions of the dorsal striatum. 
Previous research has shown that stable impairments in the adjusting steps test typically 
appear within 2-3 weeks following partial lesions (Decressac et al., 2012; Fang et al., 2006; 
Kirik et al., 1998) although others have reported a substantial impairment within 24 hours of 
lesion surgery (Grealish et al., 2008).Impaired use of the forepaws requires more extensive 
lesions than is required to detect akinesia impairment (Kirik et al., 1998). Given the 
progressive nature of the partial lesion model it is possible that deficits in skilled forepaw use 
in the sunflower seed handling test could take additional time to emerge compared to the 
adjusting steps test.  Rotation after d-amphetamine emerges within 7 to 14 days after lesion 
surgery whereas rotation after apomorphine requires about 3 weeks to emerge (Fang et al., 
2006; Kirik et al., 1998). These findings indicate that the appearance of motor impairments is 
time-sensitive following partial lesions. It is therefore necessary to establish the time-course 
for motor impairments in our rats using our surgical and behavioural testing techniques prior 
to examining the influence of PROG. 
 The second objective of this experiment was to identify a suitable time-point to 
initiate PROG treatment in subsequent experiments. The optimal treatment time-point would 
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be when impairments are first present but are not yet fully developed. The onset of motor 
symptoms in PD patients occurs when about 60% SNpc neurons have been lost and there is a 
concomitant reduction of striatal DA by about 80% (Dauer and Prezdborski, 2003). Note that 
delaying PROG treatment until impairments are first present is consistent with current 
treatment approaches where treatment is not started until a patient presents with symptoms 
(Reichmann, 2008). The delay in treatment until after significant dopaminergic loss has 
occurred is because a diagnosis can only be made in the presence of the cardinal features of 
PD due to the lack of early disease identifying biomarkers (Sharma et al., 2013). Although 
treatments can be delayed when symptoms are relatively mild the current recommendations 
are to initiate treatment early as this leads to better long-term outcomes (Schapira et al., 
2008). Therefore, the best time-point to initiate PROG treatment in our model was taken to be 
when motor impairments were first present but not yet fully developed.  
5.3.  Materials and Methods 
5.3.1.  Animals 
Twenty male Wistar rats were used, weighing between 518g and 628g at the day of surgery. 
The rats were 7-10 months old at surgery and 9-12 months old at perfusion. Testing occurred 
during the dark phase of the rats reversed light cycle (lights on at 2000hrs). Following 
surgery rats were housed individually for the remainder of the experiment with food and 
water available ab libitum. All protocols in this study followed the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the Animal Ethics Committee, 
University of Canterbury. 
5.3.2.  Experimental design 
The experiment used a between groups design. Rats received unilateral 6-OHDA lesions of 
the striatum. Lesions were verified at day 7 with a d-amphetamine rotation test and post-
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surgery motor skills were evaluated between days 15 and 61. Rats were euthanized at day 65 
for histology (Fig. 5.1).  
 
 
Figure 5.1. Post-surgery experimental timeline. Rats received unilateral lesions with four 6-
OHDA infusions in the striatum. Lesion rats rotating in the ipsilateral direction at > 6 
turns/min on day 7 after d-amphetamine were tested for impairments in akinesia, skilled 
forepaw use, and rotations after apomorphine between days 15 and 61. Rats were sacrificed 
for TH immunohistochemistry on day 65.Adj, adjusting steps test; Apo, apomorphine rotation 
test; d-amp, d-amphetamine rotation test; Seed, sunflower seed handling test.  
5.3.3.  Surgery 
All surgical procedures were performed under general anaesthesia using isoflurane inhalation 
(4-5% for induction at 1.5 L/min oxygen; 2-3% for maintenance at 1 L/min oxygen). Rats 
received 5mg/kg carprofen i.p 1 hour prior to surgery for long term pain relief. Rats were also 
given 2ml Hartmann’s solution i.p at the start of surgery and an additional 1ml at the end of 
surgery to mitigate fluid loss. Core body temperature was monitored and maintained at 37˚C 
(+/- 1˚C) via an automatic temperature regulating system (FHC, Bowdoin, Maine, USA).  
Once anesthetised, the rat’s head was shaved and placed in a stereotaxic frame 
(atraumatic ear bars, Kopf) with the incisor bar adjusted to achieve flat skull. The incised 
scalp was retracted to reveal bregma and lambda (anterior and posterior landmarks on the 
skull), and burr holes drilled above the striatum. Unilateral striatal lesions were achieved by 
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four 2µl injections of freshly prepared 6-OHDA solution (3 µg/ul freebase dissolved in a 
vehicle solution of 0.2 mg/ml L-ascorbic acid in 0.9% w/v NaCl).The following four 
coordinates were used, as described by Kirik et al. (1998): AP 1.3mm, ML ±2.7mm; AP 
0.4mm, ML ±3.1mm; AP −0.4mm, ML ±4.3mm; AP −1.3mm, ML ±4.7mm (from bregma) 
and DV −5.0mm from dura at each site (Fig. 5.2). Sham surgery rats received infusions of the 
vehicle solution alone. Infusions were made using an automated Stoelting microinfusion 
pump and a 10-μl Hamilton syringe (Reno, NV, USA) syringe fitted with PE20 tubing and a 
28 gauge cannula (Plastics One). Infusions were made at a rate of 1µl/min with the cannula 
left in place for a further minute at each site to allow diffusion of the 6-OHDA solution. The 
wound was closed with surgical silk and mepvicane (4mg/ml) and Emla cream applied 
topically for pain relief.  
 
Figure 5.2. Target striatal infusion sites (blue ovals) for 6-OHDA lesion surgery. Numbers 
indicate distance from bregma in millimetres (plates adapted from Paxinos and Watson, 
1998).  
5.3.4.  Statement regarding use of desipramine 
The neurotoxin 6-OHDA is relatively selective for the catecholaminergic neurons DA and 
NA (Dauer and Przedborski, 2003). To protect the NAergic system from the toxic effects of 
6-OHDA studies sometimes administer the NA transport blocker desipramine prior to surgery 
(e.g. Breit et al., 2007; Casas et al., 2011; Shin et al., 2014). However, desipramine pre-
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treatment is not always used in the 6-OHDA model (e.g. Decressac et al., 2012; Grealish et 
al., 2014; Krishnamurthi et al., 2009; Walsh et al., 2010). In the current thesis desipramine 
was not used. First, we recognise that PD is a multi-system disease affecting numerous 
neurotransmitter systems including NA although the striatal target is poorly innervated by 
NAergic fibres (Delaville et al., 2011). There is also evidence implicating the degeneration of 
the NAergic system for PD symptoms so their protection may be inadvisable (see Delaville et 
al., 2011 for a review). 
5.3.5.  Rotation after d-amphetamine 
Rotation after d-amphetamine sulphate (3 mg/kg i.p.; Sigma) was tested at day 7 as an ante 
mortem validation of the 6-OHDA lesion. The apparatus consisted of a clear acrylic glass box 
(48cm long by 29cm wide by 25cm high) with bedding material on the floor and a colour 
CCD camera (Imaging Source) mounted above (Fig. 5.3). Rats were allowed 5mins to 
habituate to the box before d-amphetamine was administered. Following the injection rats 
were returned to the testing box for 5mins before recording began. This time allowed the rat 
to overcome the increased activity associated with the manipulation. Rotation was recorded 
via video tracking software (OpenControl, Aguiar et al., 2007) for 90mins. Scores are 
expressed as net full body turns/min. Ipsilateral (to lesion) turns were assigned positive 
values whereas contralateral turns were given negative values. Lesion rats will preferentially 
turn in the ipsilateral (to lesion) direction. Sham surgery rats do not show a preference. The 
criterion for a successful lesion was ipsilateral rotations at > 6 turns/min (Schwarz et al., 
2006; Torres et al., 2007). Only lesion rats meeting this criterion were included in the 
experiment. 
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Figure 5.3. The apparatus used for the d-amphetamine and apomorphine rotation tests.  
5.3.6.  Rotation after apomorphine 
Rotation following apomorphine hydrochloride (0.25 mg/kg s.c., Sigma) was assessed at days 
24 and 61. The same procedure for rotation after d-amphetamine was followed except 
rotation was recorded for 60mins. Lesion rats will preferentially turn in the contralateral (to 
lesion) direction. Sham rats do not show a preference.  
5.3.7.  Adjusting steps test: Akinesia 
Forelimb akinesia was tested using the adjusting steps test. Rats were tested pre-surgery and 
at days 15-17, 28-30, and 49-51. The apparatus consisted of a 102cm long by 50cm wide 
smooth table surface. Rats were handled on the three days prior to pre-surgery testing to 
familiarise them with the experimenters grip and the testing procedure. For each trial the 
experimenter used one hand to raise the hind quarter of the rat vertically to a “wheelbarrow” 
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like position and the other hand to gently restrain the forelimb not to be tested while the 
unrestrained forepaw touched the table surface and was weight bearing (Fig. 5.4). The rat was 
slowly moved sideways (90cm in 5s) along the table surface in the medial direction with 
respect to the unrestrained forepaw (i.e. the rat is pulled to the left when the right paw is 
restrained). The number of adjusting steps made with the unrestrained forepaw was counted. 
The test was repeated twice for each forelimb on each of three consecutive days. The average 
number of steps for each forelimb over these six trials represented the rats score.  Data were 
expressed as contralateral forelimb steps/total steps x 100%. An unimpaired rat would score 
50% on this task. Lower scores indicate larger akinesia impairment.  
 
Figure 5.4. Example of the grip and positioning of the rat during the adjusting steps test 
(adapted from Tillerson et al., 2001). 
5.3.8.  Sunflower seed handling test: Skilled forepaw use 
Skilled use of the forepaws was tested using the sunflower seed handling test. Rats were 
tested pre-surgery and at post-surgery days 20-22, 34-36, 56-58.The apparatus consisted of a 
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clear acrylic glass box (48cm long by 29cm wide by 25cm high) with a wooden block 
inserted to restrict the rat to one half of the testing arena (Fig. 5.5). The box overlapped the 
edge of the table to allow the experimenter to video record (CCD colour camera, Imaging 
Source) the rat from below. To encourage eating the rat’s food was removed for 1 hour prior 
to the test. Prior to testing rats were introduced to the sunflower seeds by providing each rat 
with 5 seeds per day for two days. Rats were habituated to the testing apparatus for 5mins per 
day for three days by placing the rat in the centre of the testing arena and placing five seeds 
in the corner.  
Following habituation rats were tested once per day for three days at each testing 
occasion. Rats were placed in the centre of the box with five seeds placed in one corner. The 
number of shell pieces produced, the time taken to consume the seeds, and the number of 
adjustments made with each forepaw per seed was counted. An adjustment was defined as 
any visible released and re-grasp of the seed or any reformation of the grip on the seed using 
extension-flexion and/or abduction-adduction of the digits. For each session the scores for the 
five seeds were added together. Scores were taken as the average of the three sessions. Lesion 
rats were expected to make fewer adjustments with the impaired paw, take longer to consume 
seeds, and produce more shell pieces compared to shams. Due to technical difficulties with 
the recording equipment the forepaw adjustments and time spent eating the seeds were not 
able to be coded. Therefore, the forepaw adjustments and time spent eating the seeds 
measures are not reported.   
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Figure 5.5. The sunflower seed handling test. The image shows performance during pre-
surgery testing.  
5.3.9.  Perfusion and immunohistochemistry 
Rats were deeply anaesthetised with sodium pentobarbital (300mg/kg i.p.) at day 65 and 
transcardially perfused with 120ml cold saline followed by 180ml 4% paraformaldehyde (pH 
7.4). Brains were removed and post-fixed overnight in the same fixative then transferred to a 
cryo-protection solution (20% glycerol, 80% PB with 0.05% sodium azide, pH 7.4) until 
sectioning. Brains were cut into serial sections of 30 µm using a freezing sledge microtome 
and stored at -20˚C in a freezing solution (30% glycerol, 30% ethylene glycol, 40% PB ,pH 
7.4) until processing.  
Tyrosine hydroxylase (TH) immunohistochemistry was performed on free-floating 
sections. Sections were rinsed several times in 0.1M phosphate buffered saline containing 
0.2% Triton X-100 (PBS-tx) between each incubation period. All incubation solutions 
contained PBS-tx. Endogenous peroxidase activity was quenched by incubating sections in 
3% H2O2 for 10min. Non-specific binding of the secondary antibody was blocked using 5% 
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normal goat serum (NGS, Gibco, New Zealand) solution for 30mins. The sections were 
incubated overnight at 4˚C under gentle agitation with the rabbit polyclonal anti-TH primary 
antibody (Millipore, AB152) diluted at 1:1000 with 1% NGS. The following day, sections 
were incubated for 1 hour with biotinylated goat anti-rabbit secondary antibody (Vector 
Laboratories, BA-1000) diluted at 1:400 with 1% NGS followed by 1 hour with avidin-
biotin-peroxidase complex with 1% NGS (ABC Elite, Vector Laboratories) and visualised 
with 0.03% 3,3-diaminobenzidinetetrahydrochloride containing 0.01% H2O2 in 0.1M 
phosphate buffer. Sections were mounted on gelatine coated slides, dehydrated in an 
ascending series of alcohols, cleared in xylene and coverslipped using DPX mounting 
medium.  
5.3.10.  Quantification of tyrosine hydroxylase immunohistochemistry   
Photomicrographs of the striatum and ventral midbrain were taken using a Nikon Eclipse 
E800 microscope fitted with a Nikon DS-Fi1 camera and were analysed using ImageJ 
software (National Institute of Health, USA). The density of TH immunostaining was 
measured in three coronal sections in the striatum (AP: 0.7mm, -0.3mm. -0.7mm from 
bregma). To measure specific TH staining each section was corrected for non-specific 
background staining by subtracting the mean grey value of the medial corpus callosum 
(spanning both hemispheres) from the mean grey value of the striatum on each section.  
 
5.3.11.  Statistical analysis 
Statistical analyses using Statistica (version 12.0) were conducted to determine if striatal 6-
OHDA lesions produced significant impairment in akinesia (adjusting steps test), skilled 
forepaw use (sunflower seed handling test), and rotation after d-amphetamine and 
apomorphine compared with sham surgery rats. Differences in pre-surgery adjusting steps, 
and sunflower seed tests and in striatal THdensity, and rotation after d-amphetamine were 
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analysed using an independent samples t-test. A separate Lesion (6-OHDA vs. Sham) x Time 
(two or three time-points) ANOVA assessed the adjusting steps, sunflower seed handling, 
and apomorphine rotation test followed by post-hoc Newman-Keuls multiple comparisons 
tests where appropriate. Statistical significance was set at p<0.05. All data are expressed as 
means ± SEM. 
5.4.  Results 
5.4.1.  Rotation after d-amphetamine 
At day 7, lesions produced substantially increased ipsilateral rotations (t(16) = 15.34, 
p<0.001) after d-amphetamine confirming the success of the lesion (Fig. 5.6). Due to 
heteroscedasticity the analysis was followed up with a Mann-Whitney U test which found the 
same conclusions (Z = 3.51, p<0.001). Two of the lesion surgery rats did not rotate at the 
required >6 turns/min and were excluded from this analysis and the remainder of the study.  
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Figure 5.6. Mean turns/min after d-amphetamine at post-surgery day 7. Error bars denote 
SEM. 
5.4.2.  Adjusting steps test: Akinesia 
Prior to surgery forelimb stepping did not differ between lesion and sham surgery groups 
(p>0.20) in the adjusting steps test. Post-surgery, lesions produced substantially impaired 
forelimb stepping compared to shams (Lesion, F(1, 16) = 139.57, p<0.001; Fig. 5.7). There 
was also a main effect of Time (F(1, 16) = 9.82, p<0.001) and a significant Time x Lesion 
interaction (F(2, 32) = 8.60, p = 0.001) due to the increasingly poor performance of the lesion 
rats. Post-hoc Newman-Keuls confirmed that forelimb stepping for lesion rats was 
significantly reduced on each test occasion. 
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Figure 5.7. Contralateral forelimb stepping in the adjusting steps test. Error bars denote SEM. 
5.4.3.  Sunflower seed handling test: Skilled forepaw use 
Prior to surgery the number of shell pieces produced did not differ between lesion and sham 
groups (p>0.20) in the sunflower seed handling test. Following surgery rats with lesions 
produced more shell pieces than sham (Lesion, F(1, 16) = 14.38, p = 0.002; Fig. 5.8). There 
was a main effect of Time (F(2, 32) = 4.05, p = 0.03) due to decreasing shell pieces produced 
over testing occasions. The Time x Lesion interaction was not significant (p>0.20). 
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Figure 5.8. The mean number of shells leftover in the sunflower seed handling test. Error 
bars denote SEM.  
5.4.4.  Rotation after apomorphine 
Lesions induced significant contralateral rotations after apomorphine (Lesion, F(1, 16) = 
15.47, p = 0.001; Fig. 5.9). Neither the effect of Time (F(1, 16) = 2.42, p = 0.12) nor the 
Time x Lesion interaction (F(1, 16) = 1.61, p = .19) were significant.  
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Figure 5.9. Mean turns/min after apomorphine. Error bars denote SEM. Note: Contralateral 
turns are expressed as positive values. 
5.4.5.  Tyrosine hydroxylase 
To pilot the tyrosine hydroxylase immunohistochemistry procedure a random selection of 
seven lesion and three sham rats was used. At day 65, the 6-OHDA lesions significantly 
reduced TH density in the striatum compared to sham (t(8) = 17.98, p<0.001; Fig. 5.10). 
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Figure 5.10. Striatal TH density at day 65. (A) Representative photomicrographs for a 6-
OHDA lesion and sham rat (B) Figure showing % TH fibre density. Scale bar represents 
2mm.  
 
5.5.  Summary and discussion 
Unilateral 6-OHDA lesions of the striatum produced substantial akinesia impairments in the 
adjusting steps test, and increased rotation after d-amphetamine and apomorphine 
administration. Lesions also increased the number of shell pieces produced in the sunflower 
seed handling test. The lesions substantially decreased TH density in the striatum.  
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Tyrosine hydroxylase 
6-OHDA infusions produced a substantial lesion resulting in ~89% reduction in TH fibre 
density in the striatum at day 65 post-surgery. Previous studies have found ~80-90% 
reduction in TH striatal fibre density at two, eight, 12, and 15 weeks after lesion surgery 
(Dowd et al., 2005a; Grealish et al., 2008; 2010; Kirik et al., 1998; Walsh et al., 2011). Other 
studies reported more moderate reductions between ~50 – 80% at 12 weeks and seven 
months after surgery (Kirik et al., 2001a, 2001b). The current finding of a substantial 
depletion of striatal TH at day 65 after the 6-OHDA lesion is consistent with previous reports 
of the four-site 6-OHDA lesion model.  
Rotation after d-amphetamine 
At 7 days post-lesion 6-OHDA produced substantial ipsilateral rotation after d-amphetamine 
administration. Sham rats did not have a rotation bias so this effect is attributable to the 
unilateral 6-OHDA neurotoxin, not non-specific damage caused by the vehicle. The presence 
of this rotation bias confirmed dopamine lesions and a deficit soon after surgery. This finding 
is consistent with the original report of the unilateral four-site 6-OHDA lesion of the striatum 
by Kirik et al. (1998) where they found substantially increased rotation after d-amphetamine 
at day 7 after lesion surgery. The rate of rotation they reported (12.1 turns/min) was 
comparable to our findings (14.2 turns/min). Recent studies employing the four-site 
intrastriatal 6-OHDA lesion model have tested rotation after d-amphetamine at different 
times after surgery. Similar rates of rotation to the current experiment have been found when 
rats were first tested at two, three, four, and five-six weeks after surgery (Breysse et al., 2007; 
Carlsson et al., 2009; Grealish et al., 2008, 2010; Kirik et al., 2001a; Shin et al., 2014). In 
these studies the rate of rotation varied between ~11–18 turns/min with the exception of 
Grealish et al. (2008) who found a moderate rotation rate of ~5.5 turns/min. In their study the 
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rate of rotation was more moderate as they included all rats that displayed an ipsilateral 
rotation bias regardless of the rate of rotation. The day at which rotation after d-amphetamine 
is first tested depends on the aim of the study. The current thesis tested rotation at day 7 as a 
dopamine lesion effect needed to be detected soon after surgery prior to PROG treatments 
and subsequent tests of motor impairments (see Chapter 6). 
Adjusting steps test: Akinesia 
Lesions produced substantial forelimb akinesia impairments in the adjusting steps test 
whereas sham rats were unimpaired. This impairment in forelimb akinesia was evident at the 
start of testing on this task at day 15 but it also worsened steadily across subsequent testing. 
This finding shows that forelimb akinesia impairment can get progressively worse in this 
unilateral 6-OHDA striatal lesion model.  
Contralateral to lesion forelimb stepping is usually moderate to substantially reduced 
after four-site intrastriatal 6-OHDA lesions. The current experiment found that the percentage 
of contralateral forelimb steps out of the total steps made for both forelimbs was reduced to 
about 25% at week two, 19% at week 4, and 13% at week 7. Unimpaired rats would score 
50% whereas substantially impaired rats would score ≤15% in this task (Winkler et al., 
2006). Therefore, in the current experiment rats with lesions had moderately impaired 
forelimb stepping at week two which progressed to a substantial impairment at week 7 after 
surgery. 
Kirik et al. (1998) found that contralateral forelimb stepping was moderately reduced 
at week three after surgery which had decreased further at week eight. Kirik et al. (2001a) 
found that contralateral forelimb stepping was moderately reduced at week one and remained 
stable over 12 weeks of testing. When tested at three to four weeks after surgery moderate to 
substantially reduced contralateral forelimb stepping has been reported (Dupre et al., 2008; 
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Fang et al., 2006; Shin et al., 2014; Sun et al., 2013; Winkler et al., 2002). A stable but 
substantial impairment by day two after surgery has also been reported (Grealish et al., 2008). 
Interestingly, Kirik et al. (2001b) found that rats with both moderate and substantial forelimb 
stepping impairment at one month showed partial recovery when tested again at three and 
seven months post-surgery. This was possibly due to spontaneous sprouting of dopaminergic 
fibres and TH recovery in the striatum that can occur several months after partial 6-OHDA 
lesions (Stanic et al., 2003). 
These studies show that impaired forelimb stepping in the adjusting steps is typically 
evident within three weeks after surgery. The impairment is often stable for up to three 
months although longer term testing can show partial recovery (e.g. Kirik et al., 2001b). 
However, testing over several weeks can show some progressive impairment (e.g. Kirik et al., 
1998). Forelimb akinesia in the current experiment is consistent with previous studies as a 
forelimb stepping impairment was found at two weeks that worsened over subsequent testing.  
Sunflower seed handling test: Skilled forepaw use 
As expected rats made many forepaw adjustments on the sunflower seeds during handling 
and eating. These adjustments were too rapid to be reliably scored. Time spent handling and 
eating the seeds also could not be scored as rats regularly moved out of view of the camera. 
However, the number of shell pieces produced was easily scored. Lesion rats produced more 
shell pieces during sunflower seed handling compared to sham rats. The number of shell 
pieces produced decreased at subsequent testing occasions for both lesion and sham rats. 
Impaired grip on pasta pieces has been observed in rats with unilateral 6-OHDA 
lesions (Allred et al., 2008). If present in the current experiment impaired grip on the 
sunflower seed could account for the increase shell pieces leftover. According to Whishaw 
and Coles (1996) intact rats grip sunflower seeds with a symmetrical paw hold and curl digit 
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five (the “little finger”) around the bottom of the seed. Differences in forepaw grip on the 
seed do not likely account for the increased shells leftover in the current experiment as casual 
observations revealed that both lesion and sham rats held the sunflower seed with a typical 
grip. Typical grip styles do not exclude 6-OHDA lesion rats from having impaired 
contralateral forepaw adjustments as observed in the vermicelli pasta handling test (Allred et 
al., 2008). The increase in shells leftover among rats with lesions is not likely a result of 
forepaw use alone as shelling and eating requires an interaction between the forepaws and 
oral motor function (Kane et al., 2011). This finding suggests there may be some impairment 
in skilled forepaw use in our model although differentiating this deficit from oral motor 
function requires testing in a different task such as single-pellet skilled reaching (see Chapter 
6). 
Rotation after apomorphine 
Lesions produced significant contralateral rotation after apomorphine that was evident at day 
24 and had not diminished at day 61 post-surgery. This finding suggests there was substantial 
striatal deafferentation that had produced a persisting supersensitivity by day 24. The 
occurrence of contralateral rotation was, however, variable at day 24 with three of the ten 
lesion rats not showing a contralateral rotation bias. At day 61 all lesion rats preferentially 
rotated in the contralateral direction. So the time-course of this supersensitivity is variable. 
Previous studies have shown increased contralateral rotation after apomorphine at two 
through to 12 weeks after four-site intrastriatal 6-OHDA lesion surgery (Kirik et al., 1998, 
2001a). In addition, differential rates of rotation have been found in rats with moderate and 
severe impairment on the adjusting steps test. Rats that were severely impaired on the 
adjusting steps test rotated substantially after apomorphine whereas moderately impaired rats 
showed intermediate rotation at six weeks after surgery (Kirik et al., 2001b). In another study, 
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rats that had severely impaired forelimb stepping rotated substantially at six weeks, but, 
rotation had recovered at three and six months post-lesion (Winkler et al., 2006). Consistent 
with these reports the current experiment found increased contralateral rotation at day 24 that 
was maintained at day 61.  
Comparison of behavioural tests 
In the pilot study, impaired forelimb stepping on the adjusting steps test worsened over time, 
which is due to the striatal 6-OHDA infusions causing progressive degeneration of 
dopaminergic neurons in the SNpc (Walsh et al., 2011). This phenomenon is due to the 
sensitivity of the adjusting steps test to relatively small changes in dopamine depletion 
(Chang et al., 1999; Kirik et al., 1998; Olsson et al., 1995). The adjusting steps test provides a 
reliable assessment of dopamine depletion although impaired forelimb stepping is not 
exclusively dopamine associated (Chang et al., 1999; Pinna et al., 2007, 2014). Conversely, 
impaired skilled use of the forelimbs in the seed handling test is associated with both 
dopaminergic and non-dopaminergic changes after 6-OHDA lesions, such as ipsilateral motor 
cortex dysfunction in the areas responsible for skilled forelimb use (Plowman et al., 2014; 
Viaro et al., 2011). In treatment studies it would therefore be useful to include skilled 
forelimb task to assess neuronal plasticity beyond dopamine neurotransmission. By contrast, 
drug-induced rotation is most closely associated with dopamine depletion. The rotational bias 
produced by a pharmacological challenge with a dopamine agonist is dependent on 
asymmetrical dopamine neurotransmission (Ungerstedt & Arbuthnott, 1970). Drug induced 
rotation tests provide a gross assessment of dopamine related behavioural impairment but 
have limited translational value as the rotational bias is a pharmacological phenomenon. In 
treatment studies rotation after d-amphetamine will be useful as an ante-mortem validation of 
the 6-OHDA lesion prior to treatment with PROG whereas rotation after apomorphine is 
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useful as an ante-mortem indication of extensive dopamine lesions.   Identification of 
PROG treatment time-point and assessment of motor impairments 
The findings of this experiment indicated that a  dopamine depletion was present at day 7 
after surgery as shown by increased rotation after d-amphetamine which is an indication of 
asymmetrical dopamine depletion. Impairments in forelimb akinesia in the adjusting steps 
test, the primary outcome measure, were observed at day 15 and progressively worsened 
thereafter. These findings support the starting of PROG treatment as soon as possible after 
lesion verification in the d-amphetamine rotation test. PROG treatment should be started at 
day 8 to avoid interactions with d-amphetamine and to ensure any beneficial effects are due 
to neuroprotection and not interactions with 6-OHDA neurotoxin metabolism (see Chapter 6 
for further discussion). Starting PROG treatment at day 8 is ideal as a PD like impairment is 
present as shown by increased rotation after d-amphetamine but not yet fully developed as 
evidenced by progressive forelimb akinesia impairment. PROG’s influence on motor 
impairments should be assessed in both drug induced rotation and clinically relevant non-
drugged measures of motor function.  
Rotational behaviour after d-amphetamine and apomorphine has long been the ‘gold 
standard’ with which to screen potential therapeutic candidates (Pienaar et al., 2012). It is 
suggested that the reduction of rotation intensity after therapeutic intervention is evidence of 
treatment efficacy (Pinna and Morelli, 2014). For example, transplants of dopaminergic cells 
in 6-OHDA lesion rats reduces rotation after d-amphetamine to levels observed in intact rats 
and improves forelimb akinesia, sensory neglect, and forelimb use asymmetry (Grealish et 
al., 2010; Mukhida et al., 2001; Torres et al., 2008). However, skilled reaching is not 
improved despite substantial reduction in rotation after d-amphetamine and apomorphine 
(Torres et al., 2008). Furthermore, the intensity of rotation after d-amphetamine and 
apomorphine was not correlated with motor assessments of skilled reaching and skilled 
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ladder rung walking (Metz and Whishaw, 2002). These findings show that drug induced 
rotation and impaired skilled motor functions are independent consequences of 6-OHDA 
lesions. A common criticism of drug induced rotation tests is that the model is a 
pharmacological phenomenon whereas the impairments observed in clinical PD are present 
without drug induction (Meredith and Kang, 2006). In light of these findings current 
recommendations are to combine drug induced rotation tests with more clinically relevant 
measures to fully assess loss and recovery of function (Meredith and Kang, 2006; Metz and 
Whishaw, 2002; Pinenaar et al., 2012).  
The adjusting steps test is widely used and is considered a clinically relevant measure 
of akinesia, a cardinal feature of PD (e.g. Bordia et al., 2015; Pinenaar et al., 2012; Schallert 
et al., 1992; Shin et al., 2014). Furthermore, the adjusting steps test produces the most 
reliable behavioural readout following partial 6-OHDA lesions (Duty and Jenner, 2011). The 
reliability and clinical relevance of the adjusting steps test support its use as the primary 
outcome measure in PROG treatment studies. The adjusting steps test should be used in 
conjunction with drug induced rotation and skilled reaching tests to fully assess loss and 
recovery of function. 
Subsequent experiments involving PROG treatment should assess motor skills in both 
the short and longer term after lesion surgery. The rationale for assessing the relatively 
immediate and longer term consequences of PROG is to demonstrate sustained benefit of the 
treatment as this is critical to the development of new neuroprotective agents (Fisher et al., 
1999, 2009). In the current and subsequent experiments using PROG (see Chapters 6 and 7) 
motors skills were assessed between two and eight weeks after lesion surgery as this time 
period captures the relatively early to late stages after striatal 6-OHDA lesions, respectively 
(Kirik et al., 1998). 
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 In summary, this pilot experiment has established the time-course for motor 
impairments in our unilateral 6-OHDA partial lesion model of PD. Additionally, we have 
identified day 8 as a suitable time to start PROG treatment in later experiments. This 
experiment established the efficacy of the adjusting steps test as a reliable measure of 
akinesia. A possible deficit in skilled forepaw use was also found which suggests later 
experiments examining PROG’s influence should include a behavioural task involving skilled 
forelimb use. The utility of the d-amphetamine rotation test as an ante-mortem verification of 
the lesion was established and was used in subsequent experiments to determine the presence 
of a PD like impairment before PROG is administered. Increased rotation after apomorphine 
was also found in our model and will be a useful assay of PROG’s influence on 6-OHDA 
lesion induced supersensitivity.  
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Chapter 6   
Study Two: Progesterone after Large 
Intrastriatal 6-OHDA Lesions 
6.1.  Objectives 
This chapter reports the second of three experiments (see also: Chapters 5 and 7) and 
involves PROG treatment in the 6-OHDA model of PD. The objective of this experiment was 
to examine PROG’s influence on akinesia, skilled reaching, and rotation after apomorphine 
following 6-OHDA lesions. Rats were tested preoperatively on the adjusting steps test for 
akinesia (as previously)  and a single pellet skilled reaching task (a new version compared to 
the previous sunflower seed test)  and then given 6-OHDA lesions or sham surgery. As 
before, the success of the lesion was confirmed at day 7 with a d-amphetamine rotation test. 
Eight days after surgery injections of either 8 mg/kg PROG, 4mg/kg PROG or sesame oil 
vehicle were given once daily for 7 days with tapered withdrawal by sequential halving on 
the sixth and seventh days of treatment. The first injection was given intraperitoneal (i.p) and 
the remainder were given subcutaneous (s.c) Rats were tested on the adjusting steps test on 
post-surgery days 17-19, 27-29, 39-41, and 53-55, on the skilled reaching test on days 24-26 
and 49-51, and the apomorphine rotation test at days 29 and 62. Rats were sacrificed at day 
64 for tyrosine hydroxylase immunohistochemistry of the striatum. An additional group of 
rats designated ‘lesion-only control’ were euthanized at day 8 to serve as a reference for the 
analysis of tyrosine hydroxylase at the time when PROG treatment was started. This chapter 
begins with a brief recap of the justification for examining the influence of PROG in an 
animal model of PD.  
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6.2.  Introduction 
As discussed in Chapter 3, there is considerable evidence that the neurosteroid PROG 
improves functional and neurological outcomes in animal models of TBI and ischemia (see 
Deutsh et al., 2013; Stein et al., 2008 for reviews). PROG offers neuroprotection by reducing 
cerebral edema, decreasing proBDNF and proNGF, increasing BDNF, enhancing neuronal 
survival, decreasing neuronal apoptosis, reducing oxidative stress, and attenuating 
neuroinflammation in brain injury models (Deutsh et al., 2013). Despite the increasing 
evidence for the beneficial effects of PROG following brain injury PROG’s influence has 
been examined in only a few pre-clinical studies of PD (see Chapter 3). Many of the pro-
recovery effects of PROG listed are plausible mechanisms of neuroprotection in the context 
of PD also (see Figure 3.1 in Chapter 3). For example, activated microglia, a sign of 
neuroinflammation, has been reported in clinical PD brains and animal models including 
those using 6-OHDA lesions (see Hirsch and Hunot, 2009 for a review). Neuroinflammation 
is thought to contribute to the cascade that leads to neurodegeneration in PD (Barcia, 2013). 
PROG has reduced the expression of activated microglia and other markers of inflammation 
in models of TBI, ischemia, spinal crush injury, demyelinating disease, and Alzheimer’s 
disease (Deutsch et al., 2013; Wei and Xiao, 2013). PROG, therefore, could offer 
neuroprotection after 6-OHDA lesions by reducing the expression of activated microglia. To 
examine PROG’s influence on motor impairments following unilateral 6-OHDA lesions we 
used the four-site intrastriatal model as established in the pilot study (see Chapter 5). 
 To examine PROG’s efficacy on motor impairments we tested forelimb akinesia, 
skilled reaching, and rotation after apomorphine. Forelimb akinesia in the adjusting steps test 
was used as the primary behavioural outcome measure as akinesia is a cardinal feature of PD 
and contributes to poorer quality of life in PD patients (Olsson et al., 1995; Rahman et al., 
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2008). Contralateral rotation after apomorphine was used as an ante-mortem indication of 
PROG’s influence on 6-OHDA striatal lesion induced supersensitivity.  
 We found a possible impairment in skilled forepaw use following striatal 6-OHDA 
lesions (see study one, Chapter 5). We examined skilled forepaw use further in the current 
PROG experiment as impairments in fine motor control are a debilitating symptom in PD 
patients (Klein et al., 2012). Instead of the previous sunflower seed handling test we used a 
single-pellet reach-to-eat task as a measure of skilled forelimb use. This task was selected as 
a rat’s skilled reaching for a food target is phylogenetically and structurally similar to skilled 
reaching in humans (Klein et al., 2012). Previous studies have shown that unilateral 6-OHDA 
lesions impair skilled reaching performance of the contralateral forelimb in the single-pellet 
reaching task (Klein et al., 2007; Metz et al., 2003; Plowman et al., 2013, 2014). 
When testing the efficacy of neuroprotective agents it is crucial to administer the drug 
so that it is affecting the underlying disease pathology rather than interacting with the 
neurotoxin’s metabolism. It is not known if PROG will interact with 6-OHDA metabolism 
but to ensure that any beneficial effects of PROG are due to neuroprotection and not 
interactions with6-OHDA metabolism we used a treatment protocol whereby PROG 
treatment was not started until the 6-OHDA neurotoxin had metabolized and the cell death 
cascade had commenced. This approach to examining neuroprotective agents in PD models 
has been used elsewhere (Hung et al., 2012). Previous studies have shown that SN cell death 
emerges from 3 days after four-site intrastriatal 6-OHDA infusions and then progressively 
worsens thereafter (Cicchetti et al., 2002; Walsh et al., 2011). Therefore, PROG treatment 
should not be started before day 3 post-lesion. In addition, PROG treatment should not be 
started until a PD like impairment is present, as discussed in Chapter 5. In the pilot 
experiment (see Chapter 5) we found a PD like impairment was present at post-surgery day 7 
as evidenced by increased rotation after d-amphetamine. To avoid interactions with d-
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amphetamine we started PROG treatment at day 8 after surgery. At this point 6-OHDA 
metabolism had terminated, the cell death cascade had commenced, and a PD like 
impairment was present.  
 The PROG doses used in the current experiment were 8 mg/kg and 4 mg/kg. These 
doses were selected as they represent common doses used in the literature that have improved 
functional and neurological outcomes in rat models of TBI (Grossman et al., 2004; Roof et 
al., 1996; Shear et al., 2002), and stroke (Jiang et al., 1996; Sayeed et al., 2007; Yousuf et al., 
2014). PROG was administered once daily for seven days. This length of treatment represents 
a standard treatment regime in TBI and stroke models (e.g. Geddes et al., 2014; Yousuf et al., 
2014). Suddenly withdrawing PROG after repeated dosing can exacerbate the lesion effects, 
produce an inflammatory rebound effect, and increase anxiety like behaviours (Cutler et al., 
2005; Cutler et al., 2006). We therefore used tapered withdrawal by sequential halving of the 
dose on the sixth and seventh days of treatment as this has been shown to overcome the 
PROG withdrawal syndrome (Cutler et al., 2005). 
 The novel aim of this study was to examine the beneficial influence of PROG 
treatment in the 6-OHDA striatal lesion model of PD. As discussed the pleiotropic actions of 
PROG may be beneficial in the 6-OHDA lesion model by reducing neuroinflammation, 
oxidative stress, and neuronal apoptosis, and increasing trophic support. This experiment 
represents the first study in this field to examine whether PROG reduces striatal 6-OHDA 
lesion induced impairments on akinesia, skilled reaching, and rotation after apomorphine. 
Furthermore, this experiment investigated PROG’s influence on motor impairments in terms 
of both short and longer term outcomes.  
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6.3.  Materials and Methods 
6.3.1.  Animals 
Fifty-nine male Wistar rats were used, weighing between 531g and 756g at the day of 
surgery. The lesion control, sacrificed at day 8 after surgery, were ~7 months old. The rats 
used in the main experiment were 8-13 months old at surgery and 10-15 months old at 
perfusion. Testing occurred during the dark phase of the rats reversed light cycle (lights on at 
2000hrs). Rats were housed individually for five days of post-surgery recovery after which 
they were housed in groups of 3-4 for the remainder of the study. All protocols in this study 
followed the NIH Guide for the Care and Use of Laboratory Animals and were approved by 
the Animal Ethics Committee University of Canterbury. Two rats were lost after surgery and 
four rats were euthanized several weeks after surgery due to respiratory distress due to 
unknown reasons.  
6.3.2.  Experimental design 
The experiment used a between groups design with the experimenter blinded to the PROG 
treatment group of the lesion rats. Matched rats were assigned to groups (4 mg/kg PROG, 8 
mg/kg PROG, vehicle, or sham) according to their pre-surgery hit rate performance on the 
skilled reaching test. The lesion-only control group were handled prior to surgery but were 
not trained or tested on the skilled reaching or adjusting steps test. The sequence of 6-OHDA 
lesion surgery, PROG treatment, and motor skills testing is shown in Fig. 6.1.  
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Figure 6.1. Experimental timeline. Rats were unilaterally lesioned with a 4-site 6-OHDA 
lesion of the striatum. Lesion rats rotating in the ipsilateral (to lesion) direction at the 
criterion of>6 turns/min at day 7 after d-amphetamine were matched to treatment groups 
according to baseline skilled reaching hit rate. Progesterone was given once daily on days 8-
14. Akinesia in an adjusting steps test and skilled forelimb use in a single pellet reaching task 
were tested between days 17 and 53. Contralateral (to lesion) rotation after apomorphine were 
measured at days 29 and 62. Lesion control rats were euthanized at day 8 and all other rats 
were euthanized at day 64 for histology. Adj, adjusting steps test; Apo, apomorphine rotation 
test; d-amp, d-amphetamine rotation test; PROG, progesterone; skill, single pellet skilled 
reaching test. 
6.3.3.  Surgery 
The same surgery protocol as described in Chapter 5 was used except rats were operated on 
the side contralateral to their preferred paw as identified in the pre-surgery skilled reaching 
task. All lesion control rats received infusions on the right side.  
6.3.4.  Rotation after d-amphetamine and apomorphine  
Rats were tested for rotation after d-amphetamine at post-surgery day 7 and apomorphine at 
days 29 and 62 using the same procedure as described in chapter 5.  
6.3.5.  Progesterone treatment 
Eight days after surgery rats with 6-OHDA lesions were given either 4 mg/kg PROG (Sigma, 
Castle Hill, Australia, n = 11), 8 mg/kg PROG (n = 9) or vehicle (n = 10) once daily for seven 
days. Tapered withdrawal of the PROG treatment in both groups was used by sequentially 
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halving the dose on the sixth and seventh days of treatment. Sham rats (n = 8) received 
injections of the vehicle alone. PROG was dissolved in sesame oil (Sigma) and injected at a 
volume of 0.4 ml/kg. The first injection was given i.p. to allow for rapid absorption and the 
remainder were given s.c, with injections being administered between 10:00am and noon 
each day. Lesion control rats (n = 7) did not receive any injections. These treatment 
procedures were suggested by Prof. Don Stein and Assistant Prof. Iqbal Sayeed of Emory 
University, Atlanta, Georgia who are experts regarding PROG neuroprotection (personal 
communications). The bottles containing the PROG and vehicle solutions were labelled by an 
independent investigator who kept the code in a locked safe that could not be accessed by the 
experimenter responsible for the assessment of outcomes. The experimenter remained 
blinded to the treatment condition for all lesion rats until all data had been collected and 
analysed.  
6.3.6.  Adjusting steps test: Akinesia 
Forelimb akinesia was measured pre-surgery and at post-surgery days 17-19, 27-29, 39-41, 
and 53-55 using the same procedure as described in Chapter 5.  
6.3.7.  Single pellet-reaching task: Skilled reaching 
Skilled reaching was tested using a “reach to eat” task. Rats were tested pre-surgery and at 
post-surgery days 24-26 and 49-51. 
Food restriction. Prior to pre-surgery training rats were gradually food deprived to 
90-95% of their ad libitum body weight by food restriction. Five days prior to training rats 
were habituated to the pellet reaching targets. Each rat received twenty 45mg dustless 
precision chocolate-flavoured pellets (Bioserve, Frenchtown, NJ, USA) in their home cage 
about 1 hour prior to daily feeding. These standardised pellets (size, shape, weight) ensured 
consistency of the reaching target. Rats were returned to free-feeding following pre-surgery 
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testing. In post-surgery sessions rats were again food deprived to ~ 95% of their ad libitum 
body weight over the four days prior to testing. 
Reaching box. The reaching box was made of clear acrylic glass measuring 21cm 
long x 14cm wide x 16cm high with a hinged lid (Fig. 6.2). The floor was made of 0.9cm
2
 
grids so that dropped pellets fell and could not be retrieved. The front of the apparatus 
consisted of a removable clear window. The centre of the habituation window used to 
establish forelimb preferences contained a vertical slot measuring 1.8cm wide that extended 
from the floor to a height of 12cm (Fig. 6.2 A, B). A 4cm deep platform was mounted 3.25cm 
above the floor in front of the slot on the outside of the window. The four wells used to hold 
pellets were located 2cm from the inside edge of the window. The centre of the two medial 
wells was located 0.25cm either side of the centre of the slot. The centre of the lateral wells 
was placed in line with the edges of the vertical slot. The location of the lateral wells 
encouraged use of the contralateral paw as the paw pronates medially to grasp and it prevents 
a rat from retrieving the pellet with its tongue. A different window was used for testing and 
contained two vertical slots each located 1.5cm from the side walls of the box (Fig. 6.2 C, D). 
The location of the slots prevented the rat from using the paw contralateral to the side wall 
thus permitting independent assessment of each forelimb. In front of each of these testing 
slots there was a 1.5cm deep notch that extended 0.5cm past the medial edge of the slot. This 
notch meant that the rat could not slide the pellet to its mouth from the platform, instead 
requiring the pellet to be grasped and lifted.  
 
Study Two: Progesterone after Large Intrastriatal 6-OHDA Lesions 
116 
 
 
Figure 6.2. The reaching box apparatus used for single pellet skilled reaching. Views of the 
habituation (A, B) and testing windows (C, D). The habituation window consisted of a single 
central vertical slot whereas the testing window had two vertical slots located near the side 
walls of the reaching box.  
Training. Rats were trained in the skilled reaching box for one 10min session per day 
for four weeks. The first phase familiarised the rat with the reaching box and the location of 
the pellets using the habituation window. Rats were placed in the box with several pellets 
placed on the platform within reach of the rat’s tongue. Rats were required to eat pellets from 
the platform before progressing to reach training, which took two sessions. The second phase 
shaped reaching behaviour. A reach was defined as any advance of the forepaw through the 
slot towards the target. The pellets were moved away from the slot to encourage use of the 
paws. Rats required up to two sessions to develop a preference for reaching. The third phase 
of training established the rats paw dominance. For each trial rats were presented with one 
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pellet in each of the four wells. Rats were free to reach with either paw. Paw dominance was 
defined as the paw used to take the pellet in at least 70% of trials for three consecutive days.  
The final phase trained skilled reaching of the dominant forelimb using the window 
with two side slots (i.e. the “testing” window). Each session consisted of 20 trials with one 
pellet per trial placed in the most medial well of the slot ipsilateral to the dominant paw. On 
each trial the rat was required to reset its body posture by moving away from the slot before 
presentation of the next pellet. This ensured that each trial consisted of a discrete reach. If the 
rat reached when a pellet was not present it was required to move away before the next pellet 
was presented. Reaching when a pellet was not present was minimised by withholding pellets 
on random trials. This encouraged the rat to probe the slot by sniffing and reach only when a 
pellet was present (Fig. 6.3). After the rat was making discrete reaches it received daily 
sessions consisting of 10 warm-up trials followed by 20 scored trials. The rat was trained 
until its average “hit” rate for the preceding three sessions was 70%. Finally, the rat received 
three videotaped sessions (Panasonic digital video camera recorder; Model SDR-H85) that 
served as the rat’s average baseline performance. Rats were matched to groups according to 
their baseline hit rate on this task.  
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Figure 6.3. Example of a successful skilled reaching sequence during pre-surgery testing. 
The rat orients to the pellet by sniffing (A) then advances its paw through the slot (B) to grasp 
the pellet (C) then retracts its paw to eat the pellet (D).  
Scoring reaching success. Two end-point measures were used to quantify skilled 
reaching accuracy. A “success” occurred when in one reach attempt the rat grasped the pellet, 
brought it back inside the box, and ate it. If the rat required more than one reach to grasp and 
eat the pellet then these trials were added to the “success” trials to derive an overall “hit” rate. 
If the pellet was dropped or dislodged from the well it was considered an “unsuccessful” 
reach. Rats were allowed up to five reaches per trial after which the pellet was removed and 
the trial counted as an unsuccessful reach. Three sessions were averaged at each testing time-
point. The “success” rate was calculated as number of success/20 x 100%. The “hit” rate was 
calculated as number of hits/20 x 100%.  
A B
C D
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Post-surgery testing. Rats were tested between days 24-26 and days 49-51. To 
ensure equivalency in the recency of skilled reaching experience, all rats received “refresher” 
sessions on the three days prior to testing. Rats received one refresher session per day 
consisting of 20 non-scored trials.  
6.3.8.  Perfusion and immunohistochemistry 
Lesion-only control rats were euthanized at day 8 at the time of day when PROG treatment 
would have been administered i.e. between 10:00am and noon. The remaining rats were 
euthanized at day 64. The same perfusion, TH immunohistochemistry, and quantification 
procedures as described in Chapter 5 were used.  
6.3.9.  Statistical analysis 
Statistical analyses (Statistica software, version 12.0) were conducted to determine if the 
impairments in akinesia (adjusting steps test), skilled reaching (single-pellet skilled reaching 
task), and rotation after apomorphine produced by striatal 6-OHDA lesions were reduced by 
PROG treatment. Differences in pre-surgery performance on the adjusting steps and skilled 
reaching tasks, rotation after d-amphetamine, and striatal TH density were analysed by a one-
way ANOVA (five groups; 4 mg/kg PROG, 8 mg/kg PROG, vehicle, sham, and lesion-only 
control). Differences in post-surgery skilled reaching performance were also analysed with a 
one-way ANOVA as only days 49-51 could be analysed due to a feeding error at the earlier 
testing time-point (see below). The Group x Time interaction in post-surgery adjusting steps 
test and rotation after apomorphine was analysed by a two-way ANOVA (pre-surgery data 
were not included due to differences in variances). One 8 mg/kg PROG rat was excluded 
from the analysis for the rotation after apomorphine test due to a video tracking error. Post-
hoc Newman-Keuls multiple comparisons were used for significant main effects and 
interactions. Statistical significance was set at p<0.05. All data are expressed as means ± 
SEM. 
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6.4.  Results 
6.4.1.  Rotation after d-amphetamine  
At post-surgery day 7 nine of the lesion rats did not show a rotation bias at the required 
>6turns/min and were excluded from the study. The remainder produced substantially 
increased ipsilateral rotations (F(4, 40) = 59.01, p<0.001) confirming the success of the 
lesion (Fig. 6.4). Post-hoc Newman-Keuls confirmed that all lesion groups rotated 
significantly more than sham (all p<0.001) but did not rotate differently from each other (all 
p>0.20).  
 
 
Figure 6.4. Mean turns/min after d-amphetamine at day 7. Error bars denote SEM. 
6.4.2.  Adjusting steps test: Akinesia 
Prior to surgery forelimb stepping did not differ between lesion and sham surgery groups 
(p>0.20). Post-surgery, lesions caused substantially impaired forelimb stepping (Lesion, F(3, 
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34) = 19.24, p<0.001; Fig. 6.5). Post-hoc Newman-Keuls showed that all lesion groups made 
significantly fewer steps than the sham group (all p<0.001) but both 4 mg/kg PROG and 8 
mg/kg PROG treatment groups were less impaired with an intermediate level of impairment 
compared to the vehicle-treated lesion group (both p<0.01). Forelimb stepping did not differ 
between the two PROG treatment groups (p>0.20). Neither the main effect of Time (p>0.20) 
nor the Time x Group interaction (p>0.20) were significant, although the mean values for the 
vehicle-treated group worsened over time.  
 
Figure 6.5. Contralateral forelimb stepping in the adjusting steps test. Error bars denote SEM. 
6.4.3.  Single- pellet reaching task: Skilled reaching 
At the day 24-26 testing session many of the rats would not participate in the task. It was 
discovered that these rats had inadvertently received additional food from laboratory staff and 
hence were not motivated. The day 24-26 data are therefore not reported. At the day 49-51 
time-point all rats were adequately food-deprived and readily engaged in the task. 
0
10
20
30
40
50
60
Pre-surgery 17-19 27-29 39-41 53-55
C
o
n
tr
a
la
te
ra
l 
fo
re
li
m
b
 s
te
p
p
in
g
 
(%
) 
Days post-surgery 
Adjusting steps test: Akinesia 
8 mg/kg
4 mg/kg
Vehicle
Sham
 
Study Two: Progesterone after Large Intrastriatal 6-OHDA Lesions 
122 
 
Preoperatively the “success” rate during skilled reaching did not differ between lesion 
and sham surgery rats (p>0.20). At days 49-51 after surgery, lesions reduced the “success” 
rate compared to sham (F(3, 34) = 3.75 p = 0.02; Fig. 6.6). Post-hoc Newman-Keuls revealed 
that 4 mg/kg PROG, 8 mg/kg PROG and vehicle treated lesion groups had a lower “success” 
rate than the sham group (all p<0.05). Neither 4 mg/kg PROG nor 8 mg/kg PROG treatment 
improved the “success” rate compared to vehicle treated lesion rats (both p>0.20). 
Prior to surgery the “hit” rate during skilled reaching did not differ between lesion and 
sham surgery rats (p>0.20). At post-surgery testing, the lesion effect was significant  (F(3, 
34) = 2.94, p = 0.047; Fig. 6.7) and post-hoc Newman-Keuls showed that 4 mg/kg PROG, 8 
mg/kg PROG and vehicle treated lesion groups produced less “hits” than the sham group (all 
p<0.05). As with the more stringent “success” measure, treatment with 4 mg/kg PROG or 8 
mg/kg PROG did not improve the “hit” rate compared to vehicle treated lesion rats (both 
p>0.20). 
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Figure 6.6. Success rate at post-surgery days 49-51 during single-pellet skilled reaching. 
Error bars denote SEM.  
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Figure 6.7. Hit rate at post-surgery days 49-51 during single-pellet skilled reaching. Error 
bars denote SEM.  
 
6.4.4.  Rotation after apomorphine 
Lesions increased contralateral rotation after apomorphine compared to sham surgery rats 
(F(3, 33) = 4.39, p = 0.01; Fig. 6.8). Post-hoc Newman-Keuls showed that all lesion groups 
rotated more than sham (all p<0.05) but 4 mg/kg PROG or 8 mg/kg PROG treatment did not 
significantly influence rotation (both p>0.20). Neither the main effect of Time (p>0.20) nor 
the Group x Time interaction (p>0.20) were significant.  
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Figure 6.8. Mean turns/min after apomorphine. Error bars denote SEM. Note: Contralateral 
turns are expressed as positive values. 
6.4.5.  Tyrosine hydroxylase 
6-OHDA lesions significantly reduced TH density in the striatum (F(4, 39) = 48.27, p<0.001; 
Fig. 6.9). Post-hoc Newman-Keuls showed that all lesion groups had significantly lower 
striatal TH density compared to shams (all p<0.001) and this effect was not changed by 4 
mg/kg PROG or 8 mg/kg PROG treatment (all p>0.20). The TH density of lesion control rats 
that were euthanized at day 8 (and thus had not received any treatment) did not differ from 
the 8 mg/kg PROG (p = 0.14), 4 mg/kg PROG (p>0.20) or vehicle (p>0.20) treated groups 
that were euthanized at day 64. One vehicle treated lesion rat was excluded from the analysis 
due to damage to the tissue sections that did not allow for reliable quantification.  
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Figure 6.9. Striatal TH density at day 64 in all groups except lesion-only control (day 8).(A) Representative photomicrographs for a 8 mg/kg 
PROG, 4 mg/kg PROG, vehicle, lesion control, and sham rat (B) Figure showing % TH density. Scale bar represents 2mm.
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6.5.  Summary and discussion 
Lesions produced substantial rotation after d-amphetamine and apomorphine, marked 
forelimb akinesia and skilled reaching impairments, and decreased TH density in the 
striatum. Both 4 mg/kg and 8 mg/kg PROG doses successfully reduced forelimb akinesia at 
all post-surgery testing occasions, but did not change skilled reaching, rotation after 
apomorphine, or TH density.  
Tyrosine hydroxylase 
The TH density of sham rats was 85% of the non-operated side. This was a little lower than 
expected and is likely due to one sham rat having a score of just 46% although this rat did not 
show impairment on any behavioural task. At day 8 the TH density in the striatum of lesion-
only control rats was reduced to ~11%. At day 64 the TH density was similar for 8 mg/kg 
PROG (25%), 4 mg/kg PROG (18%), and vehicle (19%) groups. The 8 mg/kg PROG group 
tended to have less TH fibre reduction than the other lesion groups, but, this difference was 
not significant. There was a trend for the day 64 rats to have less reduction in TH density 
compared to lesion control rats although this difference was not significant for any group. 
Hence striatal TH fibre degeneration was probably maximal by day 8, and that PROG 
treatment was not able to induce sprouting and/or regeneration of TH positive fibres that 
could be detected seven weeks after PROG treatment had stopped. Here it should be noted 
that the rats in the lesion control group were ~7-8 months old on the day of perfusion while 
the remaining rats in the day 64 survival groups were 10-15 months old at the day of 
sacrifice. This could be a limitation of the current experiment as nigrostriatal levels of 
dopamine and its metabolites can change with ageing although significant changes are not 
usually observed until the rat is aged 18 months or older (Friedemann & Gerhardt, 1992; 
Girogi et al., 1987).  
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 These findings are consistent with previous reports that TH fibre degeneration is 
complete approximately one week after intrastriatal 6-OHDA lesion surgery (Cicchetti et al., 
2002; Rosenblad et al., 2000) and support the success of the lesion method used. Previous 
studies have shown that significant reduction in TH density has emerged at 6 hours (Walsh et 
al., 2011) and 24 hours (Blandini et al., 2007; Grealish et al., 2008) followed by a progressive 
decline in TH density that became maximal at one to two weeks after surgery. Similar to the 
current experiment, Kirik et al. (2001a) found substantial reduction in TH density at two 
weeks that had not declined further at 12 weeks after surgery.  
Rotation after d-amphetamine 
The success of the lesion was also shown by the substantial rotation at day 7 after d-
amphetamine injections. All lesion groups rotated at similar levels that were not significantly 
different from each other. This confirmed that a functional impairment was similar across the 
6-OHDA lesion groups as an ante-mortem validation of the 6-OHDA lesion prior to PROG 
for treatment groups and thus probable also for the lesion-only control rats which showed 
substantial reduction of striatal TH density at day 8 after surgery. The increased ipsilateral 
rotation observed at day 7 was comparable to previous reports as discussed in Chapter 5. For 
example, substantially increased rotation after d-amphetamine at a similar level to the current 
experiment has been observed when rats were tested at one or two weeks after surgery (Kirik 
et al., 1998, 2001a). That is, the reduction in striatal TH at day 8 and increased ipsilateral 
rotation after d-amphetamine at day 7 confirm that a PD like impairment was present at the 
time of the first PROG injection. 
Adjusting steps test primary outcome measure: Akinesia 
Lesions produced substantial contralateral forelimb akinesia whereas sham surgery had no 
effect. The forelimb akinesia impairment was evident at the start of testing at day 17 in all 
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lesion groups and was maintained during subsequent testing. Impaired forelimb stepping in 
the vehicle treated lesion rats tended to worsen across subsequent tests although this change 
was not significant. The 4 mg/kg PROG and 8 mg/kg PROG treatment groups showed 
comparable performance to each other and were consistently impaired compared to shams at 
all post-surgery time-points. However, the PROG groups were substantially less impaired 
than vehicle treated rats with lesions at all post-surgery tests. The moderate forelimb akinesia 
impairment in the vehicle-treated lesion group was consistent with the previous studies 
discussed in study one (Chapter 5). For example, moderately impaired forelimb stepping at 2 
to 8 weeks after surgery has been reported elsewhere (Dupre et al., 2008; Kirik et al., 1998) 
 In the present study PROG was administer on days 8 – 14 then stopped. Assessment 
of forelimb akinesia began at day 17. Both 4 mg/kg PROG and 8 mg/kg PROG groups 
experienced reduced forelimb akinesia compared to vehicle rats that was evident at day 17 
and maintained at subsequent testing at days 27, 39, and 53.  This suggests that PROG 
treatment gave long-term reduction in akinesia impairments in the adjusting steps test. This 
improvement is not simply symptomatic relief as the akinesia improvement was still evident 
6 weeks after PROG treatment had stopped. The mechanism of action underlying this sparing 
of akinesia impairment is not clear but it does not involve striatal TH density. While the 
benefit of PROG was relatively immediate and long-lasting it was only partial. It would be 
interesting to know whether continued or repeated treatment regimes of PROG would have a 
greater benefit on this measure.  
Other studies have also shown that forelimb akinesia can be improved independent of 
striatal dopaminergic innervation. A previous report used a novel diketopiperazine 
administered daily for 14 days starting 2 weeks after a two-site 6-OHDA striatal lesion 
(Krishnamurthi et al., 2009). Krishnamurthi et al. (2009) found long-lasting reduction in 
forelimb akinesia at 3 – 8 weeks after the treatment had been completed that was independent 
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of striatal and substantia nigra TH. This novel diketopiperazine was also benficial on 
forelimb stepping after central administration to the lateral ventricles starting 2 hours after 
lesion surgery.   In another study, both voluntary and forced running wheel exercise started 
two weeks prior to partial 6-OHDA striatal lesions and maintained for four weeks after 
surgery improved forelimb akinesia recovery without sparing striatal dopamine transporters 
or substantia nigra TH positive cell bodies (O’Dell et al., 2007).  
Single-pellet skilled reaching 
The reduction in akinesia impairment found by PROG treated lesion rats did not extend to 
skilled reaching accuracy irrespective of the dose used. 6-OHDA lesions significantly 
reduced the “hit” and “success” rates at days 49-51 in the single-pellet skilled reaching task. 
Sham surgery did not impair either measure. 
In the current experiment impaired skilled reaching accuracy was confirmed at week 7 
after 6-OHDA lesion surgery. This finding is consistent with previous reports employing the 
single-pellet skilled reaching task in the four-site intrastriatal model where impaired skilled 
reaching accuracy was observed at week 6 after surgery (Plowman et al., 2013, 2014). 
Unfortunately, a procedural error meant that the test at 2-3 weeks post-lesion could not be 
assessed. In comparison, the Montoya staircase test is another test of skilled paw reaching 
that studies have used following unilateral 6-OHDA lesions (Montoya et al., 1991). Impaired 
skilled reaching accuracy has been observed on the staircase test at 2, 6, and 12 weeks after 
four-site 6-OHDA lesions (Kirik et al., 1998, 2001a, 2001b). However, Kirik et al. (2001b) 
found that only rats with severe TH degeneration were impaired. 
The inability of PROG treatment to improve skilled reaching accuracy is similar to 
previous studies where therapeutic interventions have not been effective and therefore this 
symptom represents a difficult impairment to reverse. Skilled reaching accuracy was not 
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improved by L-DOPA on a pasta matrix reaching test (Metz et al., 2001) or ethanol on a 
single-pellet reaching task (Metz et al., 2003) following MFB lesions. Skilled reaching was 
also not improved on the staircase test after post-lesion infusions of glial cell-line derived 
neurotrophic factor (GDNF; Kirik et al., 2001a) or grafts of fetal dopaminergic neurons both 
with or without continuous exposure to GDNF (Winkler et al., 2006) in the four-site model. 
Similarly, pre-lesion treatment with the neuroprotective agent parkin in a single-site site 
striatal model did not improve skilled reaching (Vercammen et al., 2006). Therefore, 
protecting or improving dopamine transmission alone may not be sufficient to improve 
skilled reaching after dopamine depleting lesions. However, improved skilled reaching on the 
staircase test has been reported in the MFB model following post-surgery grafts of rat 
embryonic ventral mesencephalic tissue when the reward contingency of the reaching task 
was high (Corderio et al., 2010) and after pre-lesion treatment with a lentiviral vector 
expressing GDNF (Dowd et al., 2005b). Thus, varying the nature of the task and improving 
the brains resilience prior to injury may be important factors for skilled reaching. 
Rats require training to develop the necessary skill to execute successful reaches in 
skilled reaching tasks (Klein et al., 2012). Following unilateral 6-OHDA lesions rats make 
compensatory adjustments to achieve successful reaches. These compensatory adjustments 
are largely learned and are different from the reaching technique learned prior to surgery 
(Metz et al., 2002). The motor skill learning required to make successful reaches is 
experienced based and thus several studies have found improved skilled reaching following 
experiential therapy. Six weeks of daily skilled reaching rehabilitation on a single-pellet task 
started 6 weeks after four-site striatal lesion surgery substantially improved reaching 
accuracy (Plowman et al., 2014). Similarly, post-surgery rehabilitation for several weeks in 
an easy tray reaching task also improved single-pellet skilled reaching performance after 
MFB lesions (Vergara-Aragon et al., 2003). Rats pre-trained on a single-pellet task then 
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housed prior to MFB lesions in an enriched environment for six weeks with toys and various 
food items that required differing types of forepaw manipulation had improved skilled 
reaching accuracy after several weeks of post-lesion testing (Jadavji et al., 2006).  
In clinical PD skilled reaching is not improved by L-DOPA medications (Melvin et 
al., 2005; Sacrey et al., 2011), accompanying preferred musical pieces that improve other 
aspects of motor function (Sacrey et al., 2009, 2011), or pallidal deep brain stimulation 
(Melvin et al., 2005). These clinical findings together with skilled reaching impairments 
observed in the 6-OHDA lesion model show that few therapies are able to improve skilled 
reaching accuracy. The most effective therapies for skilled reaching in the 6-OHDA lesion 
model  involve either motor skill training or treatment prior to lesion surgery.  
6-OHDA lesions of the nigrostriatal pathway may induce skilled reaching deficit due 
to dysfunction of the motor cortex area responsible for forelimb motor function. For example, 
reduction in the size of intracortical microstimulation forelimb representations in the motor 
cortex ipsilateral to lesion can be a consequence of unilateral 6-OHDA lesions (Plowman et 
al., 2014; Viaro et al., 2011). However, others have reported preserved forelimb 
representations following unilateral 6-OHDA lesions (Brown et al., 2009; Metz et al., 2004). 
This inconsistency could be explained by the use of desipramine to protect norardrenergic 
fibres in the Metz et al. (2004) study and the mild dopaminergic denervation observed after 
two striatal infusions in the Brown et al. (2009) study. Due to the substantial striatal TH 
lesions in the current experiment it is possible that motor cortex forelimb representations 
were reduced although this was not measured.  
Unilateral MFB 6-OHDA lesions cause greater dysfunction of the rostral than the 
caudal region of the motor cortex (Viaro et al., 2011). This explains, in part, why lesions 
impair skilled reaching accuracy as the complex movements involved in reach-to-eat tasks 
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are represented in the rostral forelimb area (Viaro et al., 2011). The onset of motor cortex 
dysfunction occurs within a few days after MFB lesions (Viaro et al., 2011) and has been 
observed several months after four-site striatal lesions (Plowman et al., 2014). This suggests 
that cortex dysfunction after striatal dopamine depleting lesions is rapid and enduring. 
Synaptic dysfunction in the frontal cortex is thought to contribute to skilled reaching 
impairment as motormap topography of forelimb movement representations is highly 
sensitive to the number and strength of synapses in this region (Plowman et al., 2014). 
Indeed, reductions in synaptophysin and synapse numbers have been reported within the 
frontal cortex ipsilateral to 6-OHDA infusions to the SNpc (Hou et al., 2010). Skilled 
reaching training produces synaptogenesis and enhances synaptic strength (see Adkins et al., 
2006 for a review) which may account for the beneficial influence of experiential therapy on 
skilled reaching accuracy. PROG treatment on the other hand can promote synaptogenesis in 
the CA1 region of the hippocampus after global ischemia in rats (Zhao et al., 2011). 
However, to the best of our knowledge it is not known if PROG can induce synaptogenesis in 
the frontal cortex after experimental injury. 
Delaying PROG treatment until day 8 after surgery possibly accounts for why PROG 
was unable to improve skilled reaching accuracy in the current experiment. As reported by 
Viaro et al. (2011) the onset of motor cortex dysfunction is rapid and progressive reaching 
maximum at about two weeks after MFB lesions. Therefore, PROG was unable to prevent 
skilled reaching impairment as it is likely that motor cortex dysfunction was reaching its peak 
at the time of the first PROG injection. 
Although PROG treatment did not improve the endpoint measures of skilled reaching 
it is not known if the qualitative aspects of skilled reaching were changed. The behaviour 
during single-pellet skilled reaching can be subdivided into a number of qualitative 
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movement elements. In rats with 6-OHDA lesions the qualitative aspects of a reach are 
impaired even when a successful reach is made (Klein et al., 2012). Qualitative analyses can 
distinguish compensatory reaching behaviour from the original reaching behaviour 
(Alaverdashvili and Whishaw, 2013). The examination of reach quality requires high speed 
video capture which was not available in the current experiment. Future studies examining 
PROG’s influence on skilled reaching should include a qualitative analysis of the movement 
elements. A qualitative analysis would elucidate PROG’s ability to preserve normal reach 
function from compensatory reach behaviour for successful reaches. Preserved normal reach 
function is clinically significant as compensatory behaviour can limit range of motion and 
produce joint stiffness and pain in the forelimbs (Alaverdashvili and Whishaw, 2013). 
Rotation after apomorphine 
Lesions produced increased contralateral rotation after apomorphine at day 29 that was 
maintained when tested again at day 62 indicating that 6-OHDA had produced 
supersensitivity in the lesioned striatum. Sham surgery did not produce a rotation bias at 
either testing occasion. PROG treatment did not reverse apomorphine induced rotation at 
either testing occasion. At day 62 there was a trend for the 4 mg/kg PROG group to rotate 
less than their rotation at day 29 and less than other lesion groups although these differences 
were not significant. However, this decreasing rotation among 4 mg/kg PROG rats resulted 
from two rats that had a clear contralateral rotation bias at day 29 but no bias at day 62. As 
discussed in study one (Chapter 5) the increased contralateral rotation observed at days 29 
and 62 is consistent with previous findings that have tested rotation after apomorphine at 
similar days after surgery (e.g. Kirik et al., 1998, 2001a).  
The inability of PROG to reduce contralateral rotation after apomorphine is readily 
explained by the TH density finding. As discussed above, TH density in the striatum was 
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substantial at day 8 for lesion control rats and did not change for PROG and vehicle treated 
lesion rats at day 64. Supersensitivity occurs after substantial loss of TH fibres and thus 
apomorphine administration favours stimulation of the lesion side to produce contralateral 
rotation (Duty and Jenner, 2011). PROG treatment could not reduce rotation after 
apomorphine as the striatal TH fibre degeneration was already complete at the time of the 
first PROG injection.  
Summary 
The present experiment reported the first study in this field regarding PROG’s beneficial 
influence on akinesia, skilled reaching, and rotation after apomorphine in the unilateral 6-
OHDA striatal lesion model of PD. We found that 7 days of 4 mg/kg PROG and 8 mg/kg 
PROG treatment, with tapered withdrawal, started at day 8 after surgery was able to reduce 
by roughly half the lesion induced akinesia in the primary outcome measure adjusting steps 
task in both short and long-term after striatal 6-OHDA lesion surgery. This functional 
improvement was not merely symptomatic relief as the beneficial influence of PROG was 
observed up to 6 weeks after treatment had stopped. PROG, however, did not improve skilled 
reaching accuracy in the single-pellet reaching task or rotation after apomorphine. PROG, 
therefore, was beneficial for relatively simple but not complex or drug induced motor 
impairments. By day 8 after surgery we observed substantial striatal TH fibre deafferentation 
in the lesion control rats. At day 64 striatal TH density was not significantly different 
between the 4 mg/kg PROG, 8 mg/kg PROG or vehicle groups nor were these groups 
different from the lesion-only control rats sacrificed at day 8 post-surgery. This suggests that 
striatal TH fibre deafferentation, which was maximal by day 8, was not changed by PROG 
treatment. Therefore, the beneficial influence of PROG regarding forelimb akinesia was 
independent of striatal TH fibre innervation.  
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 The current experiment examined PROG’s influence following 6-OHDA lesions that 
modelled the late stages of PD degeneration. However, it is not known if PROG would also 
be beneficial following 6-OHDA lesions that model the earlier stages of PD degeneration. 
Furthermore, the assessment of skilled reaching in the current experiment was time 
consuming and precluded testing of additional motor impairments. Therefore, it is not known 
if the beneficial influence of PROG would extend to additional measures of motor 
impairments. To answer these questions the following experiment (Chapter 7) examines 
PROG’s influence on a battery of motor skills tests following 6-OHDA lesions that modelled 
the early and late stages of PD degeneration.  
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Chapter 7   
Study Three: Progesterone after Small 
and Large Intrastriatal 6-OHDA lesions 
7.1.  Objectives 
This chapter reports the third of three experiments (see also: Chapters 5 and 6) and compared 
the effects of PROG treatment after small and large unilateral 6-OHDA lesions of the 
striatum. The small and large lesions modelled the early and late stages of SN-striatal PD 
degeneration. As before, the success of the lesion was confirmed at day 7 with a d-
amphetamine rotation test, and PROG injections (8 mg/kg or sesame oil vehicle) made on 
day 8 once daily for 7 days with tapered withdrawal by sequential halving on the sixth and 
seventh days of treatment. Outcomes were assessed using a battery of motor skill tests on 
which the rats had been familiarized pre-operatively: the adjusting steps test for akinesia, 
postural instability test, whisker evoked forelimb placing test for sensorimotor integration, 
cylinder test for forelimb use asymmetry, and the corridor test for sensory neglect. Rats were 
tested for: akinesia on days 17-19, 27-29, 39-41, and 56-58; postural instability at days 20, 
42, and 59; sensorimotor integration at days 17, 27, 39, and 56; forelimb use asymmetry at 
days 20, 42, 59; sensory neglect on days 22-23, 44-45, and 61-62; in addition, rotation after 
apomorphine was tested at day 66, just prior to sacrifice at day 68. Cylinder testing at day 42 
was conducted by Meisha Nicolson (Honours project student), under the supervision of the 
author and primary supervisor. Brains have been stored for histology at a later date due to 
time constraints. This chapter begins with a brief rationale for examining PROG’s influence 
following small and large lesions and a justification for the motor skill tests used. 
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7.2.  Introduction 
In Chapter 6 we found that both 8 mg/kg and 4 mg/kg PROG treatment regimes gave long 
lasting reductions in akinesia impairments (adjusting steps) following large unilateral striatal 
6-OHDA lesions that modelled the later stages of PD degeneration. In the current experiment 
we examined whether PROG treatment would also be beneficial after small lesions that 
model the early stages of PD degeneration. To examine PROG’s influence during the early 
stages of PD degeneration we used the two site unilateral striatal 6-OHDA model (small 
lesions) as described by Decressac et al. (2012). In practice PROG’s influence at the early 
stages of PD degeneration could be examined by administering PROG within 24 hours after 
large lesion surgery. As discussed in Chapter 6, this method is not preferred when assessing 
neuroprotective agents after 6-OHDA lesions. . 
The PROG dose used in the current experiment was 8 mg/kg. We found no significant 
difference between 8 mg/kg and 4 mg/kg in study two (see Chapter 6) although 8 mg/kg 
tended to be more beneficial in the adjusting steps test. According to the PROG studies 
reviewed in Chapter 3 (see table 3.1) 8 mg/kg PROG was the most commonly used dose (14 
studies) while fewer studies had used 4 mg/kg (7 studies) thus supporting the use of 8 mg/kg 
in the current experiment. As previously, PROG was administered once daily for seven days 
with tapered withdrawal by sequential halving on the sixth and seventh days of treatment. 
Sham rats also received PROG to determine its effects in the absence of a 6-OHDA lesion.  
 As study two (see Chapter 6) showed that PROG treatment was beneficial for 
forelimb akinesia in the adjusting steps test, but not skilled reaching or rotation after 
apomorphine, in the current experiment we examined whether the beneficial effects of PROG 
on forelimb akinesia would extend to benefits on measures of postural instability, forelimb 
use asymmetry, sensorimotor integration, and sensory neglect.   
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 Postural instability is a common impairment in PD patients that contributes to the 
danger of frequent falls, which become increasingly problematic as the disease progresses 
(Jessop et al., 2006). The postural instability test following 6-OHDA lesions in rats followed 
that described by Woodlee et al. (2008). This test used in rats is similar to the “pull” or 
“push” test used in clinical exams of postural instability where the neurologist gently pushes 
or pulls a standing patient by the shoulders. The change in the centre of gravity requires the 
patient to make a catch-up step to maintain their balance. Patients with PD often present as 
having their feet “glued to the ground” and cannot make the needed catch-up step requiring 
the neurologist to catch them to prevent a fall (Woodlee et al., 2008). In the rat’s test, one 
forelimb is gently moved forward over a rough surface until a catch-up step is made. 
Woodlee et al. (2008) found that the contralateral forelimb of rats with unilateral 6-OHDA 
lesions of the MFB required further displacement to trigger a catch-up step compared to sham 
rats. They also found that the ipsilateral forelimb of lesion rats had enhanced compensatory 
function requiring less displacement to trigger a catch-up step. To date no study has 
examined postural instability in this test following small or large unilateral 6-OHDA lesions 
of the striatum. 
 Following unilateral lesions of the nigrostriatal pathway rats develop a behavioural 
asymmetry where they preferentially use the ipsilateral (“good”) forelimb to make wall 
contacts during vertical exploration of a cylinder (Schallert et al., 2000). To examine this 
forelimb use asymmetry we used the cylinder test, also described by Woodlee et al. (2008). 
The cylinder apparatus is preferred over walls in an open field or the rat’s home cage as it is 
more likely to encourage rearing and exploration with the forepaws. Increased use of the 
ipsilateral forelimb in the cylinder test has been found following unilateral 6-OHDA lesions 
of the MFB, (Schallert et al., 2000; Shin et al., 2012; Woodlee et al., 2008) and both large 
and small 6-OHDAlesions of the striatum (Carlsson et al., 2009; Shin et al., 2014). The 
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cylinder test is a clinically relevant test because L-DOPA and bromocriptine given at 
therapeutic doses reduce forelimb use asymmetry after MFB lesions (Lundblad et al., 2002). 
Furthermore, decreased forelimb use asymmetry has been found following midbrain 
dopaminergic grafts in rats with large striatal (Grealish et al., 2010) and MFB 6-OHDA 
lesions (Torres et al., 2008). The sensitivity of the cylinder test to therapeutic interventions 
supports its use in the current PROG treatment experiment.  
Deficits in sensorimotor integration also occur in PD patients (Abbruzzese and 
Berardelli, 2003). This problem can me mimicked in rats by holding them aloft whereupon 
they instinctively attempt to place their forelimbs upon nearby surfaces they sense (Woodlee 
et al., 2005). Placing can be triggered by stimulation of the vibrissae on the same or 
contralateral side of the forelimb being tested (Meredith and Kang, 2006). Rats with 
unilateral 6-OHDA lesions place the impaired paw less often than intact rats in response to 
vibrissae stimulation suggesting that motor responses following sensory stimulation require 
intact dopaminergic innervation of the dorsal striatum (Meredith and Kang, 2006). This 
reduction in whisker evoked forelimb placement indicates sensorimotor integration 
impairment. To examine sensorimotor integration impairment following striatal 6-OHDA 
lesions and the influence of PROG treatment we used the whisker evoked forelimb placement 
test described by Woodlee et al. (2005). Impaired forelimb placements following vibrissae 
stimulation have been observed after MFB (Woodlee et al., 2005, 2008; Schallert et al., 2000) 
and large striatal 6-OHDA lesions (Grealish et al., 2008).  
Rats with unilateral 6-OHDA lesions also demonstrate sensory neglect where they fail 
to orient to food items presented on the contralateral side of their body (Dowd et al., 2005a). 
We used the corridor test described by Dowd et al., (2005a) to examine sensory neglect after 
small and large lesions and the potential influence of PROG. In their study, Dowd et al. 
(2005a) placed rats with either MFB or large striatal 6-OHDA lesions in a long narrow 
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corridor lined with pairs of pots containing sugar pellets and then allowed the rats to freely 
explore and retrieve pellets. Rats with both lesion types neglected pellets from the 
contralateral side of their body, instead selectively retrieving pellets from the ipsilateral side. 
This sensory neglect test is sensitive to neuroprotective, neuroreparative, and symptomatic 
treatments. For example, ventral mesencephalic cell suspension transplants reduced this side 
bias for rats with large striatal but not MFB 6-OHDA lesions (Dowd et al., 2005a). Further 
research by Dowd et al. (2005b) showed that rats with MFB lesions did not develop a side 
retrieval bias when treated with a lentiviral vector expressing glial cell-line derived 
neurotrophic factor prior to lesion surgery. Fitzsimmons et al. (2006) found that systemic 
apomorphine administration significantly reduced the side bias among rats with large 6-
OHDA lesions of the striatum.  
In summary, this study examined the beneficial influence of PROG treatment after 
small and large 6-OHDA lesions of the striatum. As shown in Chapter 6, PROG gave long 
lasting reductions in forelimb akinesia after large lesions that modelled the later stages of PD 
degeneration. However, it is not known if PROG will reduce motor impairments after small 
lesions that model the early stages of degeneration in PD. Furthermore, it is not known if the 
beneficial effects found in Chapter 6 would extend to measures of postural instability, 
forelimb use asymmetry, sensorimotor integration, and sensory neglect. This experiment is 
original on two counts. First, it represents the first experiment to directly compare PROG 
treatment after small and large 6-OHDA lesions of the striatum. Secondly, this experiment 
provides the most comprehensive examination to date of PROG’s influence on motor 
impairments after 6-OHDA lesions. We anticipated that PROG treatment would reduce motor 
impairments following both small and large unilateral 6-OHDA lesions of the striatum.  
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7.3.  Materials and Methods 
7.3.1.  Animals 
Subjects were 62 male Wistar rats weighing between 528g and 760g at the day of surgery. 
The rats were 6-12 months old at surgery and 9-14 months old at perfusion. Rats were housed 
individually for five days of recovery then housed in groups of 3-4 for the remainder of the 
experiment. Testing took place during the dark phase of the rats reversed light cycle (lights 
on at 2000hrs). All protocols in this study followed the NIH Guide for the Care and Use of 
Laboratory Animals and were approved by the Animal Ethics Committee University of 
Canterbury. One rat did not recover from the surgery and was euthanized. Two rats were 
euthanized several weeks after surgery after developing growths under the skin.  
7.3.2.  Design 
The experiment used a 3 (lesion size) x 2 (PROG treatment) factorial design with the 
experimenter blind to the PROG treatment group of the lesion and sham rats until all analyses 
had been conducted. The sequence of surgery and testing is shown in Figure 7.1. 
 
Figure 7.1. Experimental design. Rats received either small or large unilateral lesions with 6-
OHDA targeting the striatum or sham surgery. Rotation after d-amphetamine was measured 
at day 7. Progesterone was given once daily on days 8-14. Motor skills were tested between 
days 17 and 66. The motor skills testing period included the adjusting steps, postural 
instability, whisker, cylinder, corridor, and rotation after apomorphine tests.  All rats were 
euthanized at day 68. Note: d-amp, d-amphetamine rotation test; PROG, progesterone. 
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7.3.3.  Surgery 
The same general surgical procedure as described in Chapter 5 was used except rats were 
operated on the side contralateral to their pre-surgery retrieval bias in the corridor test. Rats 
received either two (small lesions) or four (large lesions) unilateral infusions of 6-OHDA to 
the dorsal striatum. The infusion co-ordinates for the large lesions were as described in 
Chapter 5. The following co-ordinates for the small lesions were used, as described by 
Decressac et al. (2012): AP 1.2mm, ML ±2.5mm; AP 0.2mm, ML ±3.8mm (from bregma) 
and DV -5.0mm from dura (Fig. 7.2). Sham rats received four infusions of the vehicle 
solution alone to exclude the surgical effects in the presumably more severe model.  
 
Figure 7.2. Target infusion sites for 6-OHDA lesion surgery. Rats received either two (small 
lesions, red ovals) or four (large lesions, blue ovals) unilateral infusions to the dorsal 
striatum. Sham rats received four infusions of the vehicle alone (plates adapted from Paxinos 
and Watson, 1998). 
7.3.4.  Rotation after d-amphetamine and apomorphine  
Rotation after d-amphetamine was assessed at day 7 and apomorphine at day 66 using the 
same method as described in Chapter 5. In the d-amphetamine test, rats with large lesions 
were required to rotate at >6 turns/min to be included in the study. The small striatal lesions 
were the same as described by Decressac et al. (2012) who did not find significant rotation 
Bregma: 1.20 0.48 0.20 -0.40 -1.30
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after d-amphetamine. Therefore, all rats with small lesions were included in the study 
irrespective of their degree of rotation bias when tested with d-amphetamine at day 7. 
7.3.5.  Progesterone treatment 
Eight days after surgery the small lesion, large lesion, and sham rats were randomly assigned 
to receive either 8 mg/kg PROG or sesame oil vehicle once daily for seven days. The same 
treatment protocol as described in Chapter 6 was used with tapered withdrawal by sequential 
halving on the sixth and seventh day of treatment. There were n = 11 rats with small, and n = 
11 – 12 rats with large lesions, and n = 7 sham rats assigned to PROG and oil vehicle 
treatment groups. 
7.3.6.  Adjusting steps: Akinesia 
Forelimb akinesia was assessed pre-surgery and at post-surgery days 17-19, 27-29, 39-41, 
and 56-58 using the same method as described in Chapter 5.  
7.3.7.  Postural instability test 
The postural instability test was conducted pre-surgery and at post-surgery days 20, 42, and 
59. The apparatus consisted of rough textured grip tape (Safety-Walk, 3M brand) alongside a 
ruler (Fig. 7.3). Rats were held with the same grip as the adjusting steps test except the free 
forepaw was placed weight bearing on the grip tape. The purpose of the rough surface was to 
induce stepping rather than dragging or bracing in response to an imposed shift of the rat’s 
weight. The tip of the rat’s nose was aligned with the zero mark on the ruler. The rat’s centre 
of gravity was gently moved forward over the unrestrained weight bearing forelimb until a 
“catch-up” step to regain its centre of gravity was made.  The new position of the nose tip 
indicated the displacement required to trigger a catch-up step. The average displacement (cm) 
of three trials for each forelimb was measured at each testing day. Lesions are expected to 
increase displacement of the contralateral forelimb and decrease displacement of the 
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ipsilateral forelimb (Woodlee et al., 2008). Larger rats may require a greater shift in their 
centre of gravity to trigger a catch-up step. Rats were weighed on each day of testing to 
ensure body weights did not differ between groups.  
 
Figure 7.3. The postural instability test. (A) The apparatus used in this experiment. The grey 
area is the bench top and the orange area is the grip tape used for the test. (B) An example of 
a rat at the start of a trial before being moved forward and (B) the rat after making a catch-up 
step (images B and C adapted from Woodlee et al., 2008).  
7.3.8.  Whisker-evoked forelimb placement: Sensorimotor integration 
Sensorimotor integration was evaluated in the forelimb placement test pre-surgery and at 
days 17, 27, 39, and 56. In the “same-side” test rats were held with the same grip as the 
adjusting steps test except the forelimb to be tested hung free. The rat’s vibrissae ipsilateral to 
the tested paw were brushed against the side of the table to elicit a forelimb placing response 
(Fig. 7.4-A). In the “cross-midline” test the rat was held with same grip as above except it 
was turned sideways so the vibrissae to be brushed were perpendicular to the table surface. 
The downwardly turned forelimb was restrained and the downwardly turned vibrissae were 
brushed against the table surface to evoke a forelimb placement contralateral to the 
stimulated vibrissae (Fig. 7.4-B). Both the same-side, and cross-midline, tests were repeated 
10 times for each forelimb at each testing occasion. Rats received the “same-side” test first 
then were given a 15min break before receiving the “cross-midline” test. The number of 
placements for each forelimb on each test was counted. Only trials in which the rat was 
compliant and did not struggle were counted. Struggling during testing was rare as each rat 
A B C
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was habituated to the procedure over three sessions prior to pre-surgery testing. Lesions will 
reduce contralateral to lesion forelimb placements but not impair ipsilateral forelimb 
placements. Sham rats will place both forelimbs on ~100% of trials.  
 
Figure 7.4. Examples of a rat performing (A) the same-side and (B) cross-midline whisker 
evoked forelimb placing test (image adapted from Woodlee et al., 2005. Note: Hooded rats 
were not used in the current study). 
7.3.9.  Cylinder test: Forelimb use asymmetry 
Forelimb use asymmetry during vertical exploration was analysed in the cylinder test pre-
surgery and at day 42. The apparatus consisted of a flexible plastic sheet shaped to a cylinder 
(29cm diameter x 30cm high) that was flanked by mirrors to assist viewing (Fig. 7.5). Rats 
were placed in the cylinder and the number of weight bearing wall contacts made during 
rearing using the ipsilateral, contralateral, and both forepaws simultaneously was video 
recorded (Panasonic digital video camera recorder; Model SDR-H85). Forelimb use 
asymmetry was calculated as the number of ipsilateral forepaw touches plus ½ the number of 
both paw touches, divided by the total number of touches (total = ipsilateral + contralateral + 
both). This provided an asymmetry percentage score where 50% indicated a rat that explored 
symmetrically with both forelimbs. Higher scores (>50%) indicate greater reliance on the 
A B
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ipsilateral forelimb while lower scores (<50%) represent greater reliance on the contralateral 
forelimb. Rats were recorded for 20 touches of any paw or a maximum trial time of 5mins.  
Also measured was the number of “serial-stepping” behaviours with each forelimb. 
Serial-stepping was defined as an independent forepaw touch followed by several rapid 
lateral weight-shifting touches with the same limb without using the other forelimb. A serial 
step was counted as long as the sequence of steps was continuous and not broken by pauses 
lasting longer than 1 second or the animal pushing back to an unsupported rearing position. 
When calculating the asymmetry score above, any serial steps were counted as individual 
paw touches. The serial-stepping events were analysed independently as the percentage of 
serial-stepping behaviour out of the total number of independent forelimb uses for each 
forelimb. The final measure was the number of rears made during the trial as an assessment 
of vertical exploratory activity.  
 
Figure 7.5. The cylinder apparatus used to assess forelimb use asymmetry. The images depict 
a rat during per-surgery testing. (Left) An example of a right forepaw touch while the rat 
faces the camera and (Right) a right forepaw touch while the rat faces away from the camera 
visualised with the aid of the mirror. 
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7.3.10.  Corridor test: Sensory neglect 
Sensory neglect was measured in the corridor test. Rats were tested pre-surgery and on days 
22-23, 44-45, and 61-62. The apparatus consisted of a long rectangular box (150cm long x 
12cm wide x 28cm deep) made from white painted medium density fibreboard (Fig. 7.6). Ten 
adjacent pairs of small white plastic lids (2cm diameter x 0.9cm deep) were positioned along 
the floor of the corridor and were held in place with Blu-tack. The lid pairs were spaced at 
12cm intervals with the first pair placed 30cm from the starting end of the corridor. Each lid 
was filled with approximately10 chocolate pellets (45mg Dustless precision, Bioserve).  
Prior to the habituation and testing day rats were food restricted for 48hrs by once a 
day ration of 18g food per rat. Rats were returned to free-feeding in between testing 
occasions. On the two days prior to habituation rats were introduced to the chocolate pellets. 
Each rat received 20 pellets in their home cage 1hr before daily feeding.  Rats were 
habituated to the corridor for 10mins on the two days prior to pre-surgery testing where 
chocolate pellets were scattered along the floor and the rat was free to explore. For testing the 
rat was first placed in an identical but empty corridor for 5mins habituation before being 
transferred to the start end of a corridor with food wells. The rat was free to explore and eat 
pellets at will and the number of ‘retrievals’ were counted. A retrieval was defined as the rat 
poking its nose into a lid regardless of the number of pellets eaten. A new retrieval could only 
be made when the rat visited a new lid. The number of retrievals made on the left and right 
side of the rat’s body axis was counted. Trials were ended when 20 retrievals had been made 
or a maximum 5mins had elapsed. Rats were tested on two consecutive days and the scores of 
the two trials were added together. Scores were expressed as a percentage of contralateral to 
lesion retrievals of the total retrievals made from both sides of the rat’s body axis. Intact rats 
generally display a side bias for retrievals. All rats were operated on the contralateral to 
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“preferred side” to separate the effects of the lesions from the rat’s innate bias. Post-surgery, 
lesions will reduce retrievals from the contralateral side.  
Figure 7.6. The corridor test apparatus. (Top left) View from inside and (Top right) above the 
corridor. (Bottom) Schematic diagram showing the dimensions of the corridor. 
7.3.11.  Perfusion 
Rats were perfused on day 68 using the same procedure as described in Chapter 5. Due to 
time constraints no tyrosine hydroxylase histology was completed on these rats. The brains 
have been saved for histology at a later date.  
7.3.12.  Statistical analysis  
Statistical analyses using Statistica software (version 12.0) were conducted to determine if 
the impairments in akinesia (adjusting steps test), postural instability (postural instability 
test), sensorimotor integration (whisker test), forelimb use asymmetry (cylinder test), sensory 
neglect (corridor test), and rotation after apomorphine produced by small and large striatal 6-
OHDA lesions were reduced by PROG treatment. Individual outcome variables were 
analysed by an ANOVA (Lesion by Treatment) and the addition of the repeated measure of 
150cm
12cm
30cm 12cm
 
Study Three: Progesterone after Small and Large Intrastriatal 6-OHDA lesions 
150 
 
Time was included as appropriate. Pre-surgery performance on the adjusting steps, postural 
instability, whisker, and corridor tests were analysed separately from post-surgery testing. Pre 
and post-surgery performance in the cylinder test was analysed together as the sham rats 
forelimb use asymmetry appeared to change from pre to post-surgery testing.  Rotation after 
d-amphetamine at post-surgery day 7 was analysed by an ANOVA (Lesion by Treatment). 
Post-hoc Newman-Keuls multiple comparisons tests were used for significant main effects 
and interactions. Statistical significance was set at p<0.05. All data are expressed as means ± 
SEM. 
7.4.  Results 
7.4.1.  Rotation after d-amphetamine  
At post-surgery day 7 both lesion sizes produced significant ipsilateral rotations (F(2, 53) = 
65.47, p<0.001; Fig. 7.7) after d-amphetamine administration. Post-hoc Newman-Keuls 
showed that rats with a large lesion showed a rotation bias almost twice that of rats with 
small lesions, but rats with small lesions rotated more than sham rats which showed no 
rotation bias (p<0.001 for all groups). No main effect of PROG or any interactions were 
significant (all p>0.20).  
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Figure 7.7. Ipsilateral rotations after d-amphetamine at day 7 in the six groups. 
7.4.2.  Adjusting steps test: Akinesia 
Prior to surgery contralateral forelimb stepping did not differ significantly across the lesion 
groups (Lesion, F(2, 53) = 2.45, p = 0.10) in the adjusting steps test. However, there was a 
small but significant Treatment effect (F(1, 53) = 6.43, p = 0.014) where rats belonging to the 
future PROG group made marginally fewer forelimb steps (M = 49.33%) compared to future 
vehicle rats (M = 50.55%). The Lesion x Treatment interaction was not significant (F(2, 53) 
= 1.92, p = 0.16). 
Following surgery large lesions produced substantially impaired contralateral 
forelimb stepping while small lesions produced an intermediate deficit (Lesion, F(2, 53) = 
51.94, p<0.001; Fig. 7.8). Notably, PROG significantly reduced this impairment for both 
lesion groups without affecting the sham lesion group (Lesion x Treatment, F(2, 53) = 6.12, p 
= 0.004). As a result, a mild and non-significant impairment remained evident in the rats with 
small lesions while the improvement after PROG in rats with large lesions meant that they 
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now performed equivalently to vehicle treated rats with small lesions. There was also a Time 
x Lesion x Treatment interaction (F(6,159) = 2.37, p=0.032), due primarily to increasingly 
poor performance over time in the non-treated vehicle rats with large lesions. 
 
 
Figure 7.8. Contralateral forelimb stepping in the adjusting steps test. Error bars denote SEM. 
7.4.3.  Postural instability test 
First, body weights are assessed as these may influence performance on this test. Prior to 
surgery the body weight of the rats did not differ between groups and neither the Lesion nor 
Treatment effects, nor the interaction, were significant (all p>0.20; Fig. 7.9). Body weights 
also did not differ between lesion or treatment groups following surgery (both p>0.20). There 
was a significant Time x Lesion interaction (F(4, 106) = 3.02, p = 0.02) due to relatively 
increasing body weight in all groups. Post-hoc Newman-Keuls showed that body weights did 
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not differ between groups at any testing occasion (all p>0.20). No other interactions were 
significant (all p>0.20).  
 
 
Figure 7.9. Body weights on each day of testing in the postural instability test. Error bars 
denote SEM.  
Pre-operatively the displacement required to trigger a catch-up step in the 
contralateral forelimb did not differ significantly between lesion groups (F(2, 53) = 2.69, p = 
0.08; Fig. 7.10). There was however a significant main effect of Treatment (F(1, 53) = 4.57, p 
= 0.04) where the future PROG rats (M = 5.06cm)  required marginally more displacement 
than the future vehicle rats (M = 4.71cm) to trigger a catch-up step. The Lesion x Treatment 
interaction was not significant (p>0.20). 
Following surgery, large lesions substantially increased the displacement required to 
trigger a catch up step in the contralateral forelimb while small lesions produced an 
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intermediate impairment (Lesion F(2, 53) = 25.52, p<0.001; Fig. 7.10). Relative to sham, the 
large lesion effect increased over time while the small lesion effect dissipated (Time x Lesion 
F(4, 106) = 7.96, p<0.001). There were, however, no PROG treatment effects or Time x 
Lesion x Treatment interaction (both p>0.20).  
 Prior to surgery the displacement required to trigger a catch-up step in the ipsilateral 
forelimb did not differ between groups. Neither the Lesion (F(2, 53) = 1.77, p = 0.18; Fig. 
7.10), the Treatment main effect (p>0.20) nor the interaction were significant (p>0.20). Post-
operatively, large lesions decreased the displacement required to trigger a catch up step in the 
ipsilateral forelimb while small lesions produced an intermediate impairment (Lesion, F(2, 
53) = 13.45, p<0.001; Fig 7.10). In this instance, PROG reduced this impairment for the large 
lesion group only (Lesion x Treatment F(2, 53) = 5.32, p = 0.01.). The Time x Lesion x 
Treatment interaction was not significant (p>0.20). There was a significant Time x Lesion 
interaction (F(4, 106) = 3.52, p = 0.01) due to increasing displacement for the sham group. 
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Figure 7.10. Forelimb displacement in the postural instability test. (Top row) Contralateral forelimb and (Bottom row) ipsilateral forelimb 
displacements. Error bars denote SEM. * p<0.05 compared to ipsilateral forelimb of vehicle treated rats with large lesions. 
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7.4.4.  Whisker-evoked forelimb placement: Sensorimotor integration 
Prior to surgery in all rats, and post-surgery in sham rats, successful forelimb placements 
occurred at rates greater than 95% for both forelimbs regardless of the type of vibrissae 
stimulation (same-side or cross-midline). Following surgery, ipsilateral forelimb placements 
for rats with both large and small lesions occurred at rates close to 100%. The results for 
ipsilateral forelimb placements are not shown. The analysis of post-surgery data excluded 
shams as these groups showed no variation at several testing occasions due to having the 
maximum score of 100% for successful forelimb placements.   
In the lesion groups same-side vibrissae stimulation produced substantially impaired 
contralateral forelimb placements after large lesions while small lesions produced an 
intermediate deficit (Lesion, F(1,41) = 29.12, p<0.001; Fig. 7.11). PROG did not 
significantly reduce this impairment for rats with small or large lesions (Treatment, F(1,41) = 
1.93, p = .17; Lesion x Treatment, F(1, 41) = 0.36, p=0.56 ). There was a main effect of Time 
(Time, F(3, 123) = 3.19, p = 0.03) due to improving performance from day 27 to day 56 
(Post-hoc Newman-Keuls, p = 0.02). There were no significant interactions for Treatment x 
Time, (p>0.20); Lesion by Time (p>0.20); or Treatment x Lesion x Time (p<0.20). However, 
the rats with small lesions and treated with PROG produced performance that was similar to 
the Sham groups by day 56 (t(23) = 1.55, p = 0.14) whereas the group with small lesions 
given vehicle remained impaired compared to the Sham groups at day 56 (t(23) = 3.12, p  = 
0.005 ).  
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Figure 7.11. Contralateral forelimb placements on the “same side” whisker test. Error bars 
denote SEM.  
 
Following cross-midline vibrissae stimulation large lesions produced substantially 
impaired forelimb placements while small lesions produced an intermediate deficit (Lesion, 
F(1, 41) = 32.76, p<0.001; Fig. 7.12). In this instance, PROG significantly reduced poor 
performance over time shown by vehicle-treated rats with both small and large lesions (Time 
x Treatment interaction, F(3, 123) = 3.32, p= .02). There was no Treatment (F(1,41) = 3.10, p 
= .09) or Time (p>0.20) main effect. Despite the appearance that PROG had a greater effect 
after small than large lesions, neither the Time x Lesion (F(3, 123) = 1.72, p = 0.17), Lesion 
x Treatment (p>0.20) nor Time x Lesion x Treatment (p>0.20) interactions were significant. 
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Figure 7.12. Contralateral forelimb placements in the “cross midline” whisker test. Error bars 
denote SEM.  
7.4.5.  Cylinder test: Forelimb use asymmetry 
One vehicle treated rat from the large lesion group was excluded from the analysis as it 
would not participate in the task during post-surgery testing. Due to time constraints only the 
pre-surgery and day 42 videos were coded. There was a significant main effect for lesion 
(Lesion, F(2, 52) = 3.89, p = 0.03; Fig. 7.13). Post-hoc Newman-Keuls showed that, 
collapsed across the two testing sessions, rats with large (p = 0.03) but not small (p> 0.20) 
lesions had a greater reliance on the ipsilateral forelimb during the cylinder test compared to 
sham. There was a significant Lesion x Time interaction (F(2, 52) = 6.35, p = 0.003) due to 
increasing forelimb use asymmetry from pre to post-surgery in all lesion groups including 
shams, but a more marked change in the group with large lesions. Post-hoc Newman-Keuls 
showed that pre-surgery forelimb use asymmetry was not significantly different between all 
lesion and sham groups (p>0.20). However, at day 42 the rats with large lesions had an 
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increased asymmetry compared to small lesion and sham groups (p<0.05), but forelimb use 
asymmetry for rats with small lesions did not differ from sham (p>0.20). There was no effect 
of PROG (Treatment, F(1, 52) = 1.25, p >0.20; Treatment x Time, F(1, 52) = 0.67, p >0.20; 
Time x Lesion x Treatment, F(2, 52) = 0.39, p>.=0.20). 
 
Figure 7.13. Forelimb use asymmetry in the cylinder test. Error bars denote SEM.  
The occurrence of serial stepping in both forelimbs prior to surgery, and in the 
contralateral forelimb post-surgery was rare and did not occur in most groups. Due to the rare 
occurrence of this behaviour these data are not shown. After surgery, large lesions produced 
significantly increased ipsilateral forelimb serial stepping behaviour (Lesion, F(2, 52) = 4.04, 
p = 0.02; Fig. 7.14 ). Post-hoc Newman-Keuls revealed that large lesions made more serial 
steps than both small lesion and sham (both p<0.05). Serial stepping in rats with small lesion 
was low at levels comparable to sham (p>0.20). Neither the Treatment main effect nor the 
Lesion x Treatment interaction were significant (p>0.20).  
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Figure 7.14. Ipsilateral forelimb serial stepping behaviour at day 42. Error bars denote SEM.  
Rats with large and small lesions reared less frequently in the cylinder compared to 
shams (Lesion, F(2, 52) = 4.26, p = 0.02; Fig. 7.15). There was a significant main effect of 
Time due to decreasing rears from pre to post-surgery (F(1, 52) = 18.85, p<0.001) although 
the Lesion x Time interaction was not significant (p>0.20). PROG treatment did not change 
rearing in the cylinder (Treatment, p <0.20). No significant interactions were found for 
Lesion x Treatment (F(2, 52) = 2.03, p = 0.14), Time x Treatment (F(1, 52) = 1.82, p = 0.18), 
or Time x Lesion x Treatment (F(2, 52) = 2.25, p = 0.12). 
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Figure 7.15. Number of rears in the cylinder test. Error bars denote SEM.  
7.4.6.  Corridor test: Sensory neglect 
Prior to surgery contralateral retrievals did not differ between groups in the corridor test. 
Neither the main effects of Lesion, Treatment nor the Lesion x Treatment interaction were 
significant (all p>0.20).  
Following surgery, large lesions substantially reduced contralateral retrievals in the 
corridor while small lesions produced an intermediate impairment (Lesion, F(2, 53) = 24.23, 
p<0.001; Fig. 7.16). PROG treatment did not reduce this bias (p>0.20). There was improved 
performance over time (F(2, 106) = 5.08, p<0.001) but no interaction with PROG or lesion 
(all p>0.20). 
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Figure 7.16. Contralateral retrieval bias in the corridor test. Error bars denote SEM.  
7.4.7.  Rotation after apomorphine 
At day 66 only large lesions produced significantly increased contralateral rotation (Lesion, 
F(2, 52) = 27.04, p< 0.001; Fig. 7.17) after apomorphine administration. Post-hoc Newman-
Keuls revealed that rats with large lesions rotated significantly more than the small lesion and 
sham groups (p<0.001). Rats with small lesions did not rotate more than sham (p>0.20). 
Neither the main effect for Treatment nor the Lesion x Treatment interaction were significant 
(both p>0.20). One large lesion vehicle rat was excluded from the analysis due to a video 
tracking error.  
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Figure 7.17. Rotation after apomorphine at day 66. Error bars denote SEM. Note: 
Contralateral turns are expressed as positive values.  
7.5.  Summary and Discussion 
Large lesions produced substantial impairments on rotation after d-amphetamine and 
apomorphine, forelimb akinesia, postural instability, forelimb use asymmetry, sensorimotor 
integration, and sensory neglect. Small lesions produced intermediate impairments on 
forelimb akinesia, postural instability, sensorimotor integration, and sensory neglect but no 
impairment for forelimb use asymmetry and rotation after apomorphine. PROG treatment 
significantly reduced the forelimb akinesia impairment for rats with small and large lesions. 
PROG treatment also reduced ipsilateral but not contralateral forelimb impairment in the 
postural instability test for rats with large lesions, and prevented the increasingly poor 
performance for rats with small and large lesions in the cross midline whisker test but not 
significantly for the same side whisker test. PROG treatment in sham rats did not have any 
effects relative to the sesame oil vehicle on any test.  
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Lesion validation: Rotation after d-amphetamine 
Due to time constraints the 6-OHDA lesions were not examined with tyrosine hydroxylase 
immunohistochemistry. Instead, we assessed rotation after d-amphetamine as an ante-mortem 
validation of the lesion (Grealish et al., 2008). At day 7 after surgery rats with small and large 
lesions produced significant ipsilateral rotation after d-amphetamine whereas sham rats did 
not rotate as expected. Rats with large lesions rotated significantly more than rats with small 
lesions.  
 The substantially increased ipsilateral rotation observed in rats with large lesions is 
comparable to previous reports as discussed in Chapter 5 (e.g. Kirik et al., 1998; Shin et al., 
2014). Furthermore, the magnitude of rotation in the current experiment (~12 turns/min) is 
similar to the magnitude of rotation found in studies one (~14 turns/min; Chapter 5) and two 
(~11 turns/min; Chapter 6) suggesting the extent of large striatal lesions were comparable 
across experiments at day 7 after surgery.  
 In accordance with previous reports using small intrastriatal 6-OHDA lesions we 
found that our rats had moderately increased ipsilateral rotation of ~7 turns/min. For 
example, Kirik et al. (1998) reported moderate rotation of ~5 turns/min at day 7 after surgery. 
More recently, Sadan et al. (2009) reported ~3 turns/min at week 2 and Shin et al. (2014) 
observed ~6 – 7 turns/min at week 4 post-surgery. One discrepancy to these studies was 
reported by Decressac et al. (2012) who found that rats with small striatal 6-OHDA lesions 
had low but not significantly increased rotation at 3 and 8 weeks after surgery.  
 The current experiment has reported moderate and substantial rotation after d-
amphetamine at day 7 for rats with small and large lesions, respectively. The significant 
difference in the rate of rotation between rats with small and large lesions confirmed a graded 
PD like impairment prior to PROG treatment at day 8. 
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Adjusting steps test primary outcome measure: Akinesia 
The adjusting steps task was selected as the primary outcome measure as akinesia is a 
cardinal motor feature of PD (Jankovic, 2008). Prior to surgery forelimb stepping did not 
differ between lesion groups. There was a small but significant difference between PROG 
treatment groups where rats belonging to the PROG group made fewer steps compared to 
vehicle rats. While this difference was unexpected it is not problematic as the fewer steps 
made by PROG rats prior to surgery goes against the hypothesis.  
Following surgery rats with large lesions had substantially impaired forelimb stepping 
while rats with small lesions were moderately impaired. Forelimb stepping for rats with large 
lesions worsened across subsequent testing while rats with small lesions maintained a stable 
impairment. PROG treatment markedly improved the forelimb stepping impairment for rats 
with large lesions to levels similar to vehicle treated rats with small lesions. Furthermore, 
PROG treatment significantly improved forelimb stepping for rats with small lesions to a 
level comparable to sham rats. The beneficial influence of PROG on akinesia was evident at 
the first day of testing in the adjusting steps test and was maintained across subsequent 
testing, preventing the decline seen over time in rats with large lesions.  
Impaired forelimb stepping in the vehicle treated rats with large lesions is consistent 
with the previous studies discussed in Chapter 5 (e.g. Dowd and Dunnett , 2005; Kirik et al., 
1998; Shin et al., 2014). Moderately Impaired forelimb stepping in the vehicle treated rats 
with small lesions is also consistent with previous research. Small striatal 6-OHDA lesions 
moderately impaired forelimb stepping at 3-14 weeks post-surgery in several studies (e.g. 
Decressac et al., 2012; Gong et al., 2012; Kirik et al., 1998; Shin et al., 2014) although some 
have reported more substantial impairment (Krishnamurthi et al., 2009; Moloney et al., 
2010). Additionally, single 6-OHDA infusions to the striatum that produce moderate TH 
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depletion also cause moderately impaired forelimb stepping (e.g. Depino et al., 2003; Khan et 
al., 2010; Kirik et al., 1998, 2000). In each of these studies and the current thesis the 6-
OHDA infusions were made to the dorsolateral striatum. Hence, DA in this region of the 
caudate putamen appears to mediate stepping in the adjusting steps test (Chang et al., 1999) 
Consistent with study two (Chapter 6), the beneficial influence of PROG for rats with 
large lesions was replicated here and shown to extend to rats with small lesions, reducing 
impairment in the latter rats to levels comparable to sham rats. For both small and large 
lesion groups PROG’s influence was evident at the first assessment at day 17 and did not 
diminish over subsequent testing at days 27, 39, and 56. Thus, as with study two, the 
improved forelimb akinesia observed was not merely symptomatic relief as the beneficial 
influence of PROG was maintained for six weeks after treatment had stopped. The 
mechanism underlying this improvement is not clear as histology has not been performed due 
to time restrictions. However, it is not likely to involve striatal TH fibre innervation as striatal 
deafferentation would have been complete at the time of the first PROG injection given the 
findings in study two.  
Postural instability test 
The postural instability test is a newer assay of motor impairment following 
nigrostriatal dopamine depletion (Woodlee et al., 2008). As described earlier in this chapter 
Woodlee et al. (2008) reported that unilateral MFB lesions produce severe postural instability 
of the contralateral forelimb but enhanced the function of the ipsilateral forelimb. In other PD 
model studies increased postural instability of both forelimbs in the postural instability test 
has been found following systemic administration of rotenone that causes bilateral dopamine 
depletion (Cannon et al., 1999; Tapias et al., 2014) although a single unilateral intrastriatal 
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infusion did not change the displacement required to trigger a catch-up step for either 
forelimb (Carriere et al., 2014).  
Performance in the postural instability test is dependent on the body weight and size 
of the rat as would be expected according to the physics of maintaining centre of gravity. 
Woodlee et al. (2008) found that body weight was the best predictor with heavier rats 
requiring further displacement to trigger a catch-up step. At each day of testing rat’s weights 
were unlikely to have an influence because body weights did not differ between groups at any 
testing day. 
To the best of our knowledge the current experiment is the first report that employs 
the postural instability test in the context of unilateral intrastriatal 6-OHDA lesions. In line 
with the original report of Woodlee et al. (2008) who used MFB lesions, we found that both 
large and small striatal lesions induced postural instability of the contralateral forelimb with 
large striatal lesions producing a greater impairment. Consistent with Woodlee et al. (2008) 
we also found that sham operated rats tended to require further displacement to trigger a 
catch-up step compared to their pre-surgery scores. Unexpectedly, prior to surgery rats 
belonging to the PROG groups required more displacement to trigger a catch-up step in the 
contralateral forelimb compared to vehicle treated rats. This difference is not problematic, 
however, as it works against the hypothesis that PROG would reduce contralateral forelimb 
displacements. Nonetheless, PROG treatment did not reduce postural instability impairment 
of the contralateral forelimb for either small or large lesion rats.  
Consistent with Woodlee et al. (2008) both small and large lesions reduced the 
displacement required to trigger a catch-up step for the ipsilateral forelimb. This “enhanced” 
compensatory function is not surprising as previous reports show that the effects of unilateral 
dopamine depleting lesions are not restricted to the lesion hemisphere (Miklyaeva et al., 
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2007; Vergara-Aragon et al., 2003). Similar to the “enhanced” function observed in the 
current experiment, the speed with which rats with unilateral 6-OHDA MFB lesions remove 
adhesive labels from their ipsilateral forelimbs is enhanced compared to sham operated 
animals (Schallert et al., 1982, 1983). According to Woodlee et al. (2008) the enhanced 
function of the ipsilateral forelimb is not due to dopaminergic reorganisation of the 
contralateral to lesion hemisphere as they did not find an up regulation of d-amphetamine 
induced c-fos expression in the striatum. However, this does not rule out other possible 
changes to the dopaminergic system contralateral to the 6-OHDA lesion (discussed below).  
 The necessity of the rat to compensate with their “good” ipsilateral forelimb for 
initiating and maintaining most of their daily movements could account for the enhanced 
function of the ipsilateral forelimb in the postural instability test. For example, in one study, 
rats with large striatal 6-OHDA lesions relied mostly on their good limbs to defend their 
posture and to initiate or terminate movements (Miklyaeva et al., 1995). In another study, the 
experiential influence of compensating with the “good” forelimb increased dendritic 
arborisation in the motor cortex of the contralateral to lesion hemisphere after 6-OHDA MFB 
lesions (Miklyaeva et al., 2007). Together these studies show that rats with extensive 6-
OHDA lesions compensate with their “good” limbs which can lead to enhanced function of 
the ipsilateral forelimb and related morphological changes in the contralateral to lesion 
hemisphere. PROG treatment normalised the enhanced function of the ipsilateral forelimb in 
the postural instability test for rats with large but not small lesions. This suggests that rats 
with large lesions treated with PROG did not need to compensate as much with the “good” 
forelimb compared to vehicle treated rats and hence maintained normal function in the 
postural instability test. In support of this, the substantial reduction in forelimb akinesia for 
PROG treated rats with large lesions would mean that these rats could make greater use of 
their impaired forelimb thus relying less on the good forelimb.  
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Another possibility is that PROG normalised some dopaminergic changes in the 
contralateral to lesion hemisphere as there are reports that unilateral 6-OHDA lesions can 
increase dopaminergic signalling in the intact hemisphere. For example, increased 
extracellular dopamine in striatal dialysates in the contralateral to lesion hemisphere has been 
observed following 6-OHDA infusions to the SN (Robinson and Whishaw, 1988). 
Additionally, there is evidence that large 6-OHDA lesions increase striatal dopamine content 
in the non-lesion hemisphere (Warenycia and McKenzie, 1987). More recently, increased TH 
expression in the contralateral to lesion hemisphere has been reported following MFB 6-
OHDA lesions (Schlachetzki et al., 2014). Importantly, a recent study that examined PROG’s 
influence following small striatal 6-OHDA lesions found an increase in potassium-evoked 
[
3
H]-dopamine release in the contralateral to lesion striatum that was normalised by PROG 
treatment (Casas et al., 2013). Taken together these reports show that the contralateral to 
lesion hemisphere can undergo increased dopaminergic signalling following unilateral 6-
OHDA lesions that can be normalised by PROG treatment. Therefore, it is possible that the 
normalised function of the ipsilateral forelimb for rats with large lesions was due to 
normalised dopaminergic function in the contralateral to lesion hemisphere.  
Here we present the first report regarding postural instability impairments on the 
postural instability test after small and large unilateral 6-OHDA lesions of the striatum. We 
found that large lesions produced substantial postural instability of the contralateral forelimb 
and substantially enhanced compensatory function of the ipsilateral forelimb while small 
lesions produced moderate changes. PROG treatment did not reduce postural instability of 
the contralateral forelimb for rats with either small or large lesions but normalised the 
function of the ipsilateral forelimb for rats with large lesions.  
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Cylinder test: Forelimb use asymmetry  
The cylinder test is a common assay of forelimb use asymmetry following unilateral 6-
OHDA lesions. The standard measure is the number of weight bearing forepaw touches 
against the cylinder wall (Schallert et al., 2000) where unilateral 6-OHDA lesions increase 
the proportion of ipsilateral forepaw touches (e.g. Woodlee et al., 2008). 
 In the current experiment, at day 42 after surgery all groups including sham showed 
greater preference for use of the ipsilateral forelimb for weight shifting movements during 
spontaneous vertical exploration compared to pre-surgery testing. At day 42 rats with large 
but not small lesions showed greater ipsilateral forelimb use preference compared to sham 
rats suggesting that only large lesions increased ipsilateral forelimb use asymmetry. PROG 
treatment did not change forelimb use asymmetry for small or large lesion or sham groups.  
 The increased ipsilateral forelimb use asymmetry observed in rats with large lesions is 
consistent with previous research where moderate – severe ipsilateral forelimb use 
asymmetry has been reported following large 6-OHDA striatal lesions (e.g. Carlsson et al., 
2009; Grealish et al., 2010; Henning et al., 2007; Kirik et al., 2000; Shin et al., 2014). We 
observed an increase in ipsilateral forelimb use asymmetry for rats with small lesions 
although this was not significantly different from sham. In support of this result Decressac et 
al. (2012) likewise did not find increased ipsilateral forelimb use asymmetry after small 6-
OHDA lesions. However, other studies have found moderately increased ipsilateral forelimb 
use asymmetry after small (Shin et al., 2014; Spieles-Engemann et al., 2010; Yang et al., 
2009) and single-site striatal 6-OHDA lesions (Grant et al., 2009; Vercammen et al., 2006). 
The increased ipsilateral forelimb use asymmetry observed in sham rats has not been 
observed in most studies where sham operated rats were tested (e.g. Grealish et al., 2010; 
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Shin et al., 2014; Spieles-Engemann et al., 2010) although one study has reported an 
increased bias for single-site striatal sham operated rats (Grant et al., 2009).  
 A newer secondary measure during vertical exploration in the cylinder is the 
occurrence of serial stepping where rats make several rapid lateral weight shifting steps with 
the ipsilateral forelimb. This measure to the best of our knowledge has only been reported by 
Woodlee et al. (2008) who found that 65% of all ipsilateral forelimb use occurred during 
serial stepping after MFB 6-OHDA lesions. In the current experiment we found that serial 
stepping was slightly (~6-10%) yet significantly increased for rats with large lesions 
compared to sham. Rats with small lesions and sham rats had very low levels (~2%) of serial 
stepping. PROG treatment did not influence serial stepping for any group. 
 The discrepancy between the magnitudes of serial stepping observed between the 
current experiment and Woodlee et al. (2008) is likely due to the different 6-OHDA lesions 
used. The MFB lesions used by Woodlee et al. produce complete denervation of nigrostriatal 
dopamine whereas the small and large striatal lesions used in the present experiment cause 
partial and subtotal depletion, respectively. Perhaps more extensive 6-OHDA lesions are 
required to produce substantial ipsilateral forelimb serial-stepping in the cylinder test.  
 The cylinder test also allowed for the determination of spontaneous rearing activity. 
Although rearing frequency in the cylinder test is not often reported several studies have 
found decreased rearing after 6-OHDA MFB lesions (Rauch et al., 2010, Santiago et al., 
2010; Shi et al., 2004). Consistent with these studies we found that rats with small and large 
lesions reared less often than sham rats. However, PROG treatment did not influence rearing 
in the cylinder for any group.  
One possible explanation for decreased rearing could be habituation to the testing 
environment. In support of this we observed a marked decrease in rearing at day 42 compared 
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to pre-surgery performance. However, it is likely that the decreased rearing can also be 
attributed to dopamine depletion as rats with small and large lesions reared significantly less 
than sham. Therefore, decreased rearing in the cylinder among rats with lesions is more likely 
a movement related impairment as a consequence of the 6-OHDA neurotoxin.  
Impaired forelimb use in the cylinder test is sensitive to both extensive and partial 
dopamine depleting lesions (Shin et al., 2014; Shi et al., 2004). As reported in the 
introduction, therapy’s that improve dopamine transmission decrease forelimb use 
asymmetry. In the current experiment PROG was unable to improve forelimb use asymmetry 
in the cylinder test. This may be consistent with the inability of PROG treatment to improve 
striatal TH deafferentation, given the findings in study two (Chapter 6). 
Whisker-evoked forelimb placement: Sensorimotor integration 
In the current experiment we tested whisker evoked forelimb placement for both forelimbs 
upon stimulation of the vibrissae on each side of the rats head (Woodlee et al., 2005). Testing 
forelimb placement by both same-side and cross-midline vibrissae stimulation allowed us to 
distinguish if the impairment was primarily sensory or motor in nature. If the deficit was due 
primarily to sensory impairment then stimulation of the “bad” vibrissae would not evoke 
forelimb placement of either the impaired or the intact forelimb while stimulation of the 
“good” vibrissae would evoke placement of both forelimbs. In contrast, if the deficit was due 
primarily to motor impairment then the impaired forelimb would not place in response to 
stimulation of the “good” or “bad” vibrissae while placement of the intact forelimb would 
occur regardless of which vibrissae were stimulated.  
In the current experiment we found that placement of the forelimb contralateral to the 
lesion was substantially impaired in rats with large lesions while rats with small lesions had 
an intermediate deficit. Impaired contralateral forelimb placement occurred in response to 
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same-side and cross-midline vibrissae stimulation. In comparison, the ipsilateral forelimb for 
rats with lesions, and both forelimbs for shams, was unimpaired in both versions of the test. 
Together these findings show that impaired contralateral forelimb placing in rats with small 
and large lesions was due primarily to motor rather than sensory deficit. This finding is 
consistent with reports that found impaired forelimb placing on the same-side and cross-
midline test after MFB 6-OHDA lesions (Anstrom et al., 2007; Woodlee et al., 2005).   
The moderate impairment observed in rats with small lesions is consistent with 
previous research that used the same-side whisker test after small 6-OHDA striatal lesions 
(Grant et al., 2009). Following 6-OHDA lesions the same-side version is the most commonly 
used forelimb placing test. Similar to rats with large lesions in this experiment, substantial 
impairment has been reported after MFB (Monville et al., 2005; Schallert et al., 2000; 
Woodlee et al., 2008) and large striatal 6-OHDA lesions (Grealish et al., 2008). Furthermore, 
the moderate impairment after small striatal 6-OHDA lesions found in the current experiment 
has also been reported elsewhere (McCoy et al., 2008; Pienaar et al., 2008). 
PROG treatment did not improve forelimb placement following same-side vibrissae 
stimulation for rats with small or large lesions. However, in the cross-midline test PROG 
prevented the increasing impairment evident in rats with small and large lesions. The 
mechanism underlying this prevention of increasing impairment is not clear although it 
suggests that PROG preserved some motor programs responsible for forelimb placing in the 
lesion hemisphere that could be accessed via vibrissae sensory input to the intact hemisphere. 
Therefore, despite forelimb placement impairment being primarily a motor deficit, PROG 
may have provided some sensory compensation.  
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Corridor test: Sensory neglect 
 The corridor test is a newer assay of sensory neglect following nigrostriatal dopamine 
depletion (Dowd et al., 2005a). Rats with unilateral 6-OHDA lesions will neglect flavoured 
food pellets placed on the contralateral to lesion side of the corridor (Dowd et al., 2005a; 
Fitzsimmons et al., 2006). An examination of the literature revealed that 12 studies have used 
the corridor test following unilateral 6-OHDA lesions in rats. Substantial impairments have 
been observed after SNpc (Jouve et al., 2010), MFB (Cederfjall et al., 2012, 2013; Corderio 
et al., 2010; Decressac et al., 2012; Dowd et al., 2005a; 2005b; Grealish et al., 2008; Torres et 
al., 2008), and large striatal lesions (Dowd et al., 2005a; Fitzsimmons et al., 2006; Grealish et 
al., 2008; Shin et al., 2014). Moderate impairments have been observed after small 
(Decressac et al., 2012) and single site striatal lesions (Moloney et al., 2010) although one 
study found no impairment after small striatal lesions (Shin et al., 2014). This discrepancy 
can readily be explained by the extent of TH reduction observed in these studies as 
impairment in the corridor is probably dependent on nigrostriatal dopamine depletion. 
Decressac et al. (2012) found that impairment in the corridor test was significantly correlated 
with the extent of SN cell and striatal fibre TH reduction. In their study they found that the 
threshold for impairment was SN and striatal TH reduction to approximately 20%. In the 
former studies (Decressac et al., 2012; Moloney et al., 2010) TH positive cells in the SN and 
fibres in the striatum were reduced on average to 30 – 35% with a number of rats expressing 
TH below the required threshold for impairment. In the latter study (Shin et al., 2014) TH 
reduction was less severe varying between 60 – 90% with almost all rats expressing TH 
above the required impairment threshold. Interventions that improve dopamine transmission 
should therefore reduce sensory neglect impairment in the corridor test. Indeed, previous 
research shows that systemic administration of the dopamine agonist apomorphine 
(Fitzsimmons et al., 2006) and post-lesion grafts of embryonic dopaminergic cells (Corderio 
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et al., 2010; Dowd et al., 2005a; Torres et al., 2008) ameliorate sensory neglect impairment in 
the corridor test after unilateral 6-OHDA lesions. Similarly, an adeno-associated viral vector 
that co-expressed the DOPA pre-cursors TH and GTP cyclohydrolase-1 administered to the 
striatum after 6-OHDA MFB lesions also reduced sensory neglect in the corridor test 
(Cederfjall et al., 2012, 2013). 
 Consistent with previous studies we found that large lesions produced substantial 
sensory neglect in the corridor test (e.g. Dowd et al., 2005a; Shin et al., 2014) while small 
lesions produced an intermediate impairment (e.g. Decressac et al., 2012; Moloney et al., 
2010). All rats in the current experiment received lesions on the side opposite to their pre-
operative preferred retrieval bias side. Strikingly, this innate bias was reversed by 6-OHDA 
lesions. Thus, consistent with the original report of Dowd et al. (2005a), rats with unilateral 
intrastriatal 6-OHDA lesions neglected their previously preferred side. However, PROG 
treatment did not reduce sensory neglect impairment for rats with small or large lesions. 
In study two (Chapter 6) we found that PROG treatment did not prevent additional 
striatal TH fibre degeneration as the lesion was already maximal at the time of the first PROG 
injection (day 8 after surgery). In the current experiment it is likely that striatal TH fibre 
deafferentation was complete at the time of the first PROG injection for at least rats with 
large lesions and potentially for rats with small lesions as the first PROG injection was also 
applied at day 8 after surgery. Therefore, the inability of PROG to reduce sensory neglect 
impairment in the current experiment may reflect, at least in part, lack of improvement in DA 
transmission. 
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Rotation after apomorphine 
Rats with large lesions had increased contralateral rotation after apomorphine at day 66 post-
surgery. Neither sham nor rats with small lesions had a rotation bias. PROG treatment did not 
change rotation for any group. 
 The increased contralateral rotation among rats with large lesions is similar to 
previous reports that have noted low to moderate rotation following large striatal 6-OHDA 
lesions (Dowd and Dunnett, 2005; Kirik et al., 1998, 2000b; Rosenblad et al., 2000). Reports 
regarding two-site striatal 6-OHDA lesions are sparse but the current finding is consistent 
with one other study with small lesions where insufficient DA depletion resulted in no effect 
on rotation after apomorphine (Kirik et al., 1998). 
 The inability of PROG to reduce contralateral rotation after apomorphine after large 
lesions is in accordance with study two (Chapter 6). As discussed in Chapter 6 and above, 
this is not surprising as PROG was unable to repair or protect striatal TH fibre denervation 
that was already maximal at the time of the first PROG injection.  
Spontaneous recovery of function after 6-OHDA lesions 
In the current experiment we observed some spontaneous recovery of motor function in 
several tests. Sensory neglect in the corridor test improved from first testing at day 22 to the 
last test as day 61 post-surgery. This improvement was more apparent for rats with large than 
small lesions. Similarly, forelimb placement following same-side vibrissae stimulation 
improved across post-surgery testing occasions for rats with small and large lesions. In the 
postural instability test the increased displacement of the contralateral forelimb that was 
evident at day 20 for rats with small lesions recovered over subsequent testing at days 42 and 
59 post-surgery to levels similar to their pre-surgery performance. Importantly, the adjusting 
 
Study Three: Progesterone after Small and Large Intrastriatal 6-OHDA lesions 
177 
 
steps test which was our primary outcome measure produced a stable impairment for rats 
with small lesions and a progressive impairment for rats with large lesions. The adjusting 
steps test is considered the most reliable behavioural readout following small and large 6-
OHDA lesions of the striatum although recovery can occur over extended testing periods 
(Duty and Jenner, 2011). 
 The spontaneous recovery of motor function reported in this experiment is not 
surprising as motor function can recover over several weeks after striatal 6-OHDA lesions, 
especially when the lesion is moderate (Stanic et al., 2003). The recovery of function found in 
the current experiment is similar to previous reports that have used small and large striatal 6-
OHDA lesions. For example, recovery of forelimb akinesia (Kirik et al., 2001b), forelimb use 
asymmetry (Kirik et al., 2000a) and rotation after d-amphetamine (Kirik et al., 2001a) have 
been reported after large striatal 6-OHDA lesions. Furthermore, after small striatal 6-OHDA 
lesions recovery of rotation after d-amphetamine and forelimb use asymmetry has also been 
found (Yang et al., 2009). In these studies and the current experiment motor function was 
assessed in both the short and long-term after surgery which improves the chances of 
detecting spontaneous recovery following 6-OHDA lesions and determines the relative long-
term consequences of any putative treatment. 
Summary 
The current experiment reports the first study in this field to examine PROG’s beneficial 
influence on an extensive series of motor tests, including forelimb akinesia, postural 
instability, sensorimotor integration, forelimb use asymmetry, sensory neglect, and rotation 
after apomorphine following small and large 6-OHDA lesions of the striatum. We found that 
7 days of 8 mg/kg PROG treatment with tapered withdrawal reduced forelimb akinesia in 
both the short and long-term for rats with small and large lesions. This replicated the findings 
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of study two (Chapter 6) where PROG provided long term reduction in forelimb akinesia for 
rats with large lesions. Additionally, this finding was extended to rats with small lesions 
suggesting that PROG is also beneficial in lesions that model the earlier stages of PD 
degeneration. In accordance with study two the improved forelimb akinesia was not merely 
symptomatic relief as the beneficial influence of PROG was observed up to six weeks after 
treatment had stopped.  
Importantly, PROG did not exacerbate impairments for rats with lesions nor did it 
change motor skills for sham rats which suggest that PROG is not detrimental on any of the 
motor tests used in this experiment. In addition to improved forelimb akinesia, PROG 
prevented increasing impairment across subsequent testing sessions in the cross-midline 
whisker test for rats with small and large lesions and normalised ipsilateral forelimb 
displacement in the postural instability test for rats with large lesions. However, PROG did 
not influence forelimb use asymmetry, same-side whisker evoked forelimb placing, sensory 
neglect, or rotation after apomorphine.  
The neural mechanisms underlying PROG’s beneficial influence after 6-OHDA 
lesions is unclear. Due to time restrictions histology has not yet been completed on these rats. 
However, the improved functional outcomes observed in this experiment are likely to be 
independent of striatal TH fibre innervation given the finding in study two that PROG 
treatment did not change striatal TH density.   
 This chapter has reported the first experiment in this field that directly compares 
PROG treatment after small and large 6-OHDA lesions of the striatum. Furthermore, this 
experiment has provided the most comprehensive examination to date of PROG’s influence 
on motor impairments after 6-OHDA lesions. Here we have found that PROG treatment is 
beneficial following both small and large 6-OHDA lesions of the striatum. The most benefit 
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was observed on the adjusting steps test primary outcome measure of forelimb akineisa 
where the observed improvement was long-lasting.  
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Chapter 8   
General Discussion 
8.1.  Summary 
This thesis examined the beneficial influence of post-lesion treatment with the neurosteroid 
natural progesterone (PROG) in the unilateral intrastriatal 6-hydroxydopamine (6-OHDA) 
model of Parkinson’s disease (PD). The current study has shown for the first time that PROG 
treatment markedly reduced motor impairments following small and large 6-OHDA lesions 
that modelled the earlier and later stages of PD degeneration, respectively. Table 8.1 
summarises the key findings of this thesis. As shown in Table 8.1, the lesions produced 
substantial rotation bias after d-amphetamine which confirmed a functional dopamine (DA) 
impairment prior to PROG treatment. The substantial forelimb akinesia produced by lesions 
on the adjusting steps test was markedly improved by PROG treatment for rats with small 
and large lesions; this benefit after large lesions was replicated across two experiments. The 
beneficial influence of PROG for forelimb akinesia was evident at the first testing occasion 
and maintained for several weeks after treatment had stopped. Skilled reaching was 
moderately impaired for rats with large lesions, but PROG did not improve this deficit. 
Similarly, lesions induced a substantial rotation bias after apomorphine that was not reduced 
by PROG. PROG treatment did not improve postural instability of the contralateral forelimb 
but did improve the compensatory function of the ipsilateral forelimb for rats with large 
lesions on the postural instability test. Sensorimotor integration on the whisker test was 
markedly impaired for rats with small and large lesions. PROG improved forelimb 
placements for rats with small lesions on both versions of the whisker test and prevented the 
increasing impairment over time on the “cross-midline” test. Only large lesions increased 
forelimb use asymmetry on the cylinder test which was not improved by PROG treatment. 
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Rats with large lesions displayed substantial sensory neglect on the corridor test whereas rats 
with small lesions had a moderate impairment, but PROG did not attenuate this sensory 
neglect deficit for either lesion size. Lastly, large lesions severely reduced tyrosine 
hydroxylase (TH) fibre density in the striatum. The considerable reduction in striatal TH was 
evident at the time when PROG treatment was initiated and was maintained at the end of 
testing several weeks later. However, treatment with PROG did not change striatal TH 
density. Taken together these findings are the first in this field to demonstrate some beneficial 
influence of PROG treatment on motor impairments in the short-term and long-term after 
small and large 6-OHDA lesions of the striatum.  
Table 8-1 
Summary of Key Findings* 
Study 2: PROG 
dose response after 
large lesions 
Main effects Effect size  Study 3: PROG 
after small and 
large lesions 
Main effects Effect size 
Task    Task   
Rotation bias after 
d-amphetamine 
 
Large lesion   Rotation bias after d-
amphetamine 
Large lesion 
Lesion-only control   Small lesion  
8 mg/kg PROG No tested  Large PROG No tested 
 4 mg/kg PROG No tested   Small PROG No tested 
      
Akinesia: Adjusting 
steps test  
Large lesion   Akinesia: Adjusting 
steps test 
Large lesion  
   Small lesion  
 8 mg/kg PROG    Large PROG  
 4 mg/kg PROG    Small PROG  
       
Skilled reaching: 
Success rate 
Large lesion   Skilled reaching: 
Success rate 
Not measured 
     
 8 mg/kg PROG      
 4 mg/kg PROG      
      
Rotation bias after 
apomorphine 
 
Large lesion   Rotation bias after 
apomorphine 
Large lesion 
   Small lesion  
8 mg/kg PROG   Large PROG  
4 mg/kg PROG    Small PROG  
      
Postural instability: 
Contralateral 
forelimb 
Not measured   Postural instability: 
Contralateral 
forelimb 
Large lesion  
   Small lesion  
   Large PROG  
   Small PROG  
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Study 2: PROG 
dose response after 
large lesions 
Main effects Effect size  Study 3: PROG 
after small and 
large lesions 
Main effects Effect size 
Task    Task   
       
Postural instability: 
Ipsilateral forelimb 
Not measured   Postural instability: 
Ipsilateral forelimb 
Large lesion  
   Small lesion  
   Large PROG  
    Small PROG  
       
Sensorimotor 
integration: 
Whisker test (same 
side)  
Not measured   Sensorimotor 
integration: Whisker 
test (same side)  
Large lesion  
   Small lesion  
   Large PROG  
    Small PROG  
      
      
Sensorimotor 
integration: 
Whisker test (cross 
midline)  
 
Not measured   Sensorimotor 
integration: Whisker 
test (cross midline)  
 
Large lesion  
   Small lesion  
   Large PROG  
   Small PROG  
     
       
Forelimb use 
asymmetry: 
Cylinder test  
Not measured   Forelimb use 
asymmetry: Cylinder 
test  
Large lesion  
   Small lesion  
   Large PROG  
     Small PROG  
       
Sensory neglect: 
Corridor test  
Not measured   Sensory neglect: 
Corridor test  
Large lesion  
   Small lesion  
     Large PROG  
     Small PROG  
       
Striatal tyrosine-
hydroxylase fibre 
density 
Large lesion   Striatal tyrosine-
hydroxylase fibre 
density 
Not measured  
Lesion-only control     
8 mg/kg PROG     
4 mg/kg PROG     
       
       
*This table summarises the key findings from the PROG studies (Chapters 6 and 7). d = 
Cohen’s pairwise effect size. ,d ≥0.5; ,d ≥0.8; , d≥1.5; ,d ≥3.0; , d<0.5. 
See Appendix A for numerical values. Note: In study 2, the large lesion effect is compared to 
sham and the potential PROG treatment benefits are compared to large lesions. In study 3, the 
large and small lesion effects are compared to sham and the potential PROG treatment benefit 
is compared to the corresponding lesion group.  
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8.2.  6-OHDA Lesions Impair Motor Skills 
This section summarises the changes that were produced by 6-OHDA lesions in this study. 
For a detailed summary and discussion of these findings see Chapters 5-7.  
The intrastriatal 6-OHDA lesions used in this study impaired motor skills, as 
expected. Prior to treatment with PROG we validated the success of the lesions with a test of 
rotation after d-amphetamine. Consistent with previous research we found that at day 7 after 
surgery large lesions produced substantial ipsilateral rotation after d-amphetamine 
administration whereas small lesions caused moderately increased rotation (Kirik et al., 1998; 
Shin et al., 2014). Importantly, the difference in the rate of rotation between rats with small 
and large lesions confirmed that we were successful in producing a graded PD like 
impairment. In a similar test, when striatal supersensitivity to a DA agonist was examined, 
we found that only large lesions increased contralateral rotation after apomorphine (Kirik et 
al., 1998). The success of the lesion method was further validated in studies one and two 
(Chapters 5 and 6) with striatal TH density immunohistochemistry. As expected,  we found 
that striatal TH density was markedly reduced at day 8 and that this reduction was maintained 
at 9 weeks after large lesion surgery (Cicchetti et al., 2002; Grealish et al., 2010; Kirik et al., 
1998; Rosenblad et al., 2000). Taken together the d-amphetamine rotation test and striatal TH 
fibre measures show that our lesion method was successful at producing a functional DA 
impairment.  
 Akinesia is a cardinal motor feature of PD so the current study selected a priori, and 
tested first after PROG, the adjusting steps test for forelimb akinesia as the primary outcome 
measure (Dauer and Przedborski, 2003; Jankovic, 2008; Olsson et al., 1995). The large 6-
OHDA lesions produced moderately severe contralateral forelimb akinesia that, like other 
studies, was maintained at repeated testing intervals between weeks 2 and 8 after surgery 
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(Dowd and Dunnett, 2005; Kirik et al., 1998, 2000a, 2000b; Shin et al., 2014). We also 
observed that small lesions produced moderate contralateral forelimb akinesia that was 
maintained at repeated testing intervals (Decressac et al., 2012; Kirik et al., 1998; Shin et al., 
2014). These findings further support the validity of our lesion methods as impaired forelimb 
stepping in the adjusting steps test is a standard finding after intrastriatal 6-OHDA lesions.  
 In study two we included a single-pellet skilled reaching task as a measure of complex 
motor skill. The single-pellet reaching task is most often used in conjunction with MFB 
lesions, which substantially impair reaching accuracy on this task (Klein et al., 2007; Metz et 
al., 2003; Vergara-Aragon et al., 2003). Similarly, others have reported that reaching 
accuracy in this task is substantially impaired after large striatal lesions (Plowman et al., 
2013, 2014). In the current study we found that large lesions reduced skilled reaching 
accuracy to about 60% of pre-surgery performance. This reduction is less severe than after 
the large striatal lesions made by Plowman et al. (2013, 2014), who found that reaching 
accuracy was reduced to about 20% of baseline levels. This difference is, however, readily 
explained by the different pre-surgery training criterion used between our studies. In the 
Plowman et al. studies rats were trained to a minimum of 35% accuracy with an average 
group accuracy of about 45%. In the current study we trained all rats to >60% accuracy with 
the group average being >70%, which is line with previous reports (Alaverdashvili and 
Whishaw, 2008; Vergara-Aragon et al., 2003). It is likely that the more extensive pre-surgery 
training used in our study preserved post-lesion skilled reaching accuracy to greater degree 
than the less extensive training used by Plowman et al. The extensive pre-surgery training 
used in the current study shows that our skilled reaching task was robust and therefore 
suitable for assessing skilled reaching accuracy.  
 In study three we used the cylinder test to examine spontaneous forelimb use 
asymmetry (Schallert et al., 2000; Woodlee et al., 2008). As discussed in Chapter 7, we found 
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that large lesions increased preferential use of the ipsilateral forelimb compared to sham rats 
(Carlsson et al., 2009; Henning et al., 2007; Shin et al., 2014) whereas small lesions did not 
(Decressac et al., 2012). We also extended the cylinder test to include the newer measure of 
serial stepping (Woodlee et al., 2008). We found that serial stepping was slightly but 
significantly increased for rats with large lesions only. In comparison, Woodlee et al. (2008) 
found substantial serial stepping occurred after the more extensive MFB lesions. The method 
used for the cylinder test in this study was consistent with previous reports (e.g. Decressac et 
al., 2012; Grealish et al., 2010; Woodlee et al., 2008) although due to time-restrictions we 
only coded the pre-surgery and day 42 post-surgery videos. Examination of the other post-
surgery time-points may reveal additional differences once these videos are scored.  
 In study three we assessed sensory neglect in the corridor test (Dowd et al., 2005a). 
Consistent with previous research we found that large lesions markedly reduced sugar pellet 
retrievals from the contralateral to lesion side of the corridor (Dowd et al., 2005a; 
Fitzsimmons et al., 2006) while small lesions produced an intermediate impairment 
(Decressac et al., 2012) although others have not found an impairment after small lesions 
(Shin et al., 2014). The corridor test procedure used in this study was the same as previous 
reports where two test sessions were added together to determine a rats score (Cederfjall et 
al., 2012, 2013; Dowd et al., 2005a; Fitzsimmons et al., 2006). However, others have used a 
single test session (Decressac et al., 2012; Grealish et al., 2008; Torres et al., 2008) or have 
used the two most similar of three sessions (Shin et al., 2014). In our opinion any of these 
methods is suitable as our casual observations revealed that rats tended to show a consistent 
bias across test sessions.  
 In study three we used the same-side and cross-midline whisker evoked forelimb 
placing tests to examine sensorimotor integration (Woodlee et al., 2005). On the same-side 
whisker test we found that large lesions substantially impaired forelimb placement whereas 
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small lesions produced a moderate deficit (Grant et al., 2009; Grealish et al., 2008; McCoy et 
al., 2008; Pienaar et al., 2008). Similarly, on the cross-midline whisker test rats with large 
lesions were substantially impaired while rats with small lesions had an intermediate deficit 
(Anstrom et al., 2007; McCoy et al., 2008; Pienaar et al., 2008; Woodlee et al., 2005). The 
inclusion of the cross-midline test in this study in the context of a PD model is novel and to 
the best of our knowledge no study has employed this test after large striatal lesions. Testing 
forelimb placement by both same-side and cross-midline vibrissae stimulation is important as 
it allows the experimenter to distinguish if the impairment is primarily sensory or motor in 
nature. As discussed in Chapter 7, impairment on both versions of the test confirmed that the 
deficit was primarily due to a motor than sensory deficit. 
 Lastly, in study three we examined postural instability in the newer postural 
instability test (Woodlee et al., 2008). Similar to Woodlee et al. (2008) who used MFB 
lesions we found that both small and large lesions produced postural instability of the 
contralateral forelimb and enhanced compensatory function of the ipsilateral forelimb. We 
found that large lesions produced a greater change in both forelimbs compared to rats with 
small lesions. The inclusion of this test is a new addition to this field as to the best of our 
knowledge the postural instability test has not been used after small and large striatal lesions.  
 Taken together this summary shows that we were successful at producing motor 
impairments in the unilateral intrastriatal 6-OHDA lesion model of PD. We found that large 
lesions produced substantial impairments on rotation after d-amphetamine and apomorphine, 
forelimb akinesia, skilled reaching, postural instability, forelimb use asymmetry, 
sensorimotor integration, and sensory neglect. In comparison, small lesions produced lesser 
impairments on forelimb akinesia, postural instability, sensorimotor integration, and sensory 
neglect, but no impairment for forelimb use asymmetry and rotation after apomorphine. The 
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difference in severity of deficits between small and large lesions confirms that we 
successfully produced a graded PD-like impairment in our rats.  
8.3.  Progesterone Improves Some Motor Skills 
The current thesis has produced novel evidence regarding the beneficial influence of PROG 
on motor impairments after intrastriatal 6-OHDA lesions. The most striking finding was on 
the adjusting steps test for forelimb akinesia. In study two we found that 7 days of treatment 
with 4 mg/kg PROG and 8 mg/kg PROG, started at day 8 after surgery with tapered 
withdrawal on the sixth and seventh days of treatment, reduced forelimb akinesia in both the 
short-term and long-term after large striatal lesions that modelled the late stages of PD 
degeneration. We replicated this finding in study three using large lesions and 8 mg/kg 
PROG. In addition, we extended this finding to rats with small striatal lesions that modelled 
the earlier stages of PD degeneration. Taken together these findings show that PROG reduces 
forelimb akinesia in the adjusting steps test after small and large 6-OHDA lesions of the 
striatum. Furthermore, the beneficial influence of PROG was not simply symptomatic relief 
as the improvement on forelimb akinesia was sustained but did not improve further during the 
six weeks of testing after the treatment had stopped. The lack of further improvement 
supports the role for progesterone in neuroprotection, rather than promoting brain recovery. 
This finding is very promising, although it needs to be confirmed by independent replication 
in another laboratory. 
We also found that PROG provided some benefits on the postural instability and 
whisker evoked forelimb placing tests. Specifically, the enhanced compensatory function of 
the ‘good’ ipsilateral forelimb in rats with large lesions was normalised by PROG treatment 
on the postural instability test. In addition, PROG prevented the increasing impairment 
evident in rats with small and large lesions in the cross-midline version of the whisker test.  
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 It is important to recognise that while PROG improved forelimb akinesia, whisker 
evoked forelimb placing, and compensatory function of the ‘good’ forelimb, PROG did not 
improve performance in other tasks. PROG treatment did not improve skilled reaching 
accuracy on the single-pellet reaching task, forelimb use asymmetry on the cylinder test, 
sensory neglect on the corridor test, or rotation after apomorphine. The variation in the 
treatment effects across tasks was possibly caused by the stage of neuronal degeneration 
when the treatment was started. That is, at day 8 when PROG treatment was started the lesion 
induced impairments on these tasks may have progressed beyond the point for PROG to be 
beneficial. A positive note is that PROG did not exacerbate impairments for rats with lesions 
nor did it change motor skills for sham operated rats which suggests that PROG was not 
harmful on any of the motor skills tests used in this study.  
 As discussed in Chapters 6 and 7, the neural mechanisms underlying the beneficial 
influence of PROG are not clear. The benefits we observed were independent of striatal TH 
as we found that PROG did not improve striatal TH density when measured at 7 weeks after 
the treatment had stopped. However, this negative result does not rule out other potential 
dopaminergic factors such as the number of TH positive cells in the SN and VTA. Thus, the 
treatment effects of PROG are possibly mediated through neuroprotection of dopaminergic 
neurons, because improved forelimb stepping in the adjusting steps test is related to 
dopamine function but it may not be dopamine specific. Furthermore, the beneficial influence 
of PROG could have been mediated through non-dopaminergic mechanisms. For example, 
acute administration of non-dopaminergic agents such as adenosine A2A receptor or 
metabotropic glutamate R5 receptor antagonists improves forelimb stepping in the adjusting 
steps test in rats with 6-OHDA lesions (Ambrosi et al., 2010; Pinna et al., 2007, 2010). In 
another study 14 days administration of a novel diketopiperazine provided sustained long-
term improvement in the adjusting steps test independent of TH (Krishnamurthi et al., 2009). 
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Therefore, it is possible that the mechanisms responsible for the beneficial influence of 
PROG in this study were non-dopaminergic although further work elucidating these 
mechanisms is required. 
 Previous studies have shown that administration of low doses of PROG prevented 
MPTP-induced DA depletion when PROG was administered prior to and continued during 
MPTP injections in mice (Callier et al., 2001; Grandbois et al., 2000). Similarly, others have 
found that low doses of PROG also prevented DA depletion when PROG was administered 
prior to toxic injections of methamphetamine in mice (Yu et al., 2002; Yu and Liao, 2000). 
However, studies that have administered PROG after 6-OHDA lesions have shown 
inconsistent results regarding DA protection. Chao et al. (2011) found that neither 4 mg/kg 
PROG nor 8 mg/kg PROG protected DA depletion when administered once daily for 13 days 
starting 24 hours after large 6-OHDA striatal lesions. In comparison, Casas et al. (2013) 
reported that 4 mg/kg PROG administered once daily for three days from day 7 after small 6-
OHDA striatal lesions improved K
+
 evoked [
3
H]-DA from striatal slices. In study two we 
found that PROG was unable to protect striatal TH as the fibre denervation was already 
complete at the time of the first PROG injection at day 8 after large striatal lesions. Taken 
together it is possible that the timing of treatment initiation and the size of the DA lesion are 
important factors. Therefore, it is appears that PROG can increase the brains resilience to the 
DA depleting effects of neurotoxins when administered either before MPTP or 
methamphetamine lesions (Callier et al., 2001; Grandbois et al., 2000; Yu et al., 2002; Yu 
and Liao, 2000) or when administered after small striatal 6-OHDA lesions (Casas et al., 
2013) that produce mild striatal TH depletion. However, PROG does not prevent DA or TH 
loss when it is administered from 24 hours (Chao et al., 2011) or 8 days (study two) after 
large striatal 6-OHDA lesions that are known to substantially deplete striatal TH within 6-24 
hours of surgery which then reach maximum depletion within 7-10 days (Cicchetti et al., 
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2002; Rosenblad et al., 2000; Walsh et al., 2011). Therefore, it would be worthwhile 
examining TH of the stored brain sections for study three of the current thesis as this 
experiment included both small and large striatal lesions.   
 Previous studies regarding the beneficial influence of PROG after DA lesions have 
provided limited assessments of motor function outcomes. In one study the contralateral 
rotation bias after apomorphine was reversed to an ipsilateral bias following 4 mg/kg PROG 
administered once daily for three days from day 7 after small striatal lesions (Casas et al., 
2011). However, Chao et al. (2011) found no beneficial influence of PROG on rotational 
asymmetry after apomorphine. Similarly, Casas et al. (2013) found that PROG was not 
beneficial for rotational asymmetry after d-amphetamine. However, Casas et al. (2011) found 
that PROG improved a mild memory deficit in a novel object recognition test, and reversed 
depressive-like behaviour in a forced swim test after small 6-OHDA lesions.  In contrast, 
Chao et al. (2011) found  that PROG actually exacerbated spontaneous rotational asymmetry, 
hind limb foot slips on an elevated grid test, and symmetrical use of the forelimbs in the 
cylinder test when examined between days 4 and 13 after large 6-OHDA lesions. The 
findings of Chao et al. are inconsistent with our study as we found that PROG improved 
several motor skills (forelimb akinesia, enhanced compensatory function of the ipsilateral 
forelimb, and forelimb placements in the whisker test) but did not exacerbate other motor 
impairments. This inconsistency may be explained by the timing of PROG treatment after 
lesion surgery. As stated in Chapter 3, it takes approximately 3 days for 6-OHDA to 
metabolise and produce SN cell death following infusions to the striatum (Cicchetti et al., 
2002; Walsh et al., 2011). Administering PROG at 24 hours after surgery in the Chao et al. 
(2011) study likely produced interactions with 6-OHDA metabolism that exacerbated the 
lesion and subsequent motor impairments. In comparison, the current study, and that of Casas 
et al. (2011, 2013), found that PROG improved some outcomes without exacerbating 
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impairments when treatment was started 7 or 8 days after 6-OHDA lesion surgery. Therefore, 
it appears that the timing of PROG treatment after 6-OHDA infusions to the striatum is a 
critical factor. Here we have identified that 7 days of PROG treatment with tapered 
withdrawal started at day 8 after lesion surgery is an effective treatment regime.  
The current study is an improvement on previous research in this field. Casas et al. 
(2011, 2013) examined affective and cognitive behaviour but did not thoroughly examine 
motor skills after small striatal 6-OHDA lesions. In comparison, Chao et al. (2011) examined 
several motor skills but only in the short term and after large 6-OHDA striatal lesion surgery. 
The current thesis has improved on these studies on three counts. First, we examined motor 
skills on a larger battery of tests. Second, we investigated both the short and longer term 
outcomes of PROG treatment. Lastly, we provided the first direct comparison regarding the 
beneficial influence of PROG treatment after small and large 6-OHDA lesions of the 
striatum. Taken together the current study has provided the most comprehensive examination 
to date regarding PROG’s influence on motor impairments after 6-OHDA lesions. 
 Here we have shown that PROG treatment improves forelimb akinesia after 6-OHDA 
lesions. However, it is essential to consider this finding in the wider context of the PD 
treatment problem. As discussed in Chapter 2, L-DOPA is currently the gold-standard 
treatment for the motor complications of PD (Smith et al., 2012). Therefore, it needs to be 
considered if PROG will offer any benefit over L-DOPA. In the current study PROG 
improved forelimb akinesia after  large striatal lesions although these rats were still impaired 
compared to sham rats. In comparison, PROG improved forelimb akinesia for the small 
lesion group so that these rats were similar to sham rats. In all groups PROG had a beneficial 
influence of a large effect size (Table 8.1). Several studies have examined the beneficial 
influence of acute L-DOPA administration on the adjusting steps test after 6-OHDA lesions 
of the MFB. In two studies severely impaired forelimb stepping was improved to about 50% 
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of unimpaired performance after L-DOPA with approximate effect sizes (d = ~ 1.79-2.09) 
similar to the effect sizes we obtained in our study with PROG (Chang et al., 1999; Olsson et 
al., 1995). In comparison, three other studies found that L-DOPA administration returned 
severely impaired forelimb stepping to about unimpaired levels with effect sizes larger (d = ~ 
3.10) than we found in our study (Kasture et al., 2009; Pinna et al., 2007, 2010). Therefore, it 
appears that acute administration of L-DOPA in rats with MFB lesions produces an effect 
equal to or greater than the effect we found with short term PROG treatment in rats with 
small and large striatal lesions.  
 However, the beneficial influence of L-DOPA treatment only lasts for up to several 
hours and as PD progresses the beneficial duration of each dose decreases and intolerable 
side effects such as dyskinesia occur (Hornykiewicz, 2002; Tarazi et al., 2014). In 
comparison, we found that a short course of PROG treatment provided long-term 
improvement in forelimb akinesia. Thus treatment with PROG clinically may prevent the 
further worsening of akinesia, although PROG’s efficacy may vary with the stage of 
neurodegeneration at the time of treatment.  Importantly, PROG has not been associated with 
any serious side effects in over 1000 patients administered PROG in Phase II and III clinical 
trials for TBI (Skolnick et al., 2014; Wright et al., 2006, 2014; Xiao et al., 2008). Therefore, 
this raises the possibility that PROG could be used as a safe adjunct therapy alongside L-
DOPA for the treatment of akinesia. If effective, PROG has the potential to reduce the dose 
of L-DOPA required and/or to increase the beneficial duration of each dose which would 
reduce the negative side effects associated with chronic L-DOPA use.  
PROG’s potential as an adjunct therapy for akinesia should first be investigated in an 
animal model that examines the dose response and beneficial duration of L-DOPA in rats 
treated with PROG. Following positive findings we think that a small clinical trial would be 
warranted as PROG is a safe agent to give to people as discussed above. Although PROG did 
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not successfully translate to the treatment of TBI in recent Phase III trials (Skolnic et al., 
2014; Wright et al., 2014) it is still worthwhile trialling PROG for other brain injuries and 
diseases due to its safety and the extensive pre-clinical evidence regarding its beneficial 
influence in over 20 models of brain injury and disease as discussed in Chapter 3. However, 
like others (Stein, 2014; Wright et al., 2014), I believe that future clinical trials should 
consider adaptive trial design to improve translation from the laboratory to the clinic (see 
Chow and Chang, 2008 for a review of adaptive trial design methods). The benefit of PROG 
treatment is that it may be a suitableadjunct therapy that would be  simple and cheap to 
adminster, and is an invasively minimal approach that may improve PD motor symptoms. By 
comparison  other promising treatments such as cell replacement therapy and glial cell-line 
derived neurotrophic factor therapy are highly invasive and expensive, and can be associated 
with negative side effects such as graft induced dyskinesia (Kordower and Bjorklund, 2013; 
Lindvall and Bjorklund, 2014). 
8.4.  Limitations and Future Directions 
The current study examined the beneficial influence of PROG in a rodent model of PD. As 
discussed in Chapter 4, an ideal rodent model of PD should recapitulate as many of the key 
features of PD as possible. The 6-OHDA model used in this thesis closely mimics 
nigrostriatal DA degeneration and the key motor features of PD and thus is useful for 
examining novel treatments aimed at reduction of motor symptoms (Kirik et al., 1998). 
However, there is not a single model that exactly replicates PD, thus multiple models that 
reproduce different aspects of the disease should be used for drug development. The 6-
OHDA model, like many others, does not reproduce the degeneration of other neural systems 
relevant to PD pathology. Indeed, degeneration of the noradrenergic, serotonergic, 
cholinergic, and many other neural systems also occurs (Braak et al., 2003; Delaville et al., 
2011; Halliday et al., 2011). Furthermore, the 6-OHDA model does not produce Lewy 
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pathology which is a key pathological hallmark of PD (Braak et al., 2006). These non-
dopaminergic changes have not been well modelled in animals. In recognition of this 
limitation an interesting recent study found that combined 6-OHDA and noradrenalin lesions 
produced significantly worse motor impairments than DA lesion alone (Shin et al., 2014). 
Similarly, combined intranigral administration of AAV-α-synuclein and rotenone is a 
promising model that produces reliable motor impairments, nigrostriatal degeneration, and α-
synucleinopathy (Mulcahy et al., 2012). Another new approach closely replicates Lewy 
pathology though prion-like cell-to-cell transfer of aggregated α-synuclein (Luk and Lee, 
2014). These newer approaches to modelling PD could better replicate different aspects of the 
human disease. Despite the limitations of the 6-OHDA model its use to study the beneficial 
influence of PROG was appropriate as virtually all drugs currently in clinical use have shown 
efficacy in this model (Duty and Jenner, 2011). It would nonetheless be advisable to examine 
PROG in these newer models that mimic different aspects of PD pathology.  
Time constraints in the current study prevented additional histology from being 
conducted. Analysis of TH positive cell bodies in the SN and VTA were intended to be part 
of study two (Chapter 6) as the cells in the SN and to a lesser extent in the VTA are 
selectively killed by intrastriatal 6-OHDA lesions (Kirik et al., 1998; Grealish et al., 2008). 
Furthermore, due to time restrictions no histology was conducted for study three (Chapter 7). 
The lesions in study three were validated with a rotation after d-amphetamine test, as per 
previous research (Grealish et al., 2008, 2014; Torres et al., 2007). However, histology work 
is needed to evaluate the extent of the small and large lesions and to assess the beneficial 
influence of PROG on striatal and nigral TH. The stained brain sections from study two and 
stored brain sections from study three will be processed for TH histology in the future.  
Another limitation was the lack of histology regarding the mechanisms that 
contributed to PROG’s beneficial influence on motor impairments. Therefore, it is not known 
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if PROG treatment is influencing the disease process produced by 6-OHDA lesions. Future 
work should investigate markers of inflammation as this is a key pathogenic factor in PD 
(Barcia, 2013; Peterson and Flood, 2012). Previous studies have shown that expression of 
activated microglia and pro-inflammatory cytokines are increased after 6-OHDA lesions 
(Ambrosi et al., 2010; Cicchetti et al., 2002; Jin et al., 2008; Walsh et al., 2011). Importantly, 
PROG has reduced expression of activated microglia and pro-inflammatory cytokines in 
other models of experimental brain injury (Cutler et al., 2007; Garay et al., 2012; Ishrat et al., 
2010; Labombarda et al., 2011). To investigate PROG’s beneficial influence on inflammation 
future studies should stain brain sections against CD11b/OX-42, a marker of activated 
microglia. We have piloted the CD11b protocol with moderate success but further work is 
needed to optimize this protocol in our laboratory. The stored brain sections provide an 
opportunity to perform the CD11b procedure in future. This work may tell us if PROG 
treatment changed activated microglia expression and thus influenced the underlying 
degenerative process. 
In addition to inflammation, other factors that contribute to the pathology of PD 
should be investigated as the mechanisms underlying PROG’s neuroprotection are pleiotropic 
(Stein, 2008). Future studies should examine PROG’s influence on brain-derived 
neurotrophic factor, mitochondria function, oxidative stress, apoptosis, and, blood-brain 
barrier integrity as PROG has improved each of these PD related pathophysiological factors 
in other experimental models of brain injury and disease (Deutsch et al., 2013; Sayeed and 
Stein, 2009). 
Another limitation was the lack of pharmacokinetics, pharmacodynamics, and blood 
plasma levels of PROG. Examining these factors of PROG would provide important data 
regarding the absorption, half-life, central uptake, and reduction of PROG to its active 
metabolite allopregnanolone. This information would be useful for optimizing dosage in 
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future studies and help interpret the dose independent efficacy of PROG on the adjusting 
steps test in Experiment two (see Chapter 6). 
 The current study provided a thorough examination regarding the beneficial influence 
of PROG on motor impairments. However, it is not known if PROG would have benefited 
non-motor impairments which also contribute to reduced quality of life in PD (Chaudhuri et 
al., 2010). Studies that investigate non-motor impairments often employ a small bilateral 6-
OHDA lesion that does not produce obvious motor impairments (MacDowell and Chesselet, 
2012). For example, anhedonia, anxiety-like, and depressive-like behaviour have been 
reported after these lesions while motor behaviour was not affected (Santiago et al., 2010; 
Tadaiesky et al., 2008). This small bilateral lesion paradigm was not appropriate for the 
current study as the aim of this thesis was to examine overt motor impairments. It would be 
interesting to examine the beneficial influence of PROG on non-motor symptoms using these 
small bilateral lesions in a future study.   
 The current study showed that PROG treatment considerably improved forelimb 
akinesia, and to a lesser extent sensorimotor integration and compensatory function of the 
ipsilateral forelimb. However, PROG did not improve skilled reaching, sensory neglect, 
forelimb use asymmetry, or rotation after apomorphine. It is possible that the PROG treated 
rats could have shown some improvement in these and other tests if they had ‘learned to use 
progesterone’. This suggestion echoes the phenomenon known as ‘learning to use the 
transplant’, where an animal must undergo specific training in order to produce a functional 
benefit of a neural graft, especially for complex tasks (Döbrössy and Dunnett, 2001). For 
example, Mayer et al. (1992) pre-trained rats on a complex lateralised-nose poking task prior 
to unilateral ibotenic acid lesions of the striatum. Half of the rats received striatal grafts then 
all rats were re-tested on the task six months later. Both grafted and non-grafted rats with 
lesions were severely impaired whereas sham rats rapidly reacquired the task. However, the 
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graft group markedly improved only after repeated testing whereas the non-grafted lesion 
group did not. This suggests that the grafted rats needed to learn to use their transplants 
through experience in the task. In other words, the grafts provided a necessary substrate for 
new sensorimotor learning to occur (Reddington et al., 2014). In the current study it is 
possible that PROG treatment also provided a substrate for new motor skill learning to occur. 
However, most of the motor tasks used in this study were relatively simple and administered 
briefly at each testing occasion. PROG treatment may have shown efficacy in a task if the 
rats were given the opportunity to ‘learn to use progesterone’ through repeated and massed 
testing across days. This is especially relevant for the skilled reaching task which was the 
most complex motor skill test used in this study. It would therefore be of interest to 
investigate the beneficial influence of PROG in complex motor skill learning tasks that 
provide the rat with an opportunity to ‘learn to use progesterone’.  
 The current study has provided initial promising evidence regarding the beneficial 
influence of PROG in an animal model of PD. The Stroke Academic Industry Roundtable 
(STAIR) have developed a set of recommendations (Table 8.2) to guide the preclinical 
development of novel drug therapies prior to clinical trials (Fisher et al., 1999, 2009). 
Although these recommendations were developed for the study of stroke, these general 
principles can be applied to other models of brain injury and disease (Deutsch et al., 2013). 
These criteria can be used to inform the direction of future research based on the promising 
findings of this study. 
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Table 8-2. 
Summary of STAIR Criteria Relevant to Parkinson’s disease Studies 
1. Adequate dose-response curve 
2. Therapeutic time window defined 
3. Histological and functional outcome measures in both 
short and long-term 
4. Study of young then aged animals with comorbidities if that 
is the intended population for clinical trials 
5. Studied in both male and female animals 
6. Fundamentals of good scientific inquiry satisfied (e.g. 
random assignment, inclusion/exclusion criteria, blinded 
assessment of outcome etc). 
Note: Check marks indicate criteria satisfied in current study. =partially satisfied; =fully 
satisfied (Table adapted from Fisher et al., 2009, see reference for full criteria relevant to 
stroke).  
 The first criterion, adequate dose-response curve, was partially addressed in study two 
where we compared two PROG doses. We found that both doses were more or less equally 
beneficial on forelimb akinesia although we did not identify the minimum effective or 
maximum tolerable dose. It would be worthwhile investigating the influence of PROG across 
several doses to determine the dose-response curve. The doses examined should range 
between 2 mg/kg and 32 mg/kg as dose-response studies for TBI and ischemic injury have 
found that 8 mg/kg and 16 mg/kg were effective whereas 32 mg/kg provided little benefits in 
comparison (Goss et al., 2003; Wali et al., 2014; Yousuf et al., 2014). 
 The second criterion, define the therapeutic time-window, was also partially 
addressed in study three where we compared small and large lesions that modelled the earlier 
and later stages of PD degeneration, respectively. PROG treatment was beneficial for both 
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small and large lesions which suggest that treatment can be initiated at the earlier or later 
stages of PD degeneration. For both lesion types we initiated treatment at day 8 after surgery. 
Delaying treatment till day 8 was suitable for this study as the aim was to initiate treatment 
once a PD like impairment was present. However, it is not known if initiating treatment at 
different time-points after surgery would also be beneficial although one study found that 
PROG treatment started 24 hours after large intrastriatal 6-OHDA lesions exacerbated motor 
symptoms (Chao et al., 2011). A future experiment that varies the time-point for treatment 
initiation would provide additional data regarding the therapeutic time-window for PROG 
treatment in the 6-OHDA model of PD.  
Related to the therapeutic time-window is the duration of PROG treatment. In the 
current study we administered PROG for 7 days with tapered withdrawal on the sixth and 
seventh days of treatment. This treatment method was appropriate as it is the best treatment 
regime in acute brain injury models and because there is little data regarding chronic PROG 
administration (Cutler et al., 2005, 2006). Unlike acute brain injury, PD is a chronic and 
progressive disorder. Therefore, building on the promising results of the 7 day treatment 
regime, future studies should examine chronic dosing and/or repeated treatment intervals as 
these would be relevant to the treatment of PD. 
  The third criterion, acute and long-term assessment of histological and function 
outcomes, was moderately and well addressed in this study, respectively. We assessed motor 
impairments in both the short and longer-term after lesion surgery. We showed that PROG 
treatment improved forelimb akinesia when tested several days after the last PROG injection. 
Furthermore, this benefit was sustained at repeated testing intervals for six-seven weeks after 
PROG treatment had stopped. The demonstration of sustained functional benefit of PROG 
treatment is especially encouraging as STAIR recommendations emphasise improvements in 
functional outcomes (Fisher et al., 2009). We provided initial long-term histology although as 
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discussed above additional histology work is needed to fully assess the beneficial influence of 
PROG.  
 STAIR recommends that studies first use young healthy animals then move to testing 
older animals with comorbidities if that is the target population. The approximate lifespan of 
the rats used in the current study is 2-3.5 years (Sengupta, 2011). Therefore, the current study 
used healthy adult rats (about 8 months old at surgery) which are more clinically relevant 
compared to previous research which used young rats (~3 months old at surgery). It should be 
noted that the rats used in this study weighed ~600g (max 700g) at the end of the experiment 
with no difference between experimental groups (see Chapter 7, Fig. 7.9). However, the rats 
were not showing obvious signs of obesity. In future studies it would be worthwhile 
comparing the beneficial influence of PROG in lean and large rats as obesity can exacerbate 
dopamine depleting lesions (Sriram et al, 2002). The current study did not include aged rats 
due to time restrictions. Examining the influence of PROG in aged rats is particularly 
relevant as PD is primarily a disorder of the elderly (Van Den Eeden et al., 2003). Similarly, 
STAIR also recommends that male and female animals are studied. The current study used 
male rats as the hormonal cycling of female rats would have complicated findings regarding 
PROG treatment. However, future investigations should include both normal cycling and 
ovariectomized female rats to show that the beneficial influence of PROG also extends to 
female animals.  
Lastly, the current study satisfied STAIR recommendations for good scientific 
inquiry. That is, this study provided clear inclusion and exclusion criteria according to the 
rotation after d-amphetamine test and all rats that were excluded from the study were reported 
with reasons provided. Matched groups of rats according to pre-surgery behavioural 
performance were randomly assigned to treatments by an independent investigator with 
assessment of outcomes performed blinded to the treatment condition to which a rat 
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belonged. STAIR also recommends that studies report how the size of the experiment was 
planned. In the current study the number of rats used in the different conditions was 
conservative and derived on the basis that little had been established with respect to PROG 
and parkinsonian symptoms. The findings of this study can be applied to future research to 
assist sample size calculations. Taken together the execution of this study is regarded as high 
in quality as it adhered relatively well to the STAIR recommendations for good scientific 
inquiry.  
As discussed above, the key direction for future research is to investigate PROG’s 
potential as an adjunct therapy for the treatment of akinesia. Following positive findings in an 
animal model it would be appropriate to examine the beneficial influence of PROG in a pilot 
open-label clinical trial as no serious adverse events have been found in 1000+ patients tested 
thus far in clinical trials for TBI. If beneficial, PROG would be a safe adjunct treatment for 
akinesia.  
8.5.  Conclusion 
The current thesis has provided the most thorough examination to date regarding PROG’s 
influence on motor skills in an animal model of PD. Furthermore, this study has produced 
novel evidence of the beneficial effects of PROG treatment on forelimb akinesia. 
Importantly, the improved forelimb akinesia was not merely symptomatic relief as the benefit 
was sustained for up to six weeks after PROG treatment had stopped. The mechanisms 
responsible for the improved akinesia are not clear but it appears to be independent of striatal 
TH density. These initial findings are encouraging as PROG is a safe agent and is unlikely to 
have adverse side effects when used as a clinical tool in older patients. It is proposed that 
PROG be considered as a safe, and low-cost, adjunct therapy to treat akinesia in a pilot 
clinical trial once an additional animal study is complete. Taken together, the encouraging 
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findings of the current study represent a critical step in understanding the beneficial influence 
of PROG on motor impairments in an animal model of PD. 
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Appendix A 
Cohen’s d pairwise effect sizes for studies two and three 
 
 
Table 1. 
Cohen’s d Pairwise Effect Sizes for Study 2: Progesterone after large intrastriatal lesions.*  
Task Effect Cohen’s d 95% CI Power (%) 
     
Rotational bias after 
d-amphetamine 
Lesion 6.22 -7.21, -5.24 100 
8 mg/kg 0.09 -1.04, 0.86  5 
 4 mg/kg 0.6 -1.50, 0.30  26 
 Lesion only 
control 
11.98 -13.07, -10.98 100 
     
Akinesia: Adjusting 
steps test  
Lesion 3.11 2.12, 4.09 100 
8 mg/kg 1.4 0.45, 2.35 82 
 4 mg/kg 1.33 0.43, 2.22 82 
     
Skilled reaching: 
Success rate 
Lesion 1.13 0.14, 2.11 61 
8 mg/kg 0.23 -1.18, 0.72 8 
 4 mg/kg 0.06 -0.83, 0.96  5 
     
Skilled reaching: Hit 
rate 
Lesion 1.07 0.09, 2.06 57 
8 mg/kg 0.06 -1.01, 0.89  5 
 4 mg/kg 0.14 -0.76, 1.04  6 
     
Rotational bias after 
apomorphine 
Lesion 1.52 0.53, 2.50 85 
8 mg/kg 0.15 -0.83, 1.14  6 
 4 mg/kg 0.32 -0.58, 1.22, 11 
     
Striatal tyrosine-
hydroxylase fibre 
Lesion 4.8 3.79, 5.81 100 
8 mg/kg 0.53 -0.45, 1.51  19 
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Task Effect Cohen’s d 95% CI Power (%) 
density 
 
4 mg/kg 0.08 -0.85, 1.01  5 
 Lesion only 
control 
5.19 4.10, 6.28 100 
     
* Note: The large lesion effect is compared to sham and the potential PROG treatment 
benefits are compared to large lesions. 
 
 
Table 2. 
Cohen’s d Pairwise Effect Sizes for Study 3: Progesterone after small and large intrastriatal 
lesions.* 
Task Effect Cohen’s d 95% CI Power (%) 
     
Rotational bias after 
d-amphetamine 
Large lesion 4.9 4.08, 5.72 100 
Small lesion 2.68 1.86, 3.51 100 
 Large PROG 0.48 -0.45, 1.35  19 
 Small PROG 0.24 -0.64, 1.11  8 
     
Akinesia: Adjusting 
steps test  
Large lesion 4.84 4.01, 5.66 100 
Small lesion 2.02 1.20, 2.85 100 
 Large PROG 2.09 1.23, 2.94 100 
 Small PROG 1.36 0.48, 2.23 86 
     
Postural instability: 
Contralateral forelimb 
Large lesion 3.28 2.46, 4.11 100 
Small lesion 1.19 0.37, 2.01 81 
 Large PROG 0.43 -0.42, 1.28  17 
 Small PROG 0.22 -0.66, 1.09  8 
     
Postural instability: 
Ipsilateral forelimb 
Large lesion 1.91 1.09, 2.73 99 
Small lesion 0.41 -0.41, 1.23 16 
 Large PROG 1.17 0.32, 2.03 76 
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Task Effect Cohen’s d 95% CI Power (%) 
 Small PROG 0.38 -0.49, 1.26  14 
     
Sensorimotor 
integration: Whisker 
test (same side)  
Large lesion 6.45 5.63, 7.27 100 
Small lesion 1.41 0.58, 2.23 92 
 Large PROG 0.28 -0.58, 1.13  10 
 Small PROG 0.53 -0.35, 1.40 22 
     
Sensorimotor 
integration: Whisker 
test (cross midline)  
Large lesion 5.88 5.06, 6.70 100 
Small lesion 1.62 0.80, 2.44 97 
Large PROG 0.3 -0.55, 1.16  11 
Small PROG 0.71 -0.16, 1.59  36 
     
Forelimb use 
asymmetry: Cylinder 
test 
Large lesion 1.49 0.65, 2.34 93 
Small lesion 0.22 -0.60, 1.04  8 
 Large PROG 0.11 -0.77, 0.99  6 
 Small PROG 0.25 -0.63, 1.12 9 
     
Sensory neglect: 
Corridor test  
Large lesion 2.65 1.83, 3.47 100 
Small lesion 0.95 0.13, 1.77 62 
 Large PROG 0.11 -0.74, 0.97  6 
 Small PROG 0.31 -0.57, 1.18  11 
     
Rotational bias after 
apomorphine 
Large lesion -3.77 -4.62, -2.93 100 
Small lesion -0.91 -1.73, -0.09 58 
 Large PROG -0.12 -1.00, 0.76  6 
 Small PROG -0.74 -1.61, 0.14  38 
     
*Note: The large and small lesion effects are compared to sham and the potential PROG 
treatment benefit is compared to the corresponding lesion group.  
 
 
